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Abstract 
A collaborative study between the University of Salford and the National Institute of 
Pharmaceutical Research and Development (NIPRD), Nigeria, involving in vitro tests at the 
University of Salford and the use of facilities at NIPRD for invivo tests has led to the evaluation 
of a range of traditional “fever cures” for antimalarial efficacy. The main objective of this study 
is to identify a suitable antimalarial plant candidate towards the development of a 
phytopharmaceutical drug (a plant-based medicinal mixture/compound used in preventive or 
therapeutic medicine) for the treatment of malaria as a cheaper and more accessible alternative, 
inline with the WHO resolution (WHA 3049) urging nations to use their traditional systems of 
medicine as part of their healthcare systems.  
Traditionally, the mainstay of the antimalarial drug discovery process has been natural 
products. Their use however diminished over the past few decades due to several advances in 
molecular targets and technical difficulties encountered in high-thoughput screens of natural 
product leads. Natural products have played a very important role as a source of antimalarials 
(e.g. quinine and artemisinin derivatives).  In this present study, fluorescent-based in vitro 
antimalarial assays including flow cytometry (FCM) and SYBR green microtitre assay (SG) 
were optimized to screen some aqueous plant extracts which were selected based on their 
ethnopharmacological usage.  Giemsa light microscopy was used to validate the assays.  
Plasmodium berghei malaria animal model was also used to evaluate the anti-plasmodial 
activity of extracts in vivo. The results showed a strong antimalarial activity in all the six 
extracts. Bryocarpus coccineus and Bridelia ferruginea were chosen for further investigation 
due to their efficacy and the collaborative nature of the study. The IC50 values obtained in the 
in vitro antimalarial  studies in the region of 70 µg/ml and 15 µg/ml.   Bridelia ferruginea 
aqueous and methanolic extract was compared to determine any differences in IC50.  In vitro  
comparison of the aqueous and methanolic extracts of the extract revealed  an IC50 value in the 
region of 25.69 µg/ml for the aqueous extract and 15-16 µg/ml for the methanolic extract. 
Qualitative phytochemical screening of both extracts revealed the presence of various bioactive 
compounds including tannins, flavonoids, saponins and cardiac glycosides amongst others in 
both the aqueous and methanolic extract of B. ferruginea.  Anthocyanins were found present 
in the methanolic extract only.  Further investigation of the mechanism of action of the 
methanolic  B. ferruginea extract showed that the extract inhibited β-haematin formation,   
indicating the inhibition of haemazoin formation in the parasite. Lastly, the methanolic extract 
was fractionated using HPLC analysis. Various resolved peaks were obtained and subsequent 
bioassays of the collected fractions revealed that antimalarial activity was distributed across 
xix 
 
the fractions. This may suggests that isolating a single active  compound might not be 
advantageous, making a case for a phytopharmaceutical drugs.
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CHAPTER 1  
 
INTRODUCTION  
1.1 History of malaria and epidemiology 
Malaria has been known to man for thousands of years and may have been a human pathogen 
for the entire history of humanity (Joy et al., 2003). The disease probably originated in Africa 
along with man. It is believed to be a zoonotic disease affecting primates. Early records 
dating back to the Xian dynasty in China (2700 B.C) have discussed characteristic periodic 
fevers and symptoms which we now know to be classical symptoms of the disease (Cox, 
2002). The disease has affected the entire continents, except for Antarctica with historic 
literature mentioning the disease symptoms including during ‘Little Ice Age’. The disease 
was evident in many parts of Europe and referred to in some of Shakespeare’s plays (Reiter, 
2000). In 400 B.C, early Greeks like Hippocrates described the disease manifestations and 
some scriptures associated the disease to supernatural powers. Recently, evidence of malaria 
has been found in the bone tissue of two Egyptian mummies dating back to 3500 years 
(Lalremruata et al., 2013). 
During the medieval Italian period (1476), Leonardo Bruno coined the name malaria from 
‘mal’ air. During that period, the ancient romans believed that fumes of bad air came from 
swampy regions and this idea carried on till the 19th century (Opeskin, 2009). The disease 
continued to be prevalent in different parts of Europe, including the basin of central 
Switzerland, a breeding ground for mosquitoes (Bruce et al., 1988).  Malaria was evident in 
Munich in the 1940’s and continued to be a global health issue. Countries like Greece have 
a history of malaria dating back to the 4th century.  By the 1950’s, the country was considered 
one of the worst hit by the disease outside of Sub-Saharan Africa. It took a tremendous 
improvement in healthcare together with rigorous public health measures, including clearing 
of swamp to eradicate the disease in 1974. Moving outside of Europe, Russia saw an 
epidemic that killed nearly 60, 000 people in 1980. It took vigilant public health campaigns 
and efforts for Europe and the United States to successfully eradicated the disease. These 
regions however still have the Anopheles mosquito species that can transmit the disease, 
hence, reintroduction of the disease still remains a risk. Recently in 2012, there have been 
reports that the disease might have found its way back into Europe with some cases of the 
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disease being recorded in Greece.  Austerity induced budget cuts in the country have affected 
municipal insecticide spraying leaving unsprayed. Only 8 out of 56 municipals near Athens 
were sprayed in 2012. This decline in the public health measure in place posed a risk to the 
region leading to 70 cases recorded. Although the vast majority of cases were imported from 
abroad, statistics show that up to 10 percent of cases were contracted within the country 
(Telegraph, UK).  
Despite its elimination in Europe and the progress achieved in reducing morbidity and 
mortality, malaria still remains the leading cause of disease and death in many developing 
countries. About 3.3 billion people, half the world’s population are at risk of malaria 
transmission in 106 countries and territories. According to the World Health Organization’s 
World Malaria Report 2015, it is estimated that 214 million cases of malaria occurred 
worldwide leading to 438 000 death. Fifteen countries accounted for 80% of cases, and 78% 
of death. 89% of the global burden of mortality is borne by some countries in sub-Saharan 
Africa.  The Democratic Republic of the Congo and Nigeria alone account for more than 
35% of the estimated global malaria death whilst 10% cases occurred in South East Asia and 
2% in the Mediterranean region. In 2015, the millennium development goal (MDG) target 
to halt and reverse malaria was achieved with a 50-75% reduction in malaria incidence in 18 
countries. Death in children under 5 fell from 723, 000 cases in 2000 to 306, 000 in 2015. 
(WHO Report, 2015). Although there has been an overall decline in the incidence and 
mortality of the disease, the 2015 report also points out the fact that the rate of decline in 
cases has been most rapid in countries that reported the smallest amount of cases in 2000. In 
the same year, countries with a high morbidity and mortality showed a slower decline in 
incidence rate. Although not all countries have recorded a successful reduction in malaria 
infections, there has been a successful global decline in cases. Insufficient public health 
measures for malaria in some regions puts half the world’s population at risk. In 2014 alone, 
1586 cases were reported in the United Kingdom (UK) due to imported malaria most of 
which were due to travel to West African endemic areas (Public health England statistics, 
2014). Hence reductions in incidence need to be greatly accelerated in those countries 
lagging behind if sustainable global progress is to be achieved. 
The economic burden of malaria cannot be overestimated. Along with direct health costs, 
there is a significant additional encumbrance of the disease in terms of lost days of work.  
Malaria mortality rates shows a correlation with gross national income (GNI) per capita.  
Countries with higher proportions of their population living in poverty (less than US$ 1.25 
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per person per day) have higher mortality rates from malaria as a result of low domestic 
spending per capita on health and malaria control. The ability of malaria endemic countries 
to strengthen health systems depends on many factors, including a country’s physical 
infrastructure, educational systems, policies surrounding the role of the public sector, and 
the ability to ﬁnance the expansion of the sector. International spending on malaria control 
is more evenly distributed in relation to malaria burden, but a large proportion of this funding 
is spent on commodities and does not address fundamental weaknesses in health systems. 
Hence, innovative ways of providing services may be required to rapidly expand access to 
malaria interventions, particularly diagnostic testing and treatment. Such innovations will 
require community based approaches and engagement with the private sector. Malaria 
continues to pose a serious economic burden on health systems. Since 2001 in sub-Saharan 
Africa, malaria is estimated to have cost every year, on average, nearly US$ 300 million 
annually for case management alone (WHO Report, 2015). 
1.2 Malaria distribution and transmission 
The parasite is solely transmitted by the mosquitoes of the Anopheline species. The disease 
is transmitted though a bite from an infected mosquito. Parasites enter the blood stream and 
travel to the liver where the life cycle begins. The highest biting rates occurs at night between 
sunset and sunrise. Rarely, the disease is transmitted congenitally from mother to foetus and 
though transfusions and organ transplant. Malaria transmission though transfusion was one 
of the first recorded incidents of transfusion-transmitted infections (Kitchen et al., 2006). 
The distribution of the disease depends primarily on different factors including climatic 
conditions, weak economic development and poor public health measures. Malaria 
transmission is high in tropical and subtropical regions of the world, which offer suitable 
breeding conditions for the Anopheles mosquito.  Certain strains of malaria like Plasmodium 
falciparum (P. falciparum) cannot complete its growth cycle in temperatures lower than 
20°C, leading to interrupted transmission in cold climatic conditions. P. vivax, a different 
strain of the disease, is more tolerant to lower temperature and hence survives colder 
conditions. The transmission of the disease is hence seasonal. Warm regions in sub-Saharan 
Africa and New Papua Guinea have the highest distribution of the disease due to all year 
round transmission.  
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Fig 1.1: Malaria transmission: Showing the global distribution of malaria with 90% cases 
in Africa. (Source: http://vcrc.res.in/writereaddata/mapf4.gif). 
1.3 Malaria eradication and control 
Malaria was endemic in the United States (U.S) during the military occupation of Cuba in 
1906. The workforce and military personnel were greatly affected especially around the 
Panama canal construction region. At the turn of the 20th century, the American congress 
approved funds for malaria control with a view to effectively reduce the number of cases. 
Mosquito breeding sites were reduced by controlling water levels as well as insecticide 
spraying using DDT (dichloro-diphenyl-trichloroethane), an almost odourless 
organochloride. In 1942, a centre was established and named the Office for Malaria Control. 
The primary aim was to reduce the impact of malaria and other vector borne diseases in 
military zones in the USA and its territories. Several achievements were made, leading to 
the Centre for Disease Control (CDC) being founded with a major mandate to control, 
prevent and eliminate the disease both domestically and internationally.  By 1947, the 
national malaria eradication programme began operations. DDT was applied in all affected 
rural houses, drainages and breeding grounds for mosquitoes. In 1947, there were 15, 000 
reported malaria cases and by 1950, these had reduced to 2000 due to the activities of the 
CDC.  The disease was successfully eliminated due to effective control measures and the 
country was declared malaria free by 1951.The National Malaria Society put forward a 
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motion that ‘Malaria may be assumed to be no longer endemic in an area once an indigenous 
case has not been recorded for three years’. Europe also successfully eliminated the disease 
during World War II with the extensive use of DDT amongst other control measures. 
Fig 1.2: Malaria mortality in the US: Showing the mortality and morbidity rates in the 
United states prior to malaria elimination during World War (Source: 
http://www.cdc.gov/malaria/images/graph/malaria_us_curves.gif). 
Other organisations played a vital role in the fight against malaria. The World Health 
Organisation (WHO) also commenced regional campaigns to eradicate the disease in the 
1940’s and by 1955, a global eradication programme was implemented in countries with low 
to moderate transmission. Eradication efforts included massive mosquito net distribution in 
malaria endemic regions, swamp clearing, prompt drug treatments, drug and vaccine 
research and development. DDT was largely used for mosquito control in these regions to 
reduce transmission. The programme proved successful in eliminating the disease in several 
countries including Taiwan and Australia whilst dramatically reducing mortality rates in 
other countries, including Sri Lanka and India (Harison, 1978). The DDT spraying 
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programme was however not sustained due to several reasons including safety and 
environmental factors. The significant financial burden required to implement the 
programme was unsustainable and these critical factors led to the programme being 
abandoned. The programme was largely successful in countries with high socio-economic 
status, well organised healthcare systems and relatively low malaria transmission but was 
never implemented in the sub-Saharan African region where presently, more than 80% of 
the disease burden occurs. Failure to sustain the programme led to increased parasite 
resistance to DDT and antimalarial drugs resulting in a resurgence in the disease and reversal 
of earlier victories previously achieved.  By 1992, there was an improved understanding of 
the social, economic and cultural dimensions of malaria. The improved knowledge and 
experience derived from post eradication era research fuelled a renewed global focus on 
malaria. This led to the launch of the Roll-back on Malaria Initiative in 1998 by WHO which 
led to an Abuja declaration in 2000. The declaration looked into various progressive 
interventions and control measures designed to eliminate malaria as a public health issue 
though strengthening of the local healthcare systems. More recently the Bill and Melinda 
Gates foundation launched the Gates Malaria Forum in 2007 and the WHO defined four 
phases on the road to malaria elimination (Control, pre-elimination, elimination and 
prevention of re-introduction). Participating countries use the WHO set goals to achieve 
these phases with the ultimate goal of reaching the ‘prevention of re-introduction phase’. An 
increasing number of countries are moving towards elimination of the disease. 16 countries 
have successfully reported zero indigenous cases in 2014 including Sri Lanka, Turkey, 
Morocco and Uzbekistan (WHO report, 2015).  Other countries including Algeria have 
reached the pre-elimination phase with fewer than 10 indigenous cases. Interestingly, WHO 
European region, comprising of 53 countries, reported zero indigenous cases for the first 
time in 2015 in line with the Tashkent Declaration to eliminate the disease in the region by 
2015 (WHO Report, 2015). Despite all these efforts and current tools that are available to 
us, the end is still not near in the fight to end malaria. This can be clearly seen in the map 
below.  
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Fig 1.3: Current and forecasted World malaria eradication map: Showing different regions and their stage of the 
eradication programme. (Source: Malaria elimination initiative).  
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Although dramatic progress has been recorded in the last decade in the fight against 
malaria, the disease can only be eliminated worldwide though a strategic vision including 
strengthening of existing tools to achieve maximum synergy. To implement this holistic 
approach, several factors need to be considered including improving the economic plight 
of the nations involved.  
Before malaria can be successfully eradicated in any region, the government of that country 
must make a commitment to end the menace. This must involve pooling all efforts of 
government bodies, NGOs and international organisations together. Sri Lanka and Egypt 
are two countries that have demonstrated that developing countries can achieve elimination 
with government commitment. 
1.4 Discovery of the Plasmodium from a historical perspective  
Centuries ago, events like the discovery of bacteria in 1676 by Antoni Van Leeuwenhoek 
and the development of the ‘germ theory’ by Louis Pasteur in 1878 steered investigators to 
intensify the search for the causative agent of malaria. Some prominent microbiologist 
claimed the disease was caused by a bacterium, Bacillus malariae (Cox, 2010). The details 
were however patchy and it was not until in 1880 that a French army doctor named Charles 
Louis Alphonse Laveran embarked on a mission to unravel this mystery. He discovered the 
parasites in the blood cells of his patients whilst working in a military hospital in Algeria. 
He observed different course of events which we now know to be the different stages of 
the parasite. Amongst his observations was the bursting of red blood cells which coincided 
with patient fevers. Laveran also discovered that these crescentic bodies were removed by 
quinine. He realised that he was not dealing with a bacterium but a protozoan and  named 
it Oscillaria malariae. This was a ground-breaking discovery at the time, as it was the first 
time that a protozoa was identified as a disease causing agent. Unfortunately, his finding 
was rejected at the time, more particularly by the malariologists and biologists who 
believed his discovery was nothing other than disintegrating red blood cells. In 1884, 
Laveran convinced some leading malariologists including Golgi and Bignami of his 
protozoan theory. His findings were later accepted and he was awarded the Nobel prize for 
Physiology and Medicine in 1907 (Tan et al., 2008). In 1886, Camillo Golgi further 
established that there were two presentations of the disease due to the nature of fevers 
observed. One form of the disease presented tertian periodicity whilst the other a quartan 
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periodicity. He also further confirmed that these two forms were distinct, as upon maturity, 
they produced different numbers of merozoites. The rupture of these merozoites coincides 
with the tertian and quartan fever cycles. He was awarded a Nobel prize in 1906 for his 
discoveries in neurophysiology. 
In 1897, a British army doctor, Ronald Ross demonstrated that malaria could be transmitted 
from infected patients to the mosquito. He discovered parasites in the midgut of the 
Anopheline mosquito which had been previously fed for four days on a malarious patient, 
confirming the role of the Anopheles mosquito in malaria transmission. Ross continued 
with his work on malaria but on the avian animal model. After feeding mosquitoes on 
infected birds, he found the parasite in the salivary glands of the insects allowing them to 
subsequently infect other birds though a bite. He was awarded a Nobel prize for this 
breakthough discovery. His findings became very useful and critical in public health 
awareness campaigns. In 1899, another team including Bignami and Grassi demonstrated 
the complete sporogonic cycle by feeding Anopheles mosquito on malarious patients and 
subsequently feeding healthy volunteers establishing an infection. 
1.5 Plasmodium species and life cycle 
  1.5.1 Species and symptoms 
Although Laveran attributed the disease to a single species in 1890 (Oscillaria malariae),  
the Italian investigators Giovanni Batista Grassi and Raimondo Filetti introduced the 
names Plasmodium vivax and P. malariae for two other species that affect humans. 
Furthermore, William H. Welch, named the malignant tertian malaria parasite, P. 
falciparum in 1897 causing lot of controversy. This name was widely used in literature and 
accepted. By 1922, John William Watson Stephens described another human malaria 
parasite, P. ovale whilst P. knowlesi was described in 1931 by Robert Knowles and Biraj 
Gupta. Another less severe strain, the P. vivax has also been described. 
Amongst the species described above, four affect humans including P. falciparum, P. oval, 
P.vivax and P. malariae although a human case of P. Knowlesi was first reported in 1965 
(Chin et al., 1965). The different species affect different red blood cell types. P. falciparum, 
the most deadly strain infects all red blood cell types. P. ovale and P. vivax  invade young 
red blood cells or reticulocytes while P. malariae prefer senescence red blood cells. The 
incubation period for the disease varies between 7-18 days depending on the specie due to 
the differences in the length of cycle between strains.  
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The presentation of uncomplicated malaria is highly variable depending on the species 
infecting the human host.  Initial symptoms  include fever, sweats, headache, vomiting and 
malaise. P. vivax and P. malariae tend to bring on mild symptoms in immune individuals 
and severe symptoms in non-immune persons. The most severe symptoms however occur 
with P. falciparum infections which without prompt treatment could lead to life theatening 
complications including organ failure and cereberal malaria.  
1.5.2 Life cycle 
The parasite life cycle was discovered in the late/early 20th century by several scientists 
including Laveran, Mason, McCallum and Ross. The first stage of the life cycle starts when 
the anopheles mosquito takes a blood meal from a human during it  injects the parasites in 
the form of sporozoites from its saliva into the host. The parasites travel to the liver via the 
blood vessels and once there, they invade the liver cells. Over a period of days, the 
sporozoites grow and multiply though cell mitotic cell division forming haploid cells called 
the merozoites. Each liver cell is able to produce tens of thousands of these haploid forms. 
Due to the growing pressure on the liver cells, the cells burst releasing the merozoites back 
into circulation. Some malaria species are however known to remain in the liver cells in a 
dormant stage, multiplying at a later date and this is one of the main causes of relapses in 
treatment.  
Once in the blood stream, merozoites invasion of erythocytes begin very rapidly and 
specifically though receptor ligand interactions. The mechanism of erythocyte invasion is 
very complex and not fully understood both at molecular and cellular levels. The 
Plasmodium is a member of the apicomplexan due to the apical position of certain 
organelles in the parasite which are involved in parasite-host interactions during host cell 
invasion. Four distinct processes have been described with regards to parasite-host 
interaction, which include: initial merozoites binding, erythocyte re-orientation and 
deformation, junction formation and parasite entry (Gratzer and Dluzeski, 1993). 
The four processes involve a cascade of protein-protein interactions, the exact mechanism 
of which is only partially understood.  In summary, erythocyte and merozoite interaction 
is initially assumed to be though a random collision between membrane surface proteins 
on both the merozoite and erythocyte membranes. The merozoite reversibly binds the host 
erythocyte via merozoite surface proteins (MSP), the best characterized one is called MSP-
1 protein, which is abundantly distributed over the merozoite surface. Parasite re-
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orientation occurs after merozoite binding with the parasite bringing its apical end into 
close contact with the erythocyte membrane. This apical adhesion involves an irreversible 
interaction between receptors on the merozoite surface and ligands on the erythocyte cell. 
Apical antigen-1 (AMA-1) has been implicated in this re-orientaion (Mitchell, 2004).  
Several other events  occur including junction formation between the parasite and the host 
cell, formation of parasitourous vacuole and shedding of merozoite proteins. The main 
driver for parasite entry is an acto-myosin complex called glidosome. 
Once inside the erythocyte, the Plasmodium modifies the red blood cell and makes it more 
suitable for its habitation. It further undergoes a trophic phase followed by a replicative 
phase. In the case of P. falciparum parasites, cytoadherence of infected erythocytes to 
endothelial cells occurs. This results in sequestration of the mature parsites in capillaries 
and post-capillary venules. This could be responsible for the complications that arise with 
P. falciparum infections. The cytoadherence is an advantage to the parasite as it creates a 
micro-aerophillic environment which is better suited for the parasite. Another major 
advantage to the parasite is that though this mechanism, it is able to avoid the spleen, hence 
subsequent destruction. 
P. falciparum infections are also associated with knob formation. This is a structural 
alteration of the host once invasion occurs induced by the Plasmodium (Deitsch and 
Wellens, 1996).  Two main proteins have been identified that are associated to this knob 
formation. These are the knob-associated histidine rich protein (KAHP) and the erythocyte 
membrane protein-2 (PfEMP2) also called MESA. These two proteins are exposed on the 
outer surface of the infected erythocyte but localised to the cytoplasmic phase of the host 
erythocyte. The exact function of knobs is still unknown but it is thought to be involved in 
reorganising the submembrane cytoskeleton. 
Once completely in the red blood cell, the Plasmodium multiplies asexually repeatedly over 
a period of 1-3days. The red cells carrying the Plasmodium burst once several divisions 
have occurred hence releasing thousands of new merozoites into the blood stream. These 
new merozoites re-invade new blood cells within seconds increasing the parasitaemia 
within the infected person causing symptoms and other complications if left untreated. 
Some merozoite infected blood cells leave the cycle of asexual replication described and 
develop into the sexual forms called gametocytes which circulate in the blood stream. The 
sexual forms are however, not able to mate within the human host so the final stage of the 
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Plasmodium life cycle only occur when a mosquito takes a blood meal from the infected 
person.  
Once in the mosquito, digestion of the blood cells occurs in its gut leading to the release of 
gametocytes. The free released sexual forms mate and fertilize forming diploid zygotes 
which develop into actively moving ookinetes. These burrow into the mosquito midgut 
wall forming oocysts which grow though mitotic divisions to produce thousands of active 
haploid forms called sporozoites. After 8-15 days, the oocysts burst releasing sporozoites 
into the body cavity of the mosquito. The sporozoites travel and invade the salivary gland 
of the mosquito were they wait to be deposited into the next human victim during the 
mosquito’s next blood meal. 
 
 
 
 Fig 1.4 Complete life cycle of the Plasmodium: Showing the complete life cycle of the 
malaria parasite in the human and mosquito hosts. 
(Source http://www.malwest.gr/Portals/0/EID_lec17_slide8-large[1].jpg). 
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1.5.3 Erythocytic stages of P. falciparum 
Within the red blood cell, the Plasmodium goes though a trophic period followed by 
multiplication via fission called shizogony. After red cell invasion, a trophozoite grows in 
size and this is why it is described as the early trophozoite and late trophozoite stage especially 
in culture. The trophozoite repeatedly replicates its nucleus and other organelles within the 
red blood cell forming a schizont which is multinucleated. This further divides via cytokinesis 
into several identical merozoites. Due to the overwhelming number of merozoites, the red 
blood cell becomes distorted in shape and eventually bursts releasing several merozoites 
which reinvade other red blood cells within seconds. This rupture of the erythocyte causes 
the release of the parasite waste and cell debris into the circulation which causes the 
symptoms of the disease. 
 
 
 
 
Fig 1.5: Erythocytic stages of the Plasmodium: Showing a diagramatic erythocytic stages 
(Source http://idshowcase.lshtm.ac.uk/id503/ID503/M1S1/ID503_M1S1_030_020.html). 
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1.6 Clinical Symptoms 
The presentation of uncomplicated malaria is highly variable and can easily be misdiagnosed. 
The incubation period is between 7-18days depending on species. Clinical manifestations 
occur exclusively due to the asexual erythocytic stage of development of the parasites.  Initial 
symptoms are flu-like and include a high pitch fever, sweats, chills, headache, vomiting and 
anaemia. Anaemia is one of the major causes of morbidity and mortality in endemic areas. 
Low reticulocytosis has been observed in infected persons suggesting insufficient 
erythopoiesis. Studies using Plasmodium Chabaudi comparing malaria resistant mutant mice 
and susceptible mice show that neutralisation of endogenous erthtropoietin during infection 
leads to lethal anaemia, while timely administration of exogenous erythopoietin rescues mice 
although  reticulocytosis is suppressed in proportion to parasitaemia (Change and Stevenson, 
2004). Bone marrow suppression and severe anaemia have been shown to be associated with 
persistant P. falciparum infection (Helleberg et al., 2005).  Severe anaemia can develop in 
the aftermath of of an infection due to protracted bonemarrow suppression possibly due to 
residual low level parasitaemia. There are several other factors that contribute to anaemia 
including accelerated removal of erythocytes, without adequate compensation by the bone 
marrow, due to hepatosplenomegaly. Bone marrow suppression occurs in all malaria infected 
patients and also in asymptomatic P. falciparum semi-immune individuals (Kurtzhals et al., 
1999).  Majority of severe anaemia in children residing in malaria endemic regions is due to 
malaria infection. In some cases, the parasitaemia is undetectable by microscopy and case 
diagnosis is only possible though antigen detection (Hellberg et al., 2005). In these patients, 
suppressed erythopoiesis persists until parasites are completely cleared.  Data on the duration 
of bone marrow suppression after malaria infection are conflicting with some data showing 
hypoproliferative erythopoiesis for weeks following treatment (Camaccho et al., 1998), 
whilst others show that bone marrow suppression is rapidly reversed post treatment (Abdallah 
et al., 1980). Malaria infected patients have an increased ratio between the pro-inflammatory 
cytokine , tumor necrosis factor (TNF-α), and the antiinflammatory cytokine, interleukin-10 
(IL-10). Inflammatory cytokines are proposed to be a causative factor in malaria anaemia 
(Kurtzhals et al., 1998). 
Apart from the debilitating effects of anaemia, cerebral malaria is a more severe presentation. 
Treatment often involves prompt  parenteral administration of an antimalarial (quinine or 
artemisinins). Mortality rates are lower in adults than in children. The clinical hallmark of the 
disease is altered state of consciousness, seizures, neurological symptoms with coma being 
the most severe manifestation. Cerebral malaria is a leading cause of childhood neuro-
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disability in affected regions (Idro et al., 2010). The central factor in the pathogenesis of the 
disease is thought to be  sequesteration of parasites  in cerebral microvasculature resulting in 
pathophysiological changes in tissue around the sequestered parasites. Sequestration ensues 
from adherence of parasitized red blood cells (pRBCs) to the endothelial lining 
(cytoadherence) using parasite derived proteins exposed on erythocyte surface. A group of 
parasite antigens including Plasmodium falciparum erythocyte membrane protein-1 (PfEMP-
1) mediate binding to host receptors such as intercellular adhesion molecule-1 (ICAM-1). 
ICAM expression is upregulated in areas adjacent to sequestered parasites. The sequestered 
parasite mass is further increased when adherent erythocytes agglutinate with other pRBCs 
forming rosettes with non-parasitized erythocytes or using platelet-mediated clumping to bind 
to each other. In Addition, the ability of pRBCs to deform and pass though the 
microvasculature is decreased. Therefore, hypoxia and inadequate tissue perfusion may be 
major pathophysiological events (Dondorp et al., 2004). 
 
1.7 Prevention  of malaria 
Prevention and control of the disease can target either barrier methods, vaccination or 
chemoprophylaxis. The method of control is multifactorial as both the vector and the parasite 
need to be considered. This has proven difficult over the years as both vector and parasite 
seem to be highly adaptable, hence multiple strategies need to be employed. For this reason, 
there is a strong need for governments, Non-governmental organisations (NGOs), 
international agencies like UNICEF, WHO and healthcare professionals  to collaborate and 
develop a holistic strategy to combat the disease. Early intervention has proven to be an 
essential key in preventing death and reducing the spread of the disease. Currently, pregnant 
women in sub-Saharan Africa are given a prophylactic treatment although accessibility might 
be an issue. 
 
1.7.1 Vector control  
WHO recommends several methods for malaria vector control, but also  further 
recommending that the approach should be based  on knowledge of the local situation. The 
most commonly used and successful methods for vector control are insecticide spraying and 
use of insecticide-treated nets (Raghavendra et al., 2011). Indoor residual spraying is the 
practice of spraying insecticides on the interior walls of homes in malaria affected areas. 
Mosquitoes tend to rest on a nearby surface after feeding to digest the blood meal.  As 
previously discussed, the first and most popular insecticide used for IRS is DDT. While it 
16 
 
was initially used exclusively to combat malaria, its use quickly spread to agriculture leading 
to a large scale usage. The resultant misuse of DDT led to the evolution of resistant 
mosquitoes in many regions. During the 1960s, awareness of the negative consequences of 
its indiscriminate use increased, ultimately leading to bans on agricultural applications of 
DDT in many countries in the 1970s. DDT has never been banned in public health and 
advocates of its use argue that mosquito resistance stems specifically from its industrial-scale 
application in agriculture, rather than its use in public health. The WHO currently advises the 
use of 12 different insecticides in IRS operations. These include DDT and a series of 
alternative insecticides such as the pyrethoids permethin and deltamethin. Hence, the public 
health use of small amounts of DDT is permitted under the Stockholm Convention on 
Persistent Organic Pollutants (POPs), which prohibits the agricultural use of DDT. Many 
developed countries nevertheless, discourage DDT use, even in small quantities, due to its 
legacy. One major drawback  with all forms of IRS is the likelihood of the development of 
insecticide resistance via evolution of mosquitos. 
Mosquito bednets are also an important barrier method. As some mosquitoes can still pave 
their way though the net, nets are often treated with an insecticide (often permethin or 
deltamethin). Insecticide-treated nets (ITN) are estimated to be twice as effective as untreated 
nets. Although ITN are proven to be very effective against malaria less than 2% of children 
in urban areas in sub-Saharan Africa are protected by ITNs. ITNs are a very cost effective 
barrier method. Nets should be re-impregnated with insecticide every six month to maximise 
effect. This process poses a significant logistical problem in rural areas. New technologies 
like Olyset or DawaPlus allow for production of long-lasting insecticidal mosquito nets 
(LLINs), which release insecticide for approximately 5 years. 
 
1.7.2 Vaccine development 
 Over the years, there have been concerted efforts by several pharmaceutical companies and 
research organisations to search for a vaccine for malaria. Several vaccine candidates have 
been tested with limited success. Recently, in 2015, a vaccine candidate (RTS,S) was finally 
given a positive feedback by the European Medicine Agency for safety and efficacy after 
taking 30 years to develop at a cost of $800m.  RTS,S  was developed by Glaxo SmithKline. 
It is a recombinant protein engineered using genes  and the first vaccine in the World to be 
licenced for malaria and infact the first vaccine licenced for any parasitic disease (Walsh and 
Fergus, 2015).  It clinically shows protection against P. falciparum and works by triggering 
the immune system to defend its self against the Plasmodium after it enters the blood stream 
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following a mosquito bite. The vaccine however shows no protection against the liver form, 
P. vivax. It has not yet been cleared for use in children, but is being considered by the WHO 
due to the ambiguous results obtained from its trials. Furthermore, only 27% protection was 
observed in children who received up to 4 boosters at   6, 10, 14 and 18 month of age. The 
groups that did not receive the dose only showed 18% protection (WHO, 2015). Also 
increased cases of seizures and meningitis were noted in children of older age groups. The 
fact that repeated boosters are needed for it  to be effective will raise questions regarding 
compliance and cost implications. In 2015, The WHO’s Strategic Advisory Group of Experts 
on Immunization (SAGE) and the Malaria Policy Advisory Committee (MPAC) jointly 
recommended a pilot implementation of the vaccine in Africa (WHO, 2015 Media Release). 
In yet another development, another vaccine, PfSPZ  developed by Sanaria has been shown 
in a recent trial to offer up to 1 year protection. It is based on an activated sporozoite. (Nature 
Medicine Magazine, 2016). 
The exact mechanism of action of RTS,S is yet to be elucidated, however the immunologic 
basis of the protection against malaria offered by the vaccine is via the induction of high 
levels of antibodies and CD4+ T cells specific for circumsporozoite protein (CSP) (White et 
al., 2013). 
 
1.7.3 Chemoprophylaxis 
Several approaches are involved including disruptive, suppressive and causal prophylaxis. 
Disruptive prophylaxis is an experimental approach which involves preventing the parasite 
from binding erythocytes. This is achieved by blocking calcium signalling between the 
parasite and the host cell.  Suppressive prophylaxis uses drugs that are only effective in killing 
the erythocytic parasite stages. Chloroquine, proguanil, mefloquine, and doxycycline are 
suppressive prophylactics. These drugs have no effect until the liver stage is complete. That 
is why these prophylactics must continue to be taken for four weeks after leaving the area of 
risk. Causal prophylactics target not only the blood stages of malaria, but the initial liver stage 
as well. This means that the user can stop taking the drug seven days after leaving the area of 
risk. Malarone (a combination drug of atovaquone and proguanil)  and primaquine are the 
only causal prophylactics in current use hence, used as the first line treatment prophylactics 
for people travelling to malaria endemic regions. 
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1.8 Chemotherapy in malaria 
Chemotherapy remains the most important means of controling malaria. Treatment usually 
depends on several factors including severity of diseases, malaria specie and the part of the 
world infection was acquired. Determination of specie and region is usually useful in order 
to determine drug susceptibility. Other factors include the clinical situation of the infected 
person for example adult, child or pregnant female. There are several anti-malarials that are 
used in practice. Some have previously been used as monotherapy while others are currently 
used as combination therapy. Combination therapy involves the simultaneous administration 
of two or more blood schizonticidal agents with different modes of action and different 
biochemical targets in the parasite. Prior to chemotherapy, prompt parasitological 
confirmation is required which can be achieved by various methods to be discussed in later 
section of the report. The gold diagnostic standard is microscopy which is cheap and fast. In 
P. falciparum endemic areas where infection can be fatal in the event of treatment delay, 
drugs are often given on suspicion of malaria and laboratory confirmation done later. Several 
antimalarials are used for the treatment of the disease. They are often classified according to 
their biological activity or according to the structural nature of the compound.  
 
1.8.1 Classification by biological activity 
Compounds are classified according to the stage of the parasite life cycle activity resides. 
Different compounds target the different developmental stages of the parasite both within the 
host and vectors. According to the Centre for Disease control (CDC), there are five main 
categories under this classification. 
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   Biological classification                        Target 
Blood schizonticides 
 
Compounds in this category exert their antimalarial 
effect in the erythocytic stage of the life cycle. Examples 
of drugs in this category include quinine, mepacrine, the 
4-aminoquinolines including chloroquine and 
amodiaquine. The 4-aminoquinolines have a rapid action 
and are hence used for clinical suppression of symptoms 
(Bruce-chwatt, 1962). 
 
 
Gametocidal drugs 
 
Several compounds fall into this class including the 8-
aminoquinolines example pamaquine and primaquine. 
They target the sexual forms of the parasite in blood hence 
blocking transmission in the mosquito. Quinine, 
mepracrine, amodiaquine and chloroquine are also active 
against sexual forms of the parasite in the blood in P.vivax 
and P. malariae ( Kiszewski, 2011).  
 
Sporontocides 
 
These compounds target the mosquito life cycle. They 
inhibit growth and development of oocysts in the 
mosquito, hence, preventing transmission. They are also 
called gametostatic drugs. They include proguanil, 
chlorproguanil and pyrimethamine  (Omar et al., 1974). 
 
Secondary tissue 
schizonticides or anti-
relapse drugs 
These compounds exert their effect on dormozoites of the 
P. vivax and P. malariae infections of the liver. These 
dormozoites would ordinarily lead to relapse of symptoms 
and reoccurrence of disease. Examples of the drugs in this 
category include pamaquine and primaquine (Alonso et 
al., 2011). 
 
 
Table 1.1 Classification of antimalarials: Showing classification of antimalarials by 
biological activity. 
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1.8.2 Classification by structure 
 Drugs are classified according to similarities in their chemical structure which may 
sometimes result in similarities in mode of action. 
1.8.2.1 4-aminoquinolines 
 
   
Fig 1.6: Chemical structure of 4-aminoquinoline: Showing the structure of IUPAC name 
quinolin-4-amine 
The 4-aminoquinolines are a group of structurally related compounds which all have the 
quinoline pharmacophore. They have  an amino group at position 4 of the quinoline ring as 
represented in the structure in fig 1.6 above. The 4-aminoquinolines were synthesized from 
the pharmacophore of quinine. Examples include chloroquine, amodiaquine and 
hydroxychloroquine. 
I) Chloroquine 
Chloroquine has the structure in fig 1.7 below with the quinoline ring and an amino 
substitution at position 4.  
 
Fig 1.7: Chemical structure of Chloroquine: Showing the structure of CQ,  IUPAC name: 
RS)-N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine 
Chloroquine phosphate was the drug of choice for all Plasmodium strains except for the 
chloroquine- resistant strains. P. malariae strains tend to be susceptible to chloroquine but 
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there is a high resistance with P. falciparum. The drug can be used as prophylactic treatment 
for P. vivax and P. ovale. Chloroquine acts by interacting with DNA, hence, inhibiting certain 
parasite enzymes. Plasmodium resistance to the drug is yet been confirmed in Central 
America, middle east and the Caribbeans. Chloroquine works by diffusing into red blood 
cells. Once in the red blood cells, the drug molecule becomes protonated due to its weak basic 
properties and the acidic nature of the food vacuole preventing it from exiting the vacuole 
leading to its accumulation in the lysosomes. This is why it is called a lysomotropic agent. 
The malaria parasite lives in the red blood cell where it acquires amino acids though the 
degradation of haemoglobin. Once the parasite acquires the amino acids, it uses it to construct 
its own proteins for energy and metabolism and this digestion occurs in the parasite food 
vacuole. The end result is the production of the soluble haem which bio-crystallizes to the 
nontoxic haemazoin, accumulating in the vacuole as crystals. Since chloroquine accumulates 
in the parasite food vacuole as well, it is thought to prevent the bio-crystallization of haem 
hence leading to the accumulation of the toxic molecule causing parasite death (Leeds et al., 
2002).  
ii)  Amodiaquine 
This drug is more effective than chloroquine in treating chloroquine-resistant P. falciparum 
infections. It also offers more protection when used as a prophylactic compared to 
chloroquine. It differs from chloroquine in structure due to the incorporation of an aromatic 
structure in the chloroquine side chain. The drug is only susceptible to low chloroquine 
resistant P. falciparum infections. In cases of high resistance, an alternative treatment is 
sought. The main problem with amodiaquine is hepatotoxicity, which commonly occurs due 
to biotransformation of the p-aminophenol moiety into a quinoneimine, reducing the 
therapeutic value of the drug. The drug is no longer in the market in developed countries 
although the side effect is thought to only occur with long term prophylactic use (Olliaro et 
al., 1996). 
 
iii) Hydroxychloroquine 
This has a similar structure to chloroquine and differs by the presence of a hydroxyl group at 
the end of its side chain hence the name. 
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1.8.2.2 Arylamino-alcohols 
These group of compounds consist of alkaloids extracted from the bark of Cinchona tree and 
their synthetic derivatives. Quinine, a naturally occurring alkaloid was the first antimalarial 
discovered  since the 18th century and remained the antimalarial of choice up until the 1940’s. 
Structurally, it consists of a conjugated aromatic quinoline ring fused to a bicycle quinuclidine 
ring.  Other synthetic derivatives were developed by the US army during World War I due to 
the scarcity of quinine from Germany. Mefloquine and halofantrine are the main synthetic 
derivatives. Although more antimalarials have been developed and are more widely used, 
quinine still remains the drug of choice for the treatment of complicated and severe 
chloroquine resistant P. falciparum malaria (Gilles, 1991). The exact mechanism of action is 
yet to be understood. They differ from the 4-aminoquinolines but also  seem to interfere with 
haem digestion (Famin et al., 2002). 
1.8.2.3 8-Aminoquinolines 
 These classes of aminoquinolines have an amine at position 8 of the quinoline rings. Three 
main antimalarials belong to this group. These include pamaquine, primaquine and 
tafenoquine. They are closely related in structure to the 4-aminoquinolines.  
 
 
Fig 1.8: Chemical structure of 8-aminoquinoline: Showing the structure of 8-
aminoquinoline 
The 8-aminoquinolines are the first group of compounds to be synthesized specifically for 
antimalarial activity. By the 1940s, there was a need for new more potent and less toxic 
antimalarials. The USA initiated a programme which led to the development of several 
compounds in this group of which pamaquine and primaquine seemed the most effective 
(Cooper, 1953). Pamaquine is no longer used anywhere in the world but primaquine is still in 
use, although it is still not licenced for use in the UK for travellers.  Primaquine is effective 
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against P. vivax and P. ovale and was also found to be effective as a prophylactic treatment 
for P. ovale as it eradicates malaria hypnozoites from the liver (Jones et al., 1948).  
 
Fig 1.9: Chemical structure of primaquine: Showing the structure of primaquine 
1.8.2.4 Artemisinins and related compounds 
Artemisinin and its derivatives are a group of compounds with a rapid parasite clearance rate 
that are active against P. falciparum malaria. Artemisinin was discovered from the bark 
extract  of Artemisia annua, traditionally used in Chinese traditional medicine.  It is a complex 
sesquiterpene lactone with a peroxide bridge structure as shown in fig 1.10  below. 
 
 
Fig 1.10: Chemical structure of artemisinin: Showing the complex structure or artemisinin. 
The complex structure of artemisinin has proved difficult to synthesise. Recently the drug 
precursor has been produced from chemically engineered yeast. The precursor, artemisinic 
acid, is then transported out, purified and chemically converted to artemisinin (Ro et al., 
2006). This route is still not commercially viable. Various artemisinin derivatives have been 
produced by modifying its original structure as represented in fig 1.10, forming a very 
important class of antimalarial drugs, currently the most widely used for the disease. These 
include artesunate and artemether which are prodrugs. The biologically active metabolite is 
dihydroartemisin. Artemisinins work thoughout the erythocytic asexual parasite cycle and kill 
parasites in all stages including young gametocytes (Olliaro, 2001). The exact mechanism of 
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action is still unknown although there are various proposed theories for its mechanism of 
action. Artemisinin derivatives are hypothesized to interact with Fe-II species in the parasite’s 
food vacuole, and early ring stage parasites combat this by slowing down hemoglobin 
digestion. Artemisinins are fast acting and very potent against blood-stage parasites and show 
activity against early sexual stages of the parasite, which is important for blocking 
transmission. .  Structure activity relationship studies show that the peroxidic oxygen is 
important for its activity (Avery et al., 1993). The most widely accepted hypothesis is that 
ferrohaem ferrous-protoporphyrin IX (Fe(II)PPIX) cleaves the intact peroxide in a reductive 
reaction generating radicals which in turn alkylate biomolecules leading to parasite death 
(Olliaro, 2001). Their major limitation is a short half-life, which is why they are partnered 
with longer lasting drugs. 
 
1.8.3 Antibiotics 
These include doxycycline, clindamycin and tetracycline. 
ANTIBIOTIC                                              USE 
Tetracycline Tetracyclines are used as an alternative to clindamycin in 
children. 
Doxycycline Doxycycline is a tetracycline derivative from 
oxytetracycline. It is a cheap drug and it is bacteriostatic. It 
is primarily used in combination with quinine for the 
treatment of complicated P. falciparum infections or as a 
prophylactic agent. 
Clindamycin Clindamycin is a blood schizonticide and is used in 
combination with quinine for the treatment of acute P. 
falciparum malaria. It is however contraindicated in 
children due to toxicity 
 
Table 1.2: Antibiotics used for malaria: Showing different antibiotics and their usage as 
antimalarials 
1.8.4 Antifolates 
Antimalarial antifolates have been central for prophylaxis and treatment of malaria for 
decades. Since their discovery in the 1940’s during the Second World War, no new 
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antimalarial antifolates have been developed that have reached Phase I/II stages. Limited 
work has been carried out to exploit the inhibition of the malaria folate pathway as a target 
for new drugs. The understanding of the role of folate in man led to the identification and 
development of current antifolates as therapeutic drugs. One of the major drawbacks of 
antifolate compounds is their implication in anaemia complications. Much of the work on 
antifolates was done before the World War II.  By the 1930s, evidence showed that some 
forms of anaemia, mainly megaloblastic anaemia, could be reversed by the addition of yeast 
or liver extract, leading to the hypothesis that a specific co-factor may be associated with 
anaemia. In 1941, the co-factor was identified in spinach leaves and named folic acid 
(Mitchell et al., 1941). The name was derived the word ‘folium’ which is latin for leaf. Folic 
acid was subsequently found to be effective in the treatment of anaemia. Folic acid is 
composed of a pteridine ring, para-aminobenzoic acid (pABA) and glutamate; the 
compound is also called pteroyl glutamic acid (PGA). Soon after its synthesis, several 
reports demonstrated that it is not a naturally occurring folate. Its primary function in the 
body is as a co-factor to various methyltransferases involved in serine, methionine, 
thymidine and purine biosynthesis. 
Antifolates drugs work by antagonising the actions of folic acid (vitamin B9). Folate co-
factors are essential for the synthesis and metabolism of amino acids, consequently 
antifolates inhibit cell division, DNA/RNA synthesis and repair and protein synthesis 
(Hyde, 2005; Hyde 2007). Some such as proguanil, pyrimethamine and trimethoprim 
selectively inhibit folate's actions in microbial organisms such as bacteria, protozoa and 
fungi (Nzila et al., 2005) 
Antifolate agents used in the treatment of malarial infection are sub-divided into two classes: 
inhibitors of dihydropteroate synthase (DHPS), known as class I antifolates and inhibitors 
of dihydrofolate reductase (DHFR), the class II antifolates. DHFR catalyses the reduction 
of dihydrofolate to tetrahydrofolate, a very important pathway in most living cells. DHFR 
is a very interesting target for antifolates from a pharmacological point of view due to its  
selectivity for the parasite enzyme, binding with a greater affinity than for human enzyme. 
Although both class I and class II antifolates target the folate pathway, they have been used 
in combination for malaria therapy. The combination has shown a synergistic activity in 
antimalarial therapy (Gregson and Plowe, 2005).  
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1.8.4.1 Inhibitors of DHFR  
These mediate their antimalarial activity by inhibiting the enzyme DHFR. They have a 
higher affinity for binding the P. falciparum DHFR than human type. Differences in their 
binding affinity account for their good therapeutic index. However, a report indicated that 
the malaria parasite and its host differ fundamentally in the way that translation of DHFR-
TS is regulated, such that the parasite enzyme is less readily replenished when targeted by 
anti-DHFR inhibitors (Zgang et al., 2002). Studies by Nirmalan et al., 2002  however did 
not support these findings. Their study found that malaria parasites treated with DHFR or 
thymidalate synthetase (TS) inhibitors resulted in a seven fold increase DHFR-TS levels. 
The results are not as expected based on the results of previous RNA-protein binding 
experiments have shown enzyme levels to remain contant in drug treated parasites. In 
addition, the increase in enzyme levels could not be attributed to an increase in mRNA as 
the levels remained constant before and after treatment (Nirmalan et al., 2002; Nirmalan et 
al., 2004). 
i) Proguanil 
Proguanil was discovered during the Second World War as a result of a British research 
programme on antimalarials. The drug was found to be more active than quinine against the 
avian specie of the disease and further research prompted its use in humans. Studies have 
demonstrated that proguanil is a prodrug and metabolizes to its triazine form 
chlorcycloguanil, an inhibitor of the parasite DHFR (Crowther et al., 1953). This drug has 
been used alone as a prophylactic agent against malaria or in combination with chloroquine 
although its effectivity was not established in regions such as New Papua Guinea 
(Henderson et al., 1986).  Proguanil is also used in combination with  atovaquone, an 
inhibitor of the electron-transport system, targeting a cytochome P450 enzyme isoform.  The 
combination is synergistic (Indresh et al., 1999).  Though proguanil can be converted in vivo 
into cycloguanil, an inhibitor of DHFR, proguanil and atovaquone are the active agents and 
the mechanism of synergy between these drugs is not well understood. The potency of 
proguanil led to the search for its analogues. Studies on the analogues demonstrated that 
chlorination of the phenyl ring and increasing the link between the phenyl ring and the 
diaminopyrimidine ring, increase the potency of these class of antifolates. These studies led 
to the discovery of chlorproguanil, clociguanil amongst others (Alexis, 2006). 
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ii)Pyrimethamine 
Pyrimethamine belongs to the 2,4-diaminopyrimidine derivative family. They were 
synthesized in the 1940s as folic acid analogues for the treatment of tumours. Falco et al., 
1951 observed the similarity in their structures with proguanil. This sparked an interest in 
them as antimalarials. The screening of their antimalarial activity led to the identification of 
pyrimethamine. This has been the most widely used antimalarial antifolate agent so far. It 
is used in combination with sulfadoxine or sulfalene, and to a lesser extent it has been used 
in monotherapy under the trade name, Daraprim®. This drug is widely used as an 
antimalarial prophylactic agent in sub-Saharan Africa.  
1.8.4.2 DHPS inhibitors  
DHPS inhibitors are sulfadrugs which block the de novo folate synthesis pathway of the 
malaria parasite. These sulfadrugs belong to two families: sulphonamide and sulphone. 
Attempts to use sulfadrugs as monotherapy for malaria have not been very successful. The 
low efficacy and high toxicity of these drugs have discouraged their use. Interest in DHPS 
inhibitors resurfaced when they were discovered to act synergistically with DHFR inhibitors 
which triggered their use in combination therapy. Among the available DHPS inhibitors for 
malaria, dapsone is the most potent.  Dapsone was used in combination with pyrimethamine 
as Maloprim®,  now widely used in combination with chlorproguanil for the treatment of 
malaria. It is commercially available as lapdap. 
1.8.4.3 Pyrimethamine and sulfadrug combinations 
Pyrimethamine is a long acting drug and has been combined with several sulfadrugs 
including sulfadiazine, sulfametopyrazine, sulfamethoxine, sulfadimethoxine, 
sulfaphenazole and sulfasoxazole (McGregor et al., 1963; Hurly et al., 1959). None of these 
combinations have  been developed further as antimalarial agents. Instead, pyrimethamine 
was combined with sulfadoxine (Fansidar®), and combined with sulfalene (Metakelfin®). 
These two sulfadrugs have a long elimination profile, like pyrimethamine, with half-lives  
of over 80 h (Watkins et al., 1993). The combination of pyrimethamine with the short 
actiong dapsone (Maloprim®) has shown a low effcicacy.  The half-life of dapsone is around 
24h (Winstanley et al., 1997) . 
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1.8.4.4 Trimethoprim and sulfadrugs 
Trimethoprim is a DHFR inhibitor and although a known antibacterial, it was combined 
with sulfadrugs for the treatment of malaria. Trimethoprim was combined with 
sulfamethoxazole (this is the antibacterial combination known as Septrim® or Bactrim®, 
co-trimoxazole), sulfalene and sulfametopyrazine (Peters et al., 1987). The use of 
trimethoprim did not present any advantage over pyrimethamine, so the drug combination 
was abandoned as an antimalarial. Clinical studies have demonstrated that this drug remains 
efficacious against P. falciparum infections in areas where resistance to the combination 
pyrimethamine/sulfadoxine is still low (Thera et al., 2005).  
In general antifolate combinations drugs are used both for treatment and prophylaxis of 
uncomplicated malaria as artemisinin combination therapy is the first line treatment for the 
disease. 
1.8.5 New drugs 
Several drugs fall into this classification, the most important of which is atovaquone. 
Atovaquone is used both for prophylaxis and treatment of malaria infections and also used 
in combination with proguanil. The exact mechanism of action is unknown but it is thought 
to interfere with parasite mitochondrial function. Resistance develops rapidly when used as 
a monotherapy but it is highly efficient when used as a combination. The main draw back 
for atovaquone is its high cost, hence not accessible to the poor countries where malaria is 
most endemic. 
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Fig 1.11: Antimalarial targets:  Showing the various drug targets for antimalarials. Source: 
Greenwood et al., 2008. 
1.9 Antimalarial drug resistance 
Antimalarial drug resistance is often referred to when an antimalarial drug shows reduced 
or no efficacy in patients or during tests. This often leads to an increase in the half maximal 
effective concentration of the drug (EC50). This is the concentration of the drug required to 
produce half of the maximal effect of the drug. The result is a shift in the dose response 
curve as depicted in fig 1.12 below. 
 
 
Fig 1.12: Effect of drug resistanace on a dose-response curve: Showing the effect of drug 
resistance on a typical dose-response. Increasing resistance leads to a rightward shift. 
Hence  a  higher dose is required  to achieve the desired EC50. (Source: White, 2004). 
Several methods can be used to investigate drug resistance, including in vivo and in vitro 
tests; animal model studies and molecular characterization. In many cases, these tests are 
not used and presumptive treatment is the rule. Detection of treatment failure is also 
presumptive and this can be misleading as many symptoms of malaria are non-specific and 
can be experienced in other diseases. Re-occurrence of symptoms are often thought to be 
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due to malaria treatment failure although other factors could be attributed to it (Marsh et al., 
1998). 
1.9.1 Background to antimalarial resistance 
The wide spread use and misuse of chloroquine and other antimalarials have stemmed the 
emergence of parasite strains that are resistant to drug treatment. Parasites have currently 
shown resistance to almost all drugs in use. This is a colossal public health concern as all 
efforts to fight the disease are crippled (Marsh, 1998). Furthermore, resistance to other 
frontline antimalarials is on the increase, which compromises the effort for the fight against 
the deadly disease (Von seidlein and Greenwood, 2003). Geographical locations may impact 
on the development of resistance. Drug resistance has also been implicated in the spread of 
the disease to other regions and re-emergence of the parasites in areas where the disease has 
previously been eradicated.  P. falciparum resistance to chloroquine first emerged from 
South East Asia in the 1950’s and the resistance spread to other parts of Asia and eventually 
Africa within a span of thirty years (Hastings et al., 2000). Other important antimalarials 
that were discovered after chloroquine such as fansidar (pyrimethamine-sulfadoxine) 
showed an even worse trend with resistance spreading even more rapidly from the South 
East Asian region to Africa (Black et al., 1981). Mefloquine, another antimalarial that was 
introduced showed resistance very quickly within five years of its introduction and this 
resistance first emerged in Thailand, Cambodia and Vietnam (SE Asia) probably owing to 
their wide usage. Due to the high resistance of these drugs especially for P. falciparum 
malaria, they are no longer used for the treatment of complicated P. falciparum malaria 
(Wernsdorfer et al., 1994). 
Chloroquine is  still the drug of choice for P. vivax although its efficacy is declining in 
endemic regions with few resistant strains recorded 30years after chloroquine resistance to 
P. falciparum emerged (Rieckman et al., 1989). Recent reports indicate resistance to the 
current frontline treatment, artemisinin. Two confirmed foci for the resistance are the Thai-
Cambodian and the Thai-Myanmar borders. Studies have shown changes in parasite 
clearance half lives in patients over a span of 10 years. Patients have shown an increased 
parasite clearance half –life. In 2001, reports showed a clearance half- life of 2.6 h whilst in 
2010, a clearance half-life of 3.7 h was recorded. The studies also showed an increased 
proportion of parasites with slow clearance (Phyto et al., 2010). A supportive study by 
Cheeseman et al.,  2012 also demonstrated this by mapping single-letter DNA differences 
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among 91 parasites. The team found evidence of recent strong selection most likely due to 
evolutionary pressure to evolve drug resistance in 33 regions of the P. falciparum genome. 
The researchers further looked for associations between each of these genomic regions and 
clearance rates, using an archive of blood samples taken from Thai malaria patients between 
2001 and 2010. Less than 5% of the parasites from 2001 showed slow clearance rates but  
by 2010, more than 50% did. The study further showed that variations at two adjacent areas 
on chomosome 13 of the parasite genome were strongly associated with drug resistance. 
The researchers estimate that this region accounts for at least one-third of the heritable 
variation in clearance rates. The exact mechanism is however yet to be understood.  
The issue of resistance is a great public health concern and hinders the global efforts for the 
fight against the disease thast poses a huge theat to the lives of many. There are no reports 
of its spread to Africa yet, where the huge burden of the disease lies  but it will only be a 
matter of time if it is not controlled. 
 
Drug Introduction Year resistance 
reported 
Difference (years) 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulfadoxine-
pyrimethamine 
1967 1967 <1 
Mefloquine 1977 1982 5 
Atovaquone 1996 1996 <1 
Artemisinins 1971 2006? 35 
 
Table 1.3: Drug resistance development: Showing the development of resistance for P. 
falciparum over the decades. (Source: Wongsrichanalai et al., 2002). 
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1.9.2 Mechanisms of resistance 
 Antimalarial drug resistance may develop via different mechanisms. Biochemical 
mechanisms of resistance have been well defined for chloroquine, antifolates and 
atovaquone. Molecular markers for P. falciparum resistance for these drugs are available.  
I. Chloroquine: This drug normally exerts its antimalarial activity by accumulating in the 
parasite food vacuole inhibiting the bio-crystallization of the toxic haem to haemazoin. 
Resistance occurs when the parasite develops an increased capacity to expel chloroquine 
via the efflux pump at a rate that is 40 to 50 times faster in resistant strains than in normal 
strains. This effect will hence not allow the drug to reach therapeutic levels required to 
cause inhibition (Folay et al., 1997). Proton pump inhibitors such as verapamil have been 
shown to reverse chloroquine resistance (Martin et al., 1987). 
II. Antifolates: Resistance arises due to a mutation in the parasite genome leading to a 
reduced sensitivity to the given drug. For some drugs, it only takes a single mutation for 
the parasite to develop resistance to the drug whilst others require multiple mutations. In 
this circumstance, drug pressure will kill the susceptible population leaving the parasites 
with the advantageous mutated gene, in this case the resistant ones. The resistant parasites 
will multiply leading to a new generation of resistant strains. Antifolate drug resistance is 
mediated via this mechanism. Gene mutations encoding for resistance to both 
dihydrofolate reductase and dihydropteroate reductase, (the two enzymes that are inhibited 
by antifolates) occurs. Several combinations of mutations may occur in these enzymes 
leading to varying degrees of resistance to antifolate drugs (Plowe et al., 1998). 
III. Atovaquone: Atovaquone normally exerts its antimalarial activity though the electron 
transport chain. Resistance arises due to a single point mutation in the cytochome b gene 
which is involved in the electron transport chain. Atovaquone resistance occurs very 
rapidly when the drug is used as monotherapy (Korsinczky et al., 2000). Resistance can 
be slowed by using the drug in combination with proguanil (malarone) or in combination 
with tetracycline. 
IV. Sulphadoxine/pyrimethamine resistance: Specific gene mutations encoding for the DHPS 
and DHFR enzymes have been identified. The enzymes from resistant strains bind to 
pyrimethamine with less affinity (400-800 fold) than to enzymes of drug sensitive strains. 
DHFR mutations appear to be more important in causing treatment failure than DHPS 
mutations (Gatton et al., 2004) 
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Some malaria strains are resistant to multiple drugs. Multi drug resistance refers to strains 
resistant to chloroquine, mefloquine and pyrimethamine sulfadoxine combination.  This has 
been documented worldwide and is attributed to mutations in a specific gene loci (Reed et al., 
2000). In Thailand, P. falciparum is highly resistant to chloroquine, pyrimethamine + 
sulfadoxine combination as well as quinine. In Sudan, a high percentage of different 
chloroquine resistant isolates of P. falciparum parasites have been shown to be resistant to 
more than one drug (Elbashir et al., 2008). 
1.9.3 Factors contributing to resistance 
Several factors have contributed to the development of resistance. These include parasite 
biology, treatment failure and pharmacokinetics. 
I. Treatment failure: One important point to note is that treatment failure does not necessarily 
mean resistance but could be a contributing factor to resistance. Treatment failure could 
arise due to several factors including incorrect dosing, drug interactions, misdiagnosis, 
patient compliance, poor drug adsorption. 
II. Parasite biology: This is an outcome of natural selection. Increased drug pressure leads to 
an expected Darwian biological phenomenon of ‘survival of the fittest’. In any large 
population, a few strains will have the ability to overcome potential noxious stimuli, in this 
case the ability to overcome antimalarial drug treatment. Antimalarial drugs hence kill the 
susceptible strains leaving those with the advantageous traits. Susceptible strains can also 
acquire resistance though mutations, accepting resistant genes from nearby organisms 
leading to cross resistance. Furthermore, effective antimalarial treatment is thought to clear 
majority of parasites in the blood stream leaving a few residuum parasites. These residuum 
parasites get cleared by the immune system. In an immune person, the clearance is in a 
specific way while in the non- immune person, it is in a non-specific manner. Similarly, in 
the immunocompromised person or children, residuum parasite clearance also occurs in a 
non-specific manner as the immune system is weak. This non-specific clearance of residuum 
parasites is an important factor in the development of resistance. Because the non -specific 
clearance of the parasites by the immune system is not as effective as the  specific clearance 
of the parasites, immunocompromised patients and children might have some of these 
residuum parasites uncleared. Overtime, the remaining parasites multiply and grow and 
because they have previously been exposed to drug treatment, they might have conferred 
the advantageous resistant gene leading to resistance (Wernsdorfer et al., 1991). 
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III. Pharmacokinetics: Different pharmacokinetic issues may be a contributing factor in the 
conferment of resistance. Normally in antimalarial chemotherapy, drugs with long half-life 
are often preferred over those with a short half-life. This allows for a simpler dose regimen 
thereby increasing patient compliance. Although this may seem an advantage on one hand, 
it is also a disadvantage on the other. A drug with a long half-life has a longer elimination 
period and this could increase the chances of the development of resistance. Drug 
combinations are often designed based on mechanism of action profiles of individual drugs. 
The main flaw with these strategies is pharmacokinetic profiles are not often taken into 
consideration in combination therapy. In the case of the combination of pyrimethamine + 
sulfadoxine, pyrimethamine has a half-life of 80-100 h while sulfadoxine on the has a half-
life of 100 to 200 h. This means that pyrimethamine clears long before sulfadoxine, leaving 
the sulfadoxine acting alone without the synergistic effect that occurs with the drug 
combination (Watkins et al., 1993). In Thailand, combinations of mefloquine with 
pyrimethamine+sulfadoxine are sometimes used. This situation is even worse than the 
example previously described as mefloquine on its own has a half-life of 336-432 h. This 
means that in that combination regimen, mefloquine is left to act alone for over 200 h after 
pyrimethamine + sulfadoxine have cleared (Palmet et al., 1993). 
IV. Drug administration: Dose regimens are based on age rather than weight hence another 
important pharmacokinetic factor that contributes to emergence of resistance. Children in 
particular, often have different weights and the assumption that children fall into certain 
weight ranges according to age groups is not always the case. This might lead to a situation 
of over dosing or under dosing.  
V. Drug pressure: This might be one of the biggest contributing factors for the development 
of resistance. Several programs involve mass drug administration and these have a great 
impact on parasite resistance (Wernsdorfer, 1994). Resistance has been shown to be higher 
in regions with higher accessibility to antimalarials such as urban areas than in regions with 
less or no accessibility to antimalarials such as rural areas (Ettling et al., 1995). 
VI. Counterfeit drugs: Substandard and counterfeit drugs contribute enormously to drug 
resistance. WHO estimates that 60% of counterfeit drugs do not have any active 
ingredients,17% contain too much or too little and the remaining 16% contain the wrong 
active ingredients ((WHO, 2003). The WHO further estimated that nearly half of the global 
pharmaceutical market  is occupied by counterfeit drugs (WHO, 2006). As parasites are 
exposed to subminimal doses, this will lead to resistance. 
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1.10 Combination therapy 
The WHO treatment guidelines (2015, report) are based on updated treatment 
recommendations based on new evidence as well treatment regimens that can be used to 
prevent  malaria in high risk groups. The rational use of antimalarials is very important and 
highly recommended. It is advocated that treatment should be given to confirmed cases and 
drugs should be used in combination to prevent or delay the development of resistance. The 
guidelines also recommend appropriate weight based dosing to improve the chances of 
curing the disease in affected individuals. Various treatment regimens are currently 
available. Uncomplicated malaria treatment regimen includes a combination of two or more 
unrelated drugs with one preferably being an artemisinin derivative. The artemisinins are 
highly efficacious and act rapidly. They have been shown to act on all parasite 
developmental stages including reducing gametocytogenesis (Price et al., 1996).  
Combinations currently prescribed can be categorized into three: 
i) WHO recommended artemisinin based combinations 
ii) Non artemisinin and quinine based combinations 
iii) Other combinations 
Examples of combination regimens include Artemether-lumefantrine(Coartem) and 
amodiaquine-artesunate (Coarsucam). These are the most widely used combinations, 
whereas dihydroartemisinin-piperaquine (Euartesim) and artesunate-pyronaridine 
(Pyramax) are the most recently approved combinations (Anthony et al., 2012). 
Several re-formulations with doses specific for children and pregnant women are in clinical 
trials. Chloroquine, a 4-aminoquinoline, is still the recommended treatment for P. vivax 
infections because resistance has not fully developed in contrast to P. falciparum. In 
areas where chloroquine resistant P. vivax is endemic, artemisinin combination therapies 
are recommended as first-line treatment (except artesunate and sulfadoxinepyrimethamine, 
which is ineffective owing to resistance), in particular those with partner 
drugs with long half-lives (e.g. dihydroartemisinin and piperaquine and artesunate and 
amodiaquine). In all cases, a 15-day course of primaquine is required to prevent relapse 
and provide a radical cure. 
For travelers visiting areas with endemic malaria transmission, the CDC recommends 
atovaquone-proguanil (Malarone), choloroquine, doxycycline or mefloquine, with 
specific recommendations depending on individual and regional factors. 
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ARTEMISININ-BASED NON-ARTEMISININ BASED OTHERS 
Artemether-
Lumefantrine 
   Sulfadoxine-pyrimethamine  
(SP) 
 Piperaquine-
dihydroartemisinin-
trimethoprim 
        Artesunate  + 
Amodiaquine 
          SP + Chloroquine    Pyronardine + Artesunate 
     Artesunate + 
Mefloquine 
     SP + Amodiaquine Chlorproguanil-Dapsone + 
Artesunate. 
       Artesunate + 
sulfadoxine-
pyrimethamine 
       SP + Mefloquine  
 Dihydroartemisinin + 
Piperaquine 
  Tetracycline or doxycycline + 
Quinine 
 
  
Table 1.4: Antimalarial drug combinations: Showing WHO recommended antimalarial 
drug combinations. The combinations are classified into three: artemisinin based 
antimalarial combinations; the non artemisinin based combinations and other 
combinations. 
1.11 Drug discovery process 
Developing a new drug from original idea to the launch of a finished product is a complex 
process which can take 12-15 years and may cost in excess of $1 billion. The high cost 
associated with drug discovery process is attributed to several factors, one of which is the 
fact that for every 5000 to 10000 compounds that enters the research and development (R 
& D) process, only one gets to the market. This high attrition rate makes the process very 
time consuming and expensive. The idea for a target usually comes from different 
institutions including academic, commercial or clinical research sectors. 
There is an urgent need to develop new antimalarial drugs that can target the blood stages 
of the disease to alleviate sympoms; the liver stages to prevent relapses and vaccines to 
prevent the disease. Currently, there is a robust drug discovery strategy for the blood stages 
but efforts towards the liver and transmission stages are still in their infancy. Targeting these 
stages could be instrumental in eradicating the disease. New drugs must meet several 
stringent criteria to meet the current requirements for new antimalarials. They must be fast 
acting in order to prevent the disease from progressing quickly, safe for children and 
pregnant women and ideally a single dose regimen to improve compliance. The high cost 
associated to R & D of new drugs is perhaps the reason why pharmaceutical companies have 
not found it economically viable to heavily invests in diseases such as malaria, which mainly 
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affect the poor. Recent interest in the development of new antimalarials has been revived 
however, by NGO’s such as the Bill and Melinda Gates Foundation. 
 
 
 
Fig 1.13: Research and development process: Schematic representation of the R & D 
process with time span, cost and the different stages involved to develop a new drug. 
(Source:Ttrends in drug discovery and pharmaceutical research, 2002). 
1.12 Approach to drug discovery 
The main stakeholders in drug development are pharmaceutical companies and academic 
institutes. Different approaches are used for the development of new drugs which include 
rational drug design and random screening. 
The recent availability of the genome for humans, P. falciparum and Anopheles gambiae 
has steered in an exciting new era for malaria research. Furthermore, fundamental 
knowledge and bioinformatics has strengthened the basic tools required for functional 
genomics studies to be developed further. We are now at an era where there is a huge variety 
of options and different research areas for malariologist all of which are important and 
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provide a knowledge which can all be streamlined towards a final goal of achieving malaria 
eradication. 
1.12.1 Random screening of compounds 
This involves the screening of a large library of compounds against a certain disease using 
different assays. High thoughput screening (HTS) is often used with this approach. HTS is 
is often used as a starting point in the drug discovery process to screen large libraries of 
compounds against a disease using automated equipment and software. Most drugs that are 
in use today have been identified from random screening of large libraries. Compounds in 
the library can be either chemically synthesized products or natural product-based 
compounds. Historically, the mainstay for lead identification has been natural products 
which will be discussed next. 
1.12.2: Rational drug design 
The main goal of this approach is drug target identification. This usually arises from 
thorough understanding of the pathology and mechanisms of disease. The sequencing of the 
malaria parasite genome has allowed for systematic analysis of different target proteins. 
More recently in the past decade or so, the main focus of drug design has been target 
oriented. ‘Druggable genes’ identified in parasites have been aided in the identification of 
various target proteins within the parasite. Compounds have been designed using different 
computer aided drug design systems to fit the identified targets, which are subsequently 
tested. The knowledge of the metabolic pathways involved in the disease aids in the design 
of these highly specific molecules. These usually involve proteins or genes. The main 
method for protein structure determination is X-ray crystallography. X-ray crystallography 
determines the structure of a protein by passing a beam of X-rays to the crystal molecule of 
the protein which causes diffraction of the beams in different directions. The 3D structure 
is determined based on the angles and directions of the generated beams. The protein is 
designed to fit the identified target. Although a very novel approach, it is time consuming, 
costly and some proteins simply fail to crystallize. As a result, the main hitch with this model 
so far, is a very high attrition rate. Although several targets have been identified though 
organisations like the Medicine for Malaria Venture (MMV). They have a portfolio of 
compounds designed to fit targets. Some of these molecules have not being able to go into 
clinical trials due to toxicity issues (Aguero et al., 2008) that were not addressed at the point 
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of molecule design. So far, most of the identified hits have proved inefficient as drugs, 
having little or no effect on actual parasites. 
 
Fig 1.14: Rational drug design: Showing the rational route to drug design. New 
molecules are designed  based on knowledge of biological drug target. (Source: 
http://www.wiley.com/college/pratt/0471393878/instructor/activities/proteomics/index.htm
l) 
1.13 Natural products as a route to drug discovery  
Primitive man observed and appreciated the great diversity of plants available to him. Man’s 
observation of wild animals though his own trial and error led to much of the development 
of medicinal plant usage today.  Before the era of writing, the knowledge of plant medicine 
was passed on from generation to generation by word of mouth. Documentary evidence for 
the use of plant medicine can be traced back to about 4000 years where some writings were 
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found in a clay tablet in the Sumerian culture. The Egyptians have records of several 
remedies for different ailments which date back to 3000 years. In India, herbal medicine has 
played an important role in the health care system. This dates back to the collection of Hindu 
sacred verses. This practice is called Ayurveda which involves a complete lifestyle 
including medicine, philosophy, health, medicine, exercise regimens and diet. Currently, it 
may seem that the mainstay provider is modern medicine but the WHO estimates that up to 
4 billion people which is about 80% of the world’s population, use herbal or alternative 
medicine at some point in their life. WHO records also show that 74% of natural product 
derived medicines used in modern medicine are actually used for the same reasons 
traditional medicine healers used them for. Furthermore, industrialised nations are 
increasing the use of natural products example in naturopathy.  The main downside is that 
most of the herbs that are being used have not been scientifically validated nor evaluated in 
clinical trials.  With about 75% of the world’s population dependent on medicinal plants 
and no access to modern healthcare system, it is becoming increasingly important to 
evaluate natural products. Modern medicines are not affordable or available for the vast 
majority of the world’s population with 75% of the population in third world countries living 
under less than $2 a day and over 270million children having no access to healthcare (Global 
monitoring report, 2015). The pharmaceutical industry today is facing huge challenges in 
terms of cost and it is proving inefficient due to the amount of time it takes for one drug to 
be available in the market. The average cost and time of discovering and developing a new 
drug into the market is consistently increasing and there is no corresponding increase in 
safer and better drugs. Furthermore, the number of new molecular/chemical entities 
produced per company have declined and so has the number of approvals for new drugs. In 
1996, there were 53 approvals and only 23 in 2010 (FDA). There is a huge challenge today 
for pharmaceutical companies to grow and sustainability is becoming an issue which has 
given rise to several mergers and acquisitions within the industry. The cost of R & D has 
rised from $2 billion USD in 1980 to $40 billion USD in 2007 with no correlation between 
the rising cost and new drugs in the market. Also below are some details of how much cost 
has risen per approved new drug. 
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Fig 1.15 New molecular entities (NME) in  research and development: Showing NME’s 
per year versus total R&D spend in Billions of Dollars. The number of NMEs per year was 
trending upward to 1996 but now in recent years, the number appears to be going 
down.  Increased R&D spending has not helped.  The R&D spend appears to be out of 
control. (Source: http://www.discoverymanagementsolutions.com/wp-
content/uploads/2011/09/Figure-1-for-NME-doc.png). 
It is evident that the cost of R & D are exploding hence it is only strategic for other models 
to be adopted.  Approaches based on natural product-based drug discovery such as 
ethnopharmacology and traditional and complementary medicine are re-emerging as 
attractive options. Drug discovery need not be confined to molecular entities. Rationally 
designed, carefully standardized, synergistic traditional herbal formulations and botanical 
drug products with robust scientific evidence can offer more informed and hopefully safer 
alternatives in the form of phytopharmaceutical drugss, for example. Due to this concern, 
WHO initiated the  Traditional Medicine Programme (TMP) in some member states. The 
programme evaluates the traditional medicine systems and practices of different regions to 
ascertain and establish the basis for the use of different plants separating superstitions and 
harmful practice from useful real science, hence establishing a dosing system for good 
prescription services. Moreover, the WHO commission on intellectual property and 
innovation in public health  also duly recognised the promise and role of traditional medicine 
in drug development for affordable healthcare solutions. TMP has been defined as sum total 
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of knowledge, skills and practices based on theories, beliefs and experiences indigenous to 
different cultures used in the maintainance of health as well as in the diagnosis, prevention 
and treatment of physical and mental health (WHO Traditional Medicine report, 2005). 
The Republic of China has successfully achieved incorporating traditional medicine in their 
healthcare system. Traditional practices including acupuncture and herbs together with 
modern diagnostic techniques form the basis of their health care system further boosting the 
economy.  Several herbal plantations for the purpose of medicinal plant cultivation have 
provided various job opportunities.  
In India and Africa, traditional medicines although very common, have remained separate 
from the healthcare system offered by the government despite ayurvedic medicine 
commonly practised in India. Herbal medicine is becoming increasingly common in Europe 
and it is dispensed in different forms from essential oils, capsules to tinctures. In the United 
States, more than 1/3rd of the adult population use complementary and alternative medicine 
(Complementary and Alternative Medicine press release, 2004). In another survey 18.9% 
of adults were shown to use some form of alternative medicine (National centre for 
Complementary Medicine). Several trials have been funded by the National Institute of 
Health (NIH) to investigate the effectiveness of some herbal medicines. 
The World market for herbal Medicine is about $40 billion USD. In Brazil alone, it is 
estimated to be around $1billion USD. Data from WHO shows that more than half the world 
population makes use of some form of medicinal herb in searching for relief from various 
ailments. About 30% of these medicines are provided by medical prescription (WHO, 
1978). 
1.13.1 Historical importance of natural product as antimalarials 
Medicinal plants have played an important role in the fight against malaria. Based on the 
historic high success rate of natural products as a source of medicine with several examples 
of antimalarials that have been derived from natural products, there is a need to revert to use 
of natural products as a source for lead identification in malaria drug discovery.  Hence by 
choosing natural products as lead compounds, the time used to understand disease, identify 
targets, design leads to fit the targets and test the leads in ‘rational drug design’ can be cut 
by simply testing the natural product compound in different biological assays. Furthermore, 
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the lead identification process can be guided by the ethnopharmacological usage of the plant 
which is more likely to generate a hit than random selection.  
The first effective antimalarial known to man was a natural product from the bark of 
‘Chinchona’ plant, which is what we now know today as quinine. 
1.13.2 Discovery of quinine 
The tree grows on the slopes of the Andes in Peru (South America). It was mainly used by 
the natives as a tincture. It has been referred to as ‘Jesuits bark’, ‘cardinal's bark’, and ‘sacred 
bark’. The name sprang of its usage by the missionaries in the Andes in the 1630’s. A legend 
suggests earlier use by the native population. According to the legend, an Indian with a high 
fever was lost in an Andean jungle. When he drank from a pool of stagnant (standing) water, 
he found it tasted bitter. Realizing it had been contaminated by the surrounding quina-quina 
trees he thought he was poisoned. But his fever abated, and thereafter his village used 
extracts made from quina-quina bark to treat fevers. Another legend of quinine is that of the 
countess of Cinchon who visted Peru and fell ill and her fever was cured by this tree bark. 
The use of the plant as a fever cure was rapidly accepted (Kaufman and Ruveda, 2005). The 
tree was named ‘Cinchona’ in 1742 by a Swedish botanist Carol Linnaeus (1707-1778) in 
honour of the Countess of Chinchon. In 1820, Cinchona and quinine were isolated as 
alkaloids from the powdered fever tree bark by Pierre Joseph Pelletier  (Kyle et al., 1974). 
By 1834, a German Physician, Carl Warburg, had used a concoction of different herbs to 
make an antipyretic tincture called ‘Warburg’s tincture’. The tincture contained quinine, 
amongst other herbs. This tincture gained a huge international recognition at the time. The 
British government supplied this tincture to its troops in India and other colonies (Maclean, 
1875).  
In the early part of the 20th century, Java (current Indonesia) was the main producer of the  
naturally produced quinine. The events of World War I, led Germany to have no supply of 
quinine and hence they developed a synthetic substitute, Atabrine. During World War II 
when America joined, the quinine plantations in Java were controlled by Japan. American 
Soldiers fighting in North Africa were badly affected by malaria and pills obtained from 
captured Italian soldiers were sent to the United states and discovered to be chloroquine also 
manufactured by Germany. The United States produced its own supply by the end of the 
war. By 1934, Hans Andersag and co-workers synthesized chloroquine which was named 
resochin. This compound did not gain popularity due to its toxicity. The drug however, went 
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into clinical trials for malaria in World War II and was considered as an official antimalarial 
drug in 1946 naming it chloroquine. The correct chemical structure was not confirmed until 
1944 by the American chemists, Robert Burns Woodward and William Von Eggers 
Doering. Woodward won a Nobel prize. Quinine was used successfully  until resistance 
developed after its synthesis (Kyle et al., 1974). Several other natural product-derived drugs 
are in use today as antimalarials, one of the most recent examples being the development of 
artemisinin from the plant Artemisia annua. 
1.13.3 Artemisia annua. 
 
Fig 1.16 Artemisia annua plant 
The plant has a long history of use in Chinese traditional medicine for haemorrhoids since 
168BCE. By the 4th century, Ge Hong recommended its use for intermittent fevers (Wright 
et al., 2010). Although quinine has been established as an antimalarial earlier, artemisinins 
have a longer history of being used as ‘fever cures’. Artemisinins were discovered as 
antimalarials in 1971 when the Chinese Army embarked on a project to screen several plants 
against malaria. Over 2000 plants were screened and qinghao was found to be active against 
Plasmodium berghei in mice by a Chinese pharmacologist Tu Youyou. She later isolated 
artemisinin from the extract (Qinghaosu and C-ORGO, 1979). The compound went though 
further research and clinical trials and the findings of this pharmacologist were presented at 
the United Nations meeting in 1981 which led to the development of artemisinin. 
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1.13.4 Other natural product derived antimalarials 
Tetracycline, a natural product-derived compound was discovered in the 1940’s. In 1970, 
the Walter Reed research foundation discovered mefloquine and halofantrine as result of a 
random screen of over 300,000 compounds.  
1.13.5 Classes of natural product compounds with antimalarial activity 
In the previous years, there has been an immense research on natural products for 
antimalarial activity which has led to the identification of several classes of compounds that 
are active against malaria. These include alkaloids, terpenes, flavonoids, quinones, 
xanthones and coumarins, peptides,  phenols and lignans. Furthermore, several compounds 
have been isolated from various natural products with their structures determined. Fig 1.17 
below shows some natural product scaffolds that form the basis of different antimalarial 
drugs. 
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Fig 1.17: Natural product antimalarial scaffold: Structures of molecules from herbal 
medicinal products with confirmed activities in humans. Adapted from Wells et al., 2011. 
1.13.6 Natural product drug discovery process for malaria 
Traditionally, the drug discovery process for natural products involves the screening of a 
large natural product library for a disease in order to identify some hits, with the ultimate 
goal of isolating and synthezing an active compound. Alternatively, a natural product might 
be selected for drug discovery based on its ethno-pharmacological usage. The screening 
process involves the use of various in vitro and in vivo assays to screen against the disease. 
The natural product extract is subsequently purified and the active ingredient isolated with 
the ultimate goal of chemically synthezing an analogue. Fig 1.18 is a schematic 
representation of the process. 
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Fig 1.18:Natural product drug development: Schematic representation of the current 
route to natural product development. 
1.13.7 Current techniques in natural product drug discovery 
Historically, natural product screening involves using a number of techniques to isolate and 
purify the active ingredient(s) found within a crude extract. Natural products can be purified 
and isolated using a wide range of techniques, depending on the constituents to be isolated. 
Hence, different separation techniques are often used in conjunction with spectroscopic 
methods in order to achieve a successful purification and isolation of a compound.  Natural 
product scaffolds have been isolated using various techniques including chromatography. 
Fig 1.19 below is a schematic representation of a typical approach for the isolation of an 
active compound from a complex natural product mixture. 
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Fig 1.19: Bioassay guided fractionation: Showing a generic schematic flow chart of a 
typical bioassay guided fractionation process. 
The first step in natural product isolation is to have an idea of what components might be 
present in the extract, which is often researched though existing literature. In some cases, it 
might be difficult to have an idea, in which case various qualitative tests can be done to 
reveal the phytochemistry of the extract to confirm the presence of compounds such as 
phenols, flavanoids, tannins and other phytochemicals. This knowledge can be used to 
design a protocol for isolation of a compound. Certain information such as knowledge of 
the solubility, acid base properties of the compound can be critical in the isolation process. 
In recent years, the most common technique that is used for natural product separation and 
purification is chromatography. High performance liquid chromatography (HPLC) is the 
most commonly used technique. There are different types of HPLC including normal phase 
and reversed phase chromatography. Reversed phase chromatography is commonly used for 
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isolation of methanolic extracts that have highly polar compounds. Fig 1.20 shows a 
schematic representation of a HPLC system. 
  
 
Fig 1.20: HPLC system: Showing the main components of a HPLC system with a data 
acquisition system at the end which normally produces the chromatogram.  (Source:  
http://www.laboratoryinfo.com). 
The main draw back with current methods for antimalarial drug discovery, is that so far, the  
focus has been on purification and isolation of a single active compound from an extract. 
Although a vast potential of success hit rates have been recorded, many of these  have not 
been translated into drugs. Pharmaceutical companies, government regulatory bodies and 
investors have not shown enough interest and a lot of effort today is focused on target 
oriented drug design. The arguments put forward against natural product drug development  
range from issues related to reliability, accessibility and supply; seasonal or environmental 
variations in the composition of living organisms and loss of source though extinction or 
legislation. More practical concerns include complexity of natural product mixtures after 
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fractionation, the isolation of very small quantities of bioactive substance and challenging 
physicochemical properties such as solubility and stability. Most anti-malarial compounds 
isolated from natural sources are usually only moderately active, or possess challenging 
physicochemical and biological properties, and as such represent ‘hits’ rather than actual 
lead drug candidates (Vederas et al., 2009). This is probably due to the fact that natural 
products usually exist as a complex mixture of several biologically active phytochemical 
compounds. The reason why isolated compounds might only show moderate activity is 
because they often act in synergy and in some way nature has balanced the toxic effects of 
some compounds by the presence of other compounds which might neutralise that toxicity, 
hence achieving an overall effect (Ulrich-Merzenich et al., 2010). The process of 
purification might therefore lead to the loss of several active components and the synergistic 
and additive interactions between fractions might be lost too. 
There are several solutions today to the main bottlenecks in natural product drug discovery.  
Recent technological advances in biotechnology, for example have provided us with in-
depth understanding of the genomics of natural product biosynthesis. This may enable the 
efficient production of the same bioactive molecules from plant cell cultures and genetically 
engineered microorganisms hence combating the problems of supply issues. This has been 
demonstrated recently with the large-scale microbial production of the artemisinin 
precursors, amorpha-4,11-diene and artemisinic acid, from genetically modified 
Saccharomyces cerevisiae and Escherichia coli (Zeng et al., 2008). Communities could be 
massively engaged in farming for these products providing economic empowerment.  
1.13.8 Research and development pathways for medicinal plants 
The WHO has in recent times promoted the development of ethnopharmacological drug 
formulations, allowing researchers to follow different approaches. One approach that has 
been of considerable interest over the past two decades is reverse pharmacology. It is the 
science of integrating documented clinical/experiential hits into leads by transdisciplinary 
exploratory studies which further develops it into drug candidates. Though reverse 
pharmacology, complementary and alternative medicine (CAM) can be strengthed in the 
healthcare system. Botanical formulations with distinct pharmacological properties can be 
substitutes for the management of several human disorders.  Fig 1.21 below shows a 
summary of the different routes currently in traditional/herbal medicine research available 
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including the standard route of purifying and isolating the active compound from the natural 
product. 
 
 
Fig 1.21: Routes to medicinal plant research: Showing different routes for medicinal plant 
research highlighting the reverse pharmacology approach. 
Although the reverse pharmacology approach is very controversial, it has proved to be a 
much faster alternative and has so far proved very beneficial within communities. There 
have been a number of case studies that shall be discussed in due course. One of the main 
benefits/goal of this approach is to develop a phytopharmaceutical drugs. 
Phytopharmaceutical drugs have a number of benefits. They are considerably faster and 
cheaper to develop. They can be more sustainable in certain parts of the world as 
communities tend to feel it is a safer alternative. The fact that it involves agriculture also 
means it can be incorporated in poverty alleviation programs in developing nations. In the 
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case of malaria for example, using phytopharmaceutical drugs might ease pressure on 
standard drug usage hence reducing resistance. The reduction in R & D cost by this approach 
comes with the fact that proven use of the natural product in question by a certain 
community for often centuries means it can be accepted as some form of safety. The main 
advantage of a reverse pharmacology approach is that the starting point is a compound that 
is accepted to be safe and there is a track record of human usage. With a conventional 
approach on the other hand,  research often starts with finding hits which can be time 
consuming and costly. After hit identification, most studies move on to efficacy studies after 
which safety studies are done. On several occasions, hits that have been identified and 
validated in terms of efficacy  are often dropped at a later stage of the research during in 
vivo studies due to safety/toxicity issues leading to a high cost implication. 
The concept of reverse pharmacology was first developed in India in Ayurvedic medicine 
and also by Chinese government with the main aim of developing phytopharmaceutical drug 
products. Later other goverments like Brazil and some African countries adopted the model.  
1.13.9 Herbal medicine vs phytopharmaceutical drugs 
Herbal medicines are plant-based products that are used as a source of cure/prevention for 
ailments. Herbalism is considered as a form of alternative medicine. The practice is often 
based on historical use of plants by communities for certain ailments. The practice is often 
not evidence-based but rather based on historical beliefs and practices. In recent times, some 
herbal medicines have been researched and considered an important part of alternative 
medicine. There is however still major concerens with regards to the use of herbal medicine. 
The practice is often not scientifically validated, there is poor regulation in several countries 
and the drugs are often not registered nor regulated by health athuroties (GAO, 2009). The 
safety and efficacy of several herbalherbal products remain a concern due to the lack of 
scientific validation of the medicinal claims of the products. Several organisations are 
working in partnership with governements, research institutions and academia to address 
this issue. The WHO, for example is working with member countries to strengthen the 
traditional medicine systems. The latest strategy employed by the WHO focused on 
promoting safety, efficacy and quality of the traditional medicine system though the 
expansion of knowledge base and assisting in the provision of guidance on quality 
assurance, regulatory systems and standardisation (WHO 2014-2023 TM strategy, Geneva, 
2013). 
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In recent times, the concept of phytopharmaceuticals have sprang up to address the issues 
encountered with herbalism. The concept of reverse pharmacology has been often used to 
develop phytopharmaceuticals which are ‘plant-based medicines’ that are standardised and 
scientifically researched and validated. Quality assurance and regulatory bodies are often 
involved in the development of phytopharmaceuticals which is often not the case with herbal 
medicines. 
1.14 The concept of reverse pharmacology 
Reverse pharmacology is defined as the science of integrating documented clinical or 
experiential hits into leads by transdisciplinary exploratory studies and developing these 
further into a drug by clinical research. This concept is inspired by traditional medicinal 
plant knowledge and involves reversing the usual’ laboratory to clinic’ concept in normal 
drug discovery process to ‘clinic to laboratory’ as represented in Fig 1.22 below. 
 
 
 
 
 
 
Fig 1.22: Comparison of reverse pharmacology and conventional approach: A diagram 
comparing the reverse pharmacology vs conventional approach routes in the drug 
development process. 
 
 
 
Molecule Mice Man
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The scope of reverse pharmacology is to understand the mechanism of action of natural 
product formulations and optimise their efficacy, safety and acceptability based on scientific 
evidence. Hence reverse pharmacology is a combined drug discovery approach that merges 
together both conventional medicine and traditional medicine, the overall effect of which is 
a faster, cheaper and robust alternative.  
 
 
 
 
 
 
Fig 1.23: Convergence of the two disciplines: Showing how reverse pharmacology is a 
convergence between traditional medicine and conventional approach. 
Reverse pharmacology is a transdiscipline medicine that could involve several phases as 
detailed below: 
1. The first step is the experiential phase which primarily involves a documentation 
process of clinical observations of the herbal formulation investigated 
2. Exploratory studies involves further studies to establish the tolerance/toxicity of the 
formulation, any possible interactions and establishing exact therapeutic dose ranges both 
in clinic and also though in vitro and in vivo studies to evaluate the activity.  
3. Experimental studies involve both in vitro and clinical studies in various models to 
validate the safety and efficacy. This is often where most of the laboratory work comes in. 
These phases are the main phases that are used in ayurvedic formulation development. In 
conventional drug development, clinical experiences and observations take place after 
laboratory validation of a therapeutic claim.  These phases are represented methodologically 
below: 
Traditional 
Medicine             Reverse                      
                                        Pharmacology
  
Conventional 
Med 
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Fig 1.24 Chronological order of a reverse pharmacology: Showing a reverse pharmacology 
approach (Source: Wilcox et al., 2011). 
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1.14.1 Case studies of reverse pharmacology/phytopharmaceutical drug development 
Different governments across the globe have adopted the reverse pharmacology approach 
as part of their traditional medicine drug development scheme. Some case studies are 
discussed in this section. 
1.14.1.1 India as a case study for reverse pharmacology approach 
Sir Ram Nath Chopra and Gananath Sen are said to be the forefathers of reverse 
pharmacology. They successfully stimulated the interest of chemists in medicinal plant. Sir 
Ram, documented the effects of several ayurvedic medicines and used this to lay the 
foundations of reverse pharmacology. In 1931, Ganannath Sen and Bose reported on the use 
of an alkaloid extract from Rauwolfia Serpentina plant for hypertension and mania. There 
findings were ignored until 1945 when Nathan Kline, an American scientist, did some 
studies of reserpine, a derivative of the plant and found that it was more effective than 
placebo treatment in a trial of about 400 inpatients with psychiatric symptoms (Sen & Bose., 
1931; Kline 1954). 
Reverse pharmacology in India offers a major paradigm shift in drug discovery, especially 
with the recent amendment of its drug act to include a category of phytopharmaceuticals. 
This class of drugs will be developed as medicinal plants with evidence of safety and quality 
and will be distinct from traditional medicine (TM) usage of herbs and ayurvedic medicine.  
The Indian council on medical research (ICMR)  recently established an advance centre for 
reverse pharmacology with initial focus on malaria, sarcopenia and cognitive decline. India 
can clearly be considered the World’s leading country in reverse pharmacology. Recently, 
an Indian based laboratory did some extensive studies on a plant for psoriasis. The company, 
Lupin laboratories, successfully filed a new drug application for the drug and phase I trials 
began in 2004 and was successfully completed. The drug was developed conforming to FDA 
guidelines for botanicals and is estimated to be considerably cheaper than its Western 
counterpart. Another success story is in the field of Parkinson’s disease. Ancient Ayurvedic 
physicians have long used Mucuna pruriens seeds for the treatment of the disease. The dose 
used is considerably lower compared to L-dopa, the first line treatment for Parkinson’s. 
These observations led some scientist in India to collaborate with a pharmaceutical company 
and further investigate the observations. The research led to the development and approval 
of a national drug for the treatment of the disease. A new drug application was filed with 
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the FDA, as well as a patent cooperation treaty for the extraction process by the Indian 
company which led to the development of the drug, Zandopa which is now available. The 
drug is successfully used as a standardised, safe and economical natural product replacing 
synthetic L-Dopa preparations in India.  Clinical studies with Mucuna seed powder suggests 
that this natural souce of L-dopa might possess advantages over conventional L-dopa 
preparations in the long term management of Parkinson’s disease. (Katzenschlager et al., 
2004). 
1.14.1.2 Brazil as a case study 
In Brazil, about 80% of the population lack access to essential medicine (Toledo et al., 
2003). One of the major contributing factor is high cost of medication. For this reason, in 
2006, the Brazilian government decided to include phytotherapy as one of its medicinal 
options though its National policy on Integrative and Complimentary Practices (Brazil, 
2006). Since then documentary processes have followed and standardisation procedures of 
medicinal plants began. Several guidelines have been put in place though relevant 
government agencies to establish a list of regional plants to represent the popular 
phytotherapy. The policies adopted advocate for the inclusion of medicinal plant in primary 
healthcare system. Safety and efficacy standards have been called for by these agencies and 
it is argued that the same strict standards should be applied to manufacturing of medicinal 
drugs as it is with conventional drug manufacturing (Barbosa and Pinto 2005). For a drug 
to be classed as a phytopharmaceutical drugs, it must contain exclusively plant material as 
active ingredient. Addition of isolated compounds eliminates it from being classed as a 
phytopharmaceutical drugs. Hence the law allows for a product classed as a natural product 
to be marketed as long as the relevant authorities are notified and the product is cultivated 
by those who follow good agronomical practice (Brazil, 2010). Despite the current law and 
regulations that allow for use of medicinal plants, it seems the use of phytopharmaceutical 
drugss in public health is still limited. 
1.14.1.3 Africa as a case study 
A reverse pharmacology approach was adopted for the design and development of an 
antimalarial phytomedicine in Mali. The drug was successfully developed and standardised 
in 6 years only.  The study involved the selection of a remedy based on 
ethnopharmacological usage. A clinical  dose escalating trial trial followed to establish a  
dose response. Based on the results, the safest and most efficacious dose was selected and 
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another randomised controlled trial followed comparing the phytopharmaceutical drugs 
with a standard first line treatment. The active compounds within the medicinal plants were 
identified for standardization and quality control purpose (Wilcox et al., 2011). 
 
 
 
Fig 1.25: Dose optimisation study for an antimalarial phytopharmaceutical drugs: 
Showing a schematic representation of a dose optimisation study for an antimalarial 
phytopharmaceutical drugs in Mali. (Source: Wilcox et al., 2011).  
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An additional example of a phytopharmaceutical drugs developed in West Africa is called 
NIPRISAN. The drug is an anti sickling phytopharmaceutical drugs developed by the 
National institute of pharmaceutical research and development, Nigeria (NIPRD). It was 
developed from the plant Vernonia amygdalina, commonly known as the bitter leaf, due to 
its bitter/sweet taste. The main clinical trials and laboratory bench work was performed at 
the NIPRD instititute, Abuja. Following the R & D process, NIPRD collaborated with an 
Indian phytopharmaceutical drugs manufacturer, Xechem in order to commercialise the 
product. It was commercialised and introduced to the primary healthcare system for the 
treatment of sickle cell anaemia ( Perampaladas et al., 2010). 
BF001 is another herbal formulation produced from Bridelia ferruginia (B. ferruginia) in 
Ghana at the centre for scientific research and plant medicine (CSRPLM). The extract was 
developed in collaboration with WHO and is being used as an oral hypoglycaemic agent in 
the primary healthcare system. 
1.15 Methods used for natural product discovery for malaria 
Generally, the same screening methods are used for both synthesised compounds and natural 
products. The main difference is in the approach that is followed. As discussed earlier, some 
natural product screens begin by screening large database of natural products to identify 
leads whilst others involve choosing compounds based on ethnopharmacological anecdotal 
evidences and might begin with human studies (reverse pharmacology). Which ever 
approach is followed, there are some drawbacks to the current methods used currently in 
natural product research. In malaria research for example,  there is a high successful hit rate, 
with several compounds showing low IC50 values  (Cerventes et al., 2012). The main 
drawback is there is no standard for antimalarial screening of natural product remedies and 
there is no bench mark IC50 value that malariologist could refer to when investigating new 
compounds.  
Several researchers have attempted to address these issues. Wells et al., 2011 suggests that 
natural product research should be replaced by a patient data led approach which should 
involve standardised clinical observational system of ethnopharmacological compound used 
in patients. This approach is in support of previous suggestions by Chen Guofu in 1952. He 
suggested that the starting point for investigation of natural products should be by checking 
the activity in humans. This view faced various objections at the time, especially by 
clinicians and the international community whose major concerns were using unpurified 
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products in humans. Over the years, several factors have led to an acceptance of Guofu’s 
suggestion. The biggest milestone is the acceptance by authorities such as the European 
medicines agency (EMA), the United States Food and Drug Agency (US-FDA) and WHO. 
The main reason for the acceptance of the view was that since patients and communities 
take these medicinal herbal products, it is a public health concern/responsibility to validate 
their efficacy. Below is a flow chat of Wells suggestions. 
 
 
Fig 1.26: Natural product screening: Showing the developmental stages for screening a 
natural product suggested by Wells, 2011 using a reverse pharmacology approach. The 
natural product is chosen based on the ethnopharmacological usage and clinical 
observation begins.  
With regard to natural product research, researchers tend to focus on purification and 
isolation of the active compound in an extract. Natural products usually exist as complex 
mixtures of various phytochemical compounds. These compounds sometimes act in synergy 
and the combination gives the total overall effect seen in an extract (Ulrich-Merzenich et 
al., 2010). Hence by purifying the extract, it is likely that some important compounds are 
lost along the way. In the case of malaria, the parasite has developed resistance to all new 
antimalarials that have been developed including artemisinins. Although a number of 
antimalarials are natural product derived compounds, all have actually gone though the same 
process of isolating the active compound. The parasite is probably able to develop this 
resistance due to the simplistic nature of the compounds it is exposed. This theory can be 
substantiated by looking back at the history of quinine use. Quinine was used in its natural 
form for centuries with no issue of resistance. Chloroquine was successfully isolated in the 
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1950’s and it only took 10 years for resistance to develop. As mentioned earlier, fansidar, a 
combination drug of pyrimethamine and sulfadoxine, also developed resistance less than 6 
years after its introduction. Another example is mefloquine and the list goes on. Most of 
these antimalarials are natural product derived.  Hence these examples substantiate the 
argument that the Plasmodium is too complicated for simple isolated compounds and might 
have the ability to evolve quickly and develop resistance. This point can also be emphasised 
using the artemisinins as a case study. Like quinine, artemisinins have a very long history 
of use. There has never been a record of resistance. After successful development of 
artemisinins for malaria, (in a semi-synthetic form) they have remained the last hope over 
decades. Recent reports have however shown that resistance has developed in these drugs. 
Fig 1.27 shows is a timeline representation of the development of resistance after isolation 
of both quinine and artemisinin. 
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Fig 1.27: A Schematic representation of resistance drug development timeline for 
malaria: Showing the timeline for the development of resistance of antimalarials after active 
compound isolation of some antimalarial natural products. The traditional usage of the 
drug is represented by the green horizontal line whilst point of drug isolation is represented 
by the vertical green line. Resistance development is represented by the red horizontal line. 
Malaria parasite resistance developed within 10 years after chloroquine was isolated from 
the quinolones. The development of resistance took longer with the artemisinins probably 
owing to their use as semisynthetic drugs and as part of combination therapy regimes. 
1960 
Antifolates 
Malaria p rasite resis anc  to quinine, artemisinins and antifolates 
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Antifolate drug resistance developed in less than 5 years after it was isolated as a pure 
compound. 
So far, there has been no successful competitor to the artemisinins. In holding on to this last 
hope, the WHO has mandated its use as a combination therapy (earlier discussed). The 
artemisinins started to be used in a ‘semisynthetic’ form around the 1970s. These drugs are 
till the cornerstone on antimalarial therapy, thirty years on. In 2006 the first clinical case of 
resistance was reported in the Thai-Cambodian border (WHO report, 2015). It is thought 
that resistance might have began as early as 2001 when the drug was used as a monotherapy. 
The question is why have the artemisinins been successfully used for much longer the 
quinine? The answer could well lie in the fact that it has been used in a semisynthetic form. 
Artemisinin has a very complex structure which has kept several chemist on their toes. It 
has not been successfully synthesised to a commercially viable form and for this reason, it 
has been used in a semisynthetic form. This could be one of the possible reasons for the 
delayed resistance seen with these class of drugs. Fig 1.28 shows some structures or 
artemisinin related compounds. 
 
 
Fig 1.28: Artemisinin related compounds: Showing the complex structures of artemisinin 
related products. (Source: http://www.scielo.br/scielo) 
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Fig 1.29: Semi-synthetic production of artemisinin: Showing the production of a semi-
synthetic form of artemisinin though cellular engineering, allowing for a faster production 
of the medicine. (Source: http://www.jscimedcentral.com/Cell/cell-1-1002.php). 
1.16 Phenotypic screening for malaria  
The methods used are mainly either in vivo or in vitro. In vivo methods mainly involve use 
of animal models for example P. berhei (rodent malaria) or P. relictum (avian malaria). 
Most in vitro assays for malaria focus on the erythocytic asexual stages of the P. falciparum 
and P. vivax species. Assays include routine drug assays, rosetting assays, antibody 
detection, immunoglobulin and serum binding techniques as well as transmission electron 
microscopy and molecular biology techniques. 
In vitro assays are mainly used in malaria research to monitor the amount of parasites in the 
blood (parasitaemia). The gold standard is microscopy, a cheap and highly reliable 
technique allowing malaria species and stages to be differentiated microscopically. The 
main drawback is it can be tedious for multiple samples and it also requires a highly skilled 
person to correctly estimate parasitaemia. Furthermore, it is subjective, as count variations 
do occur from one microbiologist to another and it is also labour intensive. Several other 
tests have been developed over the years to increase the accuracy of parasitaemia estimation 
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and  allow for automatic reading of parasitaemia. Some of these assays are briefly discussed 
below: 
I. Isotopic assays: The most popular of this is the incorporating of radiolabelled hypoxanthine 
assay. This involves the use of high cost equipment such as scintillation counters and  
radioactive material which is expensive and requires expensive disposal of the materials. 
New guidelines only allows for use of isotopes when there is no other alternative hence the 
need for new methods. 
II. Parasite lactate dehydrogenase assay (pLDH): This assay involves the use of pLDH, a 
terminal enzyme in the glycolytic pathway as a measure of cell viability in vitro. The 
parasite pLDH is different from that of the hosts and the level of the enzyme is used as an 
indication of parasite density. Decrease in the level of pLDH is an indication of lower 
parasite density and this is used as a marker in drug sensitivity assays. 
III. Histidine rich protein II (HP2): This assay measures the level of histidine and alanine rich 
proteins produced by the parasite during multiplication. HP2 levels are closely related to 
parasite density and multiplication. Drug sensitivity assay tests are designed to monitor the 
levels of these proteins. The protein levels are measured using a simple commercially 
available enzyme linked immunosorbent assay (ELISA). 
IV. Fluorescent based methods: Several fluorescent based methods are used for antimalarial 
drug susceptibility testing. These methods take advantage of the fact that mature red blood 
cells lack nucleic acids that is deoxynucleic acid (DNA) and ribonucleic acid (RNA). The 
dyes bind to parasite DNA hence an increased fluorescence corresponds to increased 
parasitaemia. Dyes that have been previously used include SYBR green I, picoGreen and 
YOYO-1 (Weismann et al., 2006; Smilkstein et al., 2004; Quastine et al., 2006). SYBR 
Green is the most sensitive amongst the available DNA stains. It works by intercalating and 
binding to double stranded DNA which once bound, becomes fluorescent (Vossen et al., 
2010). Hence any fluorescence is due to binding of parasite DNA as erythocytes have no 
DNA. The dye also has a lower affinity for RNA making it selective. Hence during a drug 
screen, high fluorescent reading means a high presence of parasite and a lower reading 
depicts less parasite. Thus control samples will show higher fluorescence whilst treated 
samples will show lower fluorescence if a drug has antimalarial activity, indicating parasite 
killing. The SYBR Green assay has several advantages including the fact that it is  simple, 
quick and a relatively cheap method (Rason et al., 2008). The only technical equipment 
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required is a fluorescent plate reader and the dye is cheap to buy. The method is highly 
adaptable involves few steps and incubation period is only 1h (Smilkstein et al., 2004). The 
main disadvatage of this method is the high background that might often be seen. For this 
reason, some studies involve an additional erythocyte lysis step to combat this (Johnson et 
al., 2006). Another drawback is that the dye is also non specific hence it will bind any 
available double stranded DNA hence any sample contamination example white blood cells 
will cause interference in the reading or cause a high background. The dye is also capable 
of binding to single stranded DNA and RNA but at a much lower affinity than double 
stranded DNA, again contributing to background interference (Smilkstein et al., 2004).   
SYBR green can also be used in flow cytometry to detect malaria parasite. The flow 
cytometer uses the same ideology as the plate reader. The only DNA is that of the parasite 
since erythocytes lack DNA (Grimberg et al., 2011).  The FCM was used to measure nuclear 
division of the parasites within the red blood cell using a nucleic acid stain. Like the SYBR 
green plate reader assay, it also takes advantage of the fact that red blood cells do not contain 
DNA hence any nuclear material is that of the parasite. Apart from giving information about 
the nuclear division within the parasite, the technique also gives an accurate percentage 
parasitaemia. With the flow cytometer, a whole range of nucleic acid dyes are available as 
alternatives but for this project, the SYBR green is used due to its high specificity for DNA. 
Fluorecent based techniques are very attractive due to their ease of use, relatively cheap and 
less complicated compared to other techniques like radioactive isotope or ELISA based 
techniques. For this reason SYBR green plate reader and flow cytometry along side light 
microscopy are the chosen techniques for the scope of this project17  
1.17 Conclusion 
In view of the issues discussed in this current chapter,  the main aim of this study is to screen 
some plants based on ethnopharmacological usage towards the development of a 
phytopharmaceutical drugs for malaria using in vivo and in vitro methods. Some  novel 
extracts were screened and used to design a suitable workflow. Methods were optimised 
with the aim to validate the ethnopharmacological claim of the plants’ use for malaria.. The 
natural product crude extracts will be screened for antiplasmodial activity in a cell based 
assay approach.  Once activity is established, a dose response curve will be generated using 
different doses and the IC50 value will be determined. The crude extract will be fractionated 
using high thoughput liquid chromatography (HPLC) separation method to obtain broad 
fractions for testing as evidence that different components within the plant act possibly in 
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both additive and synergistic way to give an overall antimalarial activity. The main objective 
of this project is mainly to validate the ethnopharmacological claim of the plants using a 
model that will screen the crude plant for malaria. It is argued that previous plant extracts 
that were used for the treatment of malaria developed resistance few years after being 
isolated to a single active compound, as is the case with chloroquine and other antifolate 
drugs. Hence in this project, the plant material will be maintained in a wholesome form, as 
the complexity of the compound mixture might delay/prevent resistance. With these results, 
the ultimate aim of this project is to work though a collaboration with National institute for 
pharmaceutical research and development, Nigeria (NIPRD) to develop a 
phytopharmaceutical drugs that will be beneficial and cost effective to malaria endemic 
regions in Africa, as well as tackling the issue of resistance. The development of the 
phytopharmaceutical drugs is however beyong the scope of this project. 
1.18 Project objectives   
1. To screen ethnopharmacological-based plants against the multi-drug resistant malaria 
strain, K1. 
2. To optimise and use three different methods to ascertain the antimalarial efficacy of the 
selected plant extracts. 
3. To establish dose-response curves of the selected plants. 
4. To choose a plant based on the best IC50 and easy accessibility in West Africa for further 
characterisation. The accessibility of the plant is based on its biodiversity, distribution 
and ease of cultivation in West Africa and more specifically Nigeria.  
5. To investigate the possible mechanism of action and the onset of antimalarial action. 
6. To explore the in vivo pharmacological actions of the selected plants including 
antimalarial, antipyretic and analgesic activity. 
7. To use HPLC analysis to identify active fractions in the plant extract. 
8. Illustrate the suitability of the extract for development into a phytopharmaceutical 
medicine and identify standardization pathways for the extract. 
 
 
 
67 
 
 
CHAPTER 2 
 
 Materials and Methods  
2.1 Establishing P. falciparum cultures and maintainance 
Routine cultures were established and maintained according to methods previously 
described by Read and Hyde (1993). Standard operating procedures (SOPs) were followed 
with regards to use of Class II pathogens and biological safety rules. Experiments were  
carried out in the University of Salford pathogen laboratory sterile hood (ESCO class II 
Biological safety cabinet). All equipments were pre-sterilised using aseptic techniques. A 
2% virkon solution (Antec International, UK) was used to disinfect waste material before 
autoclaving and disposal.  
2.1.1 Complete media: RPMI Medium 1640 (+)25 mM HEPES and (+) L-glutamine (Gibco 
life technologies, UK) was made complete by adding 50 mg/mL gentamicin (Sigma, UK), 
2.5 ml of a 1mg/ml hypoxanthine in PBS (Fischer chemical, UK), 2.5 ml 40% glucose 
(Dextrose anhydrous, Fisher chemicals, UK), 2.5 g Bovine serum albumin (Sigma, UK). 
The above additives were dissolved in 15-20 ml of pre-sterilised RPMI media taken from a 
500 ml bottle. Once dissolved, it was filter sterilized back into the bottle using a 0.22 μm 
filter. Solutions were kept sterile by performing all procedures in the sterile hood. The 
complete media (CM) was stored at 4°C until use for up to two weeks. 
2.1.2 Blood washing: O+ human blood was obtained from the NH Blood Bank at Mancheter 
Royal Infirmary. 200 ml of the blood was transferred into sterile falcon tubes and the 
remaining blood transferred into sterile culture flasks and kept in the fridge for future use. 
The blood in the falcon tubes were centrifuged at 3400 rpm for 5 mins. The supernatant, 
containing plasma and leukococytes, was removed and discarded. Normal RMPI media 
[Wash media, (WM)] was added to each tube and the centrifugation process repeated. The 
supernatant was discarded and the process was repeated three times ensuring all leucocytes 
were depleted. Then CM was used to perform a final wash. Once the supernatant was 
discarded, an equal volume of CM was added to the 100% hematocit blood left in the tubes 
making it a 50% haematocrit blood ready for use in culture. The washed blood was labelled 
and stored in the fridge at 4°C until use. 
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2.1.3 Retrieving new cultures from frozen: A cryovial containing 0.5 ml of a 3D7 or K1 P. 
falciparum frozen culture was retrieved from a nitrogen tank and thawed in an incubator set 
at 37°C. The contents were transferred to an eppendorf tube and centrifuged at 13000 g for 
90 seconds and then transferred to a sterile hood where the supernatant was discarded. The 
pellet, consisting of the parasitized blood was gradually re-suspended in 1 ml of 10% 
sorbitol solution in PBS, with continuous mixing. The process was repeated twice and a 
third wash was performed using 5% sorbitol in PBS. A final wash in CM was performed 
and the pellet was re-suspended in 0.5 ml of CM. The re-suspended culture was added to a 
culture flask containing 10 ml complete media and 0.5 ml non parasitized blood giving a 
total of 1 ml blood in a flask containing 10 ml CM achieving a 5% haematocrit. The culture 
flask was gassed with 5% CO2, 5% O2 and 90% N2 gas (Boc Limited, UK) and  then 
incubated at 37°C for 72 h in an incubator (Leec culture safe touch 190 CO2, Leec Limited, 
UK).   
2.1.4 Light microscopy (Giemsa staining): Briefly, light microscopy was carried out by 
performing a thin blood smear on a microscopic slide. The slide was air dried and fixed with 
100% methanol. The slide was immersed in a 1:10 diluted Giemsa stain in a buffered 
thiazine-eosinate solution (BDH/WVR, UK). Oil immersion microscopy was used at X 100 
magnification using a Leica DM 500 compound microscope to view the parasites. Infected 
red blood cells were counted in  3-5 different fields of view and parasitaemia was estimated 
by  the average percentage of infected cells counted against the non-infected cells. An 
estimated 1000 cells were counted in order to establish parasitaemia. Based on the 
parasitaemia determined, subculturing was carried out at 0.5-1% parasitaemia. All 
experiments were initiated at parasitaemia levels between 0.5-1%.  
2.1.5 Maintenance of routine P. falciparum cultures: Routine cultures were performed as 
previously described by Read and Hyde, 1993. Cultures were carried out in either  25 cm3 
flasks (10 ml culture volume) or 75 cm3 flasks (30 ml volume). The experimental set up was 
however usually in smaller 12.5 cm3 flasks (5 ml volume) at 5% hematocrit. Briefly, the 
procedure was performed by removing cultures from the incubator and carefully placing 
them in a sterile culture hood carefully in order to avoid dislodging the settled parasitized 
blood layer. The clear spent media at the top was removed by slightly tilting the flask to an 
angle. Once all spent media was removed, the settled parasitized blood was mixed  and a 
drop taken out to prepare a thin blood smear as described in section 2.1.4. Once parasitaemia 
was established, the culture was diluted down to between 0.5 to 1% parasitaemia. Typically 
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a 3% parasitaemia culture was diluted by adding 2 parts new blood to 1 part parasitized 
blood making it 1% parasitaemia. Cultures that were going to be left for 72 h were diluted 
down to 0.5% parasitaemia to prevent culture overgrowth and maintain healthy cultures. 
The cultures were gased as previously described and placed in the incubator at 37°C.  
2.1.6 Sorbitol synchonisation: Newly set up cultures do not need synchonisation as only the 
ring form survives the cryopreservation process. After several cycles however, the cultures 
loose synchrony. For best experimental results, sorbitol was used to maintain this synchony 
in established cultures. The method previously described by Trager and Jensen, 1976 was 
used.  Briefly, cultures with a high parasitaemia (about 8% in our lab) of  predominantly  
ring stage were centrifuged. The spent media was discarded leaving the parasitized pellet. 
A 5% w/v sorbitol (in distilled water) was filtered though a 0.22 µm filter for sterilisation. 
9 ml of the sorbitol solution was added to 1 ml of culture pellet and incubated for 5 min at 
room temperature. The culture was centrifuged at 3400 rpm for 5 min and the supernatant 
discarded. The pellet was washed three times in complete media leaving a parasite pellet. 
The parasitaemia of this suspension was estimated using light microscopy and subculturing 
performed as previously described in section 2.1.5. The resultant culture was a synchonised 
ring stage culture. Once cultures lost synchrony, this synchronisation process was repeated 
to maintain it. 
2.2 Drug susceptibility assays  
Based on careful consideration of the various assays that are available for the estimation of 
parasitaemia, three simple, reliable and efficient techniques were chosen in the present 
study, to investigate the effect of drugs on parasitaemia. The three methods were compared 
based on the half maximal inhibitory concentration (IC50). The three methods include 
Giemsa light microscopy, SYBR green microplate assay (SG-Microplate) and SYBR green 
flow cytometry (SG-FCM). The Giemsa assay is the gold standard in malaria parasite 
detection.  
2.2.1 Optimisation of the SG-Microplate assay: The SG-Microplate assay was performed as 
previously described by Rason et al., 2008. Briefly 3D7 P. falciparum culture was grown in 
10 ml culture volume as previously described. Once the parasitaemia reached 2.5% or more, 
100 µl of the culture was put into different wells in a 96 well, black bottom culture plate 
(Nunc, Denmark). 100 µl of a 0.2 µl/ml SYBR green 1 solution (10, 000X Sigma, UK) 
diluted to 5 X in PBS was added to each well. Plates were covered and incubated in the dark 
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for an hour. Fluorescent intensity was measured with a micro plate reader (Genius Tecan) 
at an excitation of 485 nm and emission of 535 nm. The gain of the instrument was set to a 
maximum of 80 and both top read and bottom read options were compared. The assay was 
optimised to investigate the effect of several factors on background fluorescence. The first 
experiment involved a two-fold serial dilution of a high parasitaemia culture using RPMI 
media in order to determine the correlation between fluorescent intensity and parasite 
density. The results obtained necessitated further optimisation. The effect of several factors 
including haematocrit level, amount of CM present in the wells were investigated in 
subsequent experiments.  
2.2.2 Effect of haematocrit level  and media on background fluorescence: The effect of  
several factors were investigated using a 96 well plate in a SYBR green assay as described 
above. 100 µl of samples were loaded in wells and the medium and amount of haematocrit 
varied in different wells. The samples were loaded as below and serially diluted from a high 
parasitaemia to a low parasitaemia. 
  
                                                                                         
 
           
 
 
 
 
 
Fig 2.1: Serial dilution format of the SG-Microplate assay: Showing the 96 well plate 
format of the samples. Arrow indicates direction of serial dilution.  
2.2.3 Effect of complete media on the SG-microplate assay 
The results of the experiment in section 2.2.2 necessitated further investigation on the effect 
of complete medium due to the high background detected. Briefly wells were loaded with 
 Phosphate buffered 
saline (PBS) 
 Complete media (CM) 
 Wash media (WM) 
 5% hematocrit 
parasitized blood (PB) 
 10% hematocrit PB 
 
 
High to low parasiatemia 
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200 µl of complete medium, 150 µl of complete medium, 100 µl of complete media and 50 
µl of complete media. Each sample well was made up to 200 µl volume with PBS and the 
SG-Microplate protocol carried out 
2.2.4 The adopted optimised SG-Microplate protocol 
As mentioned previously in section 2.2.1, method described by Rason et al., 2008 was 
originally followed. Based on the optimisation assay results, the method was slightly 
modified by omitting the erythocyte lysis step. 100 ul of cultures were placed in 96 well 
Nunc plate and 10,000 X SYBR green diluted to 5 X in PBS was added.The haematocrit 
level was maintained at 2.5% and PBS was used as CM caused a high background. All other 
parameters were as described in section 2.2.1. 
2.2.5 Optimisation of the SG-FCM method  
The method used has previously been described by Karl et al., 2009 although minor 
modifications were made to optimise and adapt the method for our laboratory. Cultures were 
challenged either at ring stage or trophozoite stage at 0.5-1 % parasitaemia and incubated 
for 48 h or 72 h respectively. After the incubation period, samples were obtained from 
control and drug challenged culture flasks. 50 µl was taken from culture flasks incubated 
with varying doses of extract as well as the control flasks which had no treatment, each 
placed in different labelled eppendorf tubes. The samples were washed with 1 ml PBS by 
centrifuging for 1 minute at 14000 g and the supernatant discarded. 950 µl PBS was added 
to each of the samples as well as 50 ul of a 1:100 SYBR green solution. Samples were 
incubated for 1 h after which the samples were washed to remove the SYBR green. The 
samples were subsequently fixed by adding a 250 µl solution of a 1:15 dilution of 
formaldehyde. Samples were refrigerated at 4˚C for 15 minutes and the fixative was 
removed by washing the sample three times in PBS. The samples were ready to be read in 
a BD biosciences FACs flow cytometer machine. Fifty thousand events were acquired from 
each sample. The BDS biosciences software was used to generate a density plot as well as 
a forward scatter plot versus fluorescent intensity. Statistical data of events was obtained 
from the software. Gating was performed using standard gating procedures as previously 
described by Karl et al., 2009. The control sample was used to perform the initial gating and 
the challenged samples were run under the same gating procedure allowing comparison to 
be made between non-challenged and extract challenged cultures. The SG-FCM also 
allowed for gating of two different cell populations, hence unsynchonised cultures were 
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gated as mononuclear and multinuclear cell populations depicting ring stage/trophozoite as 
one sub-population and  shizont as another sub-population. This method has been previously 
described by Karl et al., 2009. The BD FACS verse software was also used to accurately 
determine parasitaemia by recording the percentage of infected cells relative to the total 
number of events recorded, in this case the erythocyte count.  
2.2.6 Comparison of the Giemsa microscopic test, SG-MicroPlate and SG-FCM  
As the different assays were used to evaluate antimalarial activity in this project, the validity 
and reliability of these assays was evaluated  by determining the IC50 values of 
dihydorartemisinin (DHA) and chloroquine (CQ) against the K1 strain of P. falciparum and 
comparing the results to literature values.  Briefly,  high parasitaemia culture that had 
previously been synchonised was used at ring stage. The culture was microscopically 
examined and diluted to a 1 % parasitaemia (5 % hematocrit) and divided into flasks of 5 
ml final volume in a 12.5 cm3 flask. Two fold doubling concentrations ranging from 1.25 
nM to 40 nM were added to the flasks in duplicate for DHA.  A flask of untreated culture 
was made to serve as drug-negative control. All flasks were incubated at 37oC.  The cultures 
were incubated for a 72 h time period. At the end of the 72 h drug exposure, the three assays 
were performed simultaneoulsy as described in sections 2.1.4, 2.2.4 and 2.2.5. Briefly, 
cultures were removed from the incubator at the end of incubation period and carefully 
placed in a sterile hood without dislodging the settled cultures.  4 ml of the spent media was 
removed and thin blood smears were prepared for each sample for Giemsa light microscopy. 
The haematocrit was  restored to 5% with 4 ml of warm PBS (37°C). 100 µl  of each sample 
was taken in triplicate and placed in a 96 well Nunc plate for the SG-Microplate assay while 
50 µl of each sample was pipette into labelled eppendorf tubes for  subsequent SG-FCM 
analysis. Each experiment was repeated three times for statistical validation.The percentage 
parasite inhibition compared to infected control samples was used to analyse data. IC50 
values were determined using normalised dose-response analysis (Graphpad Prism).  
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2.3 Optimisation assay results 
The results obtained during the optimisation assays were plotted on a graph using Graphpad 
Prism 6. The results are detailed below:  
2.3.1  Effect of haematocrit and CM on SG-Microplate assay 
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Fig 2.2: SG-Microplate assay for using different conditions: The results of the assay 
showing the influence of various factors on the SG-Microplate assay. Different conditions 
were varied including percentage haematocrit, changing media conditions ( alternating 
CM, WM or PBS). The effect of these factors on background fluorescence can be seen in the 
graph above. The data is based on three independent experiments. 
The results of this assay represented in fig 2.2 showed that high haematocrit had a high 
background fluorescence on the assay. Reducing the haematocrit from 10% to 5% lowered 
the background fluorescence but both readings are likely to interfere with the results of the 
assay. CM contributed to the high background influence and it was observed that using WM 
or PBS as an alternative reduced the background fluorescence to almost nil. Based on these 
results, further optimisation experiments were carried out to determine the best assay 
conditions for the SG-Microplate assay. 
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2.3.2 Effect of varying the amount of CM on the SG-Microplate assay 
Media caused a high background influence in the previous assay hence necessitating this 
assay to establish if reducing the amount of CM will reduce background fluorescence. The 
results of the assay showed that CM caused an increased background fluorescence. The 
higher the CM present in the wells, the higher the background fluorescence. 
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Fig 2.3: Effect of complete media on the SG-Microplate assay: Showing the effect of CM 
on background fluorescence. CM was replaced with PBS in some wells. For example well 
with 100 µl CM was made up to a volume of 200 µl by adding 100 µl PBS. The results show 
that CM contributes to high background fluorescence.  
Though a series of experiments, some data not shown, it was established that several factors 
could cause background interference in fluorescence reading. CM  and a high haematocrit 
caused a high background fluorescence interfering with experimental readings. Changing 
from CM to WM or PBS got rid of the high background. Another experiment that 
specifically investigated the effect of CM, in order to establish how much CM is acceptable 
showed that replacing CM with PBS caused a great reduction in high background. The 
higher the volume of CM removed from the wells, the lower the background interference. 
These experiments were necessary as the parasites are cultured in CM. Hence based on these 
results, the optimised protocol to be taken forward for this project will use a low haematocrit 
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of 2.5% and also replacing 150 µl of CM with PBS in wells prior to SYBR green addition 
in order to reduce background fluorescence. 
2.3.3 SG- FCM optimisation 
The a sample of the of the optimised SG-FCM assay data is shown in fig 2.4 below. The 
results show a population of red blood cells in orange and F1 and F2 boxes showing two 
population subsets of the Plasmodium representing mononucleated cells and multinucleated 
cells respectively. 
  
 
 
Fig 2.4 FCM image showing the Plasmodium at different stages: Showing SG-FCM 
analysis of control and DHA treated cultures with a near 100% parasite growth inhibition 
at a dose of 10 nM. 
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Fig 2.5 Statistical hierarchy for the FCM analysis: Showing the statistical hierarchy 
generated by the BDS system in the SG- FCM analysis. 
The results from fig 2.5 above show the normal red blood cell indicated as control 
represented by a plot of forward scatter (FSC) against fluorescent intensity (FITC). From 
the gating procedure, it can be seen that  the cells in the orange region are normal red blood 
cells with no parasites hence they do not fluorescence. Cells in the first gate, in blue show a 
high fluorescence due to DNA content of the parasitized erythocytes and the statistical data 
generated in fig 2.5 shows the percentage of these cells in the mononuclear region which is 
0.90%. The cells in the second gate, in green, are indicative of the multinucleated cells due 
to shizont formation. Hence the mononuclear gate indicates rings and trophozoite stage 
parasites while the multinuclear gated cells indicate shizonts. 
2.3.4 Comparing the Giemsa light microscopy, SG-Microplate and SG-FCM assays. 
A P. falciparum culture was treated with varying doses of DHA in order to determine the 
IC50 using all three assays.  
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Fig 2.6 Comparison of the three antimalarial assays: Comparing the selected three assays 
by determining the IC50 value of DHA. Parasites were incubated at trophozoite stage for 48 
h with doses ranging from 0.625-20 nM. A dose-response curve generated using the 
normalised dose-response plotted against the log drug concentration. The IC50 value was 
determined for each assay using non linear regression analysis on Graphpad Prism 6.0. 
Error bars represent standard error of the mean (SEM) of a triplicate data. 
 
 GiemLight microscopy IC50 
(nM)   
SYBR Green IC50 (nM)    SG-FCM IC50 (nM)   
 2.369 (1.343-4.179)  2.700 (1.456-3.542)  2.271 (1.557-4.681)   
 
Table 2.1: IC50 values obtained from the three assays: Showing the actual IC50 values 
obtained from the three different assays in the experiment represented in fig 2.5 above. The 
IC50 values in all three assays are comparable ranging from 2.271 to 2.700 nM with an 
average of 2.430 nM. Literature IC50 of DHA as determined by Fivelman et al., 2004  and 
Zongo et al., 2011 are 1.67 ± 0.43 nM and 3.15 nM which ± 1 respectively. These compare 
favourably with the average value of 2.43 nM obtained in the three assays in this current 
study. 
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Fig 2.7 Light microscopy image of control and treated parasites after Giemsa staining: 
Showing pictures obtained from the Giemsa light microscopy representing  infected 
control and DHA treated cultures. 
2.4 Aqueous or methanolic extraction of plant material 
100 g of dried plant material was air dried in shade and pounded into a coarse powder using 
a pestle and mortar. The plant material was subjected to cold maceration in water (aqueous) 
or 70% methanol ( methanolic extraction) for 24 h on a shaker.   The plant was filtered using 
whatmann paper and the resultant filtrate was concentrated using a rotary evaporator 
maintained at 70°C until a dried powder was obtained. 
2.5 Drug/extract stock preparation.  
Dihydroartemisinin (DHA) was prepared by making a 5 mM stock solution. This was 
prepared by  considering its molecular weight (MW) of 284.35 and using it for standard 
molar calculations. Briefly, 1.4 mg of the powder stock was dissolved in 1 ml of DMSO to 
obtain a primary stock concentration of 5 mM. The stock was aliquoted into small 
eppendorfs of 5 µl volume and stored at -20°C until use. Extract stocks on the other hand 
were made as 20 mg/ml stock by weighing 0.02 g and dissolving in 1ml DMSO. The 
dissolved extracts were aliquoted into eppendorfs at 50 µl volume and stored at -20°C for 
future use. 
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2.6  Phytochemical test methods 
The aqueous and methanolic bark extracts were subjected to phytochemical screening for 
the presence of terpenoids, saponins, flavonoids, sterols, glycosides, alkaloids, and 
anthaquinones according to standard procedures previously reported by Trease and Evans, 
1989. 
i) Flavonoids: A few drops of 1% ammonia solution was added to the extract sample 
in a test tube. The presence of flavanoid was confirmed by a yellow coloration. 
ii) Saponins: 0.5 g of test extract was dissolved in boiling water, allowed to cool, and 
shaken vigorously forming a froth. The froth was mixed with 3 drops of olive oil, 
and the formation of an emulsion indicated the presence of saponins.   
iii) Terpenoids: 0.5 g extract sample (aqueous or methanolic) was mixed with 2 ml of 
chloroform in a test tube. 3 ml of concentrated sulphuric acid (H2SO4) was carefully 
added to the mixture to form a layer. Presence of terpenoids was confirmed by the 
formation of an interface with a reddish brown coloration.    
iv) Glycosides: A 10 ml quantity of 50% concentrated H2SO4 was added to 0.5 g of the 
test extract in a test tube. The mixture was heated in boiling water bath for 5 min. 10 
ml of Fehling’s solutions (5 ml of solutions A and B each) was added, and the 
mixture was boiled. The presence of glycosides was indicated by the formation of a 
brick red precipitate.  
v) Tannins: 0.5 g of the test extract was boiled in 10 ml of water in a test tube. A few 
drops of 0.1% ferric chloride was added. Presence of tannins was indicated by the 
emergence of a brownish green or bluish black coloration.    
vi) Phenolic compounds: A few drops of 10% aqueous ferric chloride solution was to a 
1ml alcoholic solution of the test extract in a test tube. The presence of phenolics 
was confirmed by the emergence of blue or green color.  
vii) Alkaloids: 1 ml of 1% hydrochloric acid was added to 3 ml of the extract in a test 
tube. A few drops of Draggendorff’s reagent was added to the mixture. The presence 
of alkaloids was confirmed by the formation of a reddish brown precipitate.   
viii) Sterols: 0.5 g of the extract was extracted in 10 ml chloroform. 2 ml of acetic 
anhydride was added followed by 2 ml of concentrated H2SO4. A color change from 
violet to blue or green confirmed the presence of sterols.   
ix) Anthaquinones: 0.5 g of the extract was boiled with 10 ml of concentrated H2SO4.  
The mixture was filtered and the filtrate was shaken with 5 ml of chloroform. The 
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chloroform layer was removed, and  1 ml of 10% aqueous ammonia was added. The 
appearance of  a pink, violet, or red tint in the solution confirmed the presence of 
anthaquinones. 
2.7 Chapter Conclusion. 
In this chapter, two SG fluorescent-based assay methods were explored for the investigation 
of malarial parasite growth in cultures. Giemsa light microscopy, the standard gold malaria 
detection method, was used as a positive control to confirm the effectiveness of the assays. 
Percentage parasitaemia of cultures was calculated in all the three methods. The results of 
this chapter showed a relatively comparable results in all three assays: namely the SG-
microplate assay, the Giemsa light microscopy and the SG-FCM. The SG-FCM method was 
very useful and proved to be the most desirable method due to its accuracy in giving the 
exact parasitaemia and further information about the exact stages of the parasite. Giemsa 
light microscopy also had the advantage of giving information about parasite stages, via 
viewing the morphological changes in parasites. The main disadvantage of this method is 
its subjective nature. In the case of the SG-Microplate assay, the method showed a 
correlation between the level of fluorescence units  with parasitaemia. The higher the 
parasitaemia, the higher the level of fluorescence units. Hence, it is a useful method in drug 
assays as treated samples can be compared with control (non treated) samples in terms of 
fluorescence levels. The limiting factor with the SG-Microplate assay is parasitaemia can 
not be established and parasite stage cannot be detected. Hence data from this assay can 
only be interpreted in terms of percentage dose inhibition which can be used to establish the 
IC50 value. Hence the results of this chapter has shown that SG fluorescent-based methods 
can be a fast and reliable method of detecting parsitaemia and compare favourably to the 
standard detection method, light microscopy.  The SG-FCM assay was shown to be the most 
specific and accurate method in our laboratory, as it gives an exact parasitaemia with 
detailed stages of the parasite. The main drawback with this assay is although the reagents 
are cheap, it requires expensive laboratory equipment and it is more time consuming. The 
Giemsa light microscopy is the cheapest and fastest method, but  it requires expertise and 
can be subjective. It can also be used to determine the exact stages of the parasites. 
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CHAPTER 3  
 
Ethnopharmacological validation of selected plants from Nigeria. 
3.1 Introduction 
The 21st century has witnessed a paradigm shift from man’s reliance on tradional medicine 
(TM) to over reliance on modern medicine for the treatment of many ailments. In most 
developing nations, governments have adopted and only recognise modern day medicine in 
their healthcare system. This approach has however led to a disconnect between the common 
practices of the people and what is available within various healthcare systems. This is 
reflected in the fact that the mainstay of healthcare for over 80% of the world population in 
these regions is based on traditional medicine. The main reasons for this include poverty, 
lack of accessibility to healthcare systems and traditional beliefs such as lack of trust in 
modern medicine. In developed countries however, a new concept of herbal technology is 
gaining attention internationally with a vast amount of literature available, thereby creating 
more awareness. In recognition of this, the WHO has passed a number of resolutions in 
response to this resurgence on the study and use of TM in healthcare systems. The WHO 
has urged nations to utilize their traditional  medicine systems and develop a comprehensive 
approach to the subject of medicinal plant usage (Mashelkar et al., 2001). In view of this, 
this chapter aims to validate the ethnopharmacological claims of the antimalarial properties 
of some selected plants from Nigeria. 
3.2 Validating the ethnopharmacological claims of some plants used for malaria. 
Ethnopharmacology is the scientific study of plants that are used by a group of people within 
the same ethnicity or sharing the same cultural practices. It is usually centred around folk 
medicine and is typically linked to plant use, ethnobotany. The ethnopharmacological usage 
of plants for different diseases have been extensively studied. In malaria alone, over 1200 
plant species from 160 families have been documented for the treatment of malaria or fever 
(Willcox and Bodeker, 2004). An ethnobotanical survey is the first step in the identification, 
selection and development of the therapeutic agents from medicinal plants, however a 
detailed survey is beyond the scope of this study. In ethnobotany and natural products 
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chemistry, the mode of preparation and administration of herbal preparations are often 
crucial variables in determining efficacy in pharmacological evaluation (Levine, 1981; 
Lewis et al., 1998; Albers–Schonberg et al., 1997). Traditionally,  plants are generally 
prepared by hot water extraction, alcoholic extraction or soaking plant material in fermented 
corn water. The remedies are usually taken based on a strong beliefs and trust in the 
herbalist, whose knowledge is usually passed down generations. Most people do not 
consider the possibility of toxic effects that could arise from these herbs. The herbalist 
usually gives recommendations by giving a certain amount of plant material and asking 
individuals to boil in a specific amount of water for daily oral consumption. Some plants are 
used in bath, steam inhalations or as incense. In this study, plants were selected based on 
recommendations by herbalists in Kano and Abuja region of Nigeria. The objective was to 
validate the ethanopharmacological claims for malaria of the selected plants and ascertain 
the safety profile using both in vitro assays and in vivo tests.  
   Local name  Botanical 
name 
 Collection 
point 
 
    Tazargade (whole plant) 
 
     
 Artemisia 
maciverae 
 
  Kano 
 
 
 
Kizni   (bark)   
 
 
 Bridelia 
ferruginea 
 
 Suleja 
 
 
 
Kimbar mahalbar/halillua/tsamiyar 
 kurmi (bark) 
 
 Byrsocarpus 
Coccineus                                             
 
 Kano 
 
 
Bagaruwa 
 
 
     Bombax      
buonopozense 
 
  
Kano 
 
 
 
Hannu 
 Boswellia 
dalziellii 
 
 Kano 
 
 
Coded NIPRD extract  Coded   Coded  
 
Table 3.1 Selected plants for antimalarial studies: Showing the plants selected for this 
study and their botanical and local names. 
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3.3 Background on selected plants 
3.3.1 Artemisia maciverae: 
Artemisia marciverae belongs to the plant genus Artemisia. This is a large, diverse genus of 
plants with between 200 and 400 species belonging to the daisy family Asteraceae. Most 
species have strong aromas and bitter tastes, most likely due to the presence of terpenoids 
and sesquiterpene lactones. Artemisia annua from which artemisinin was derived from 
belongs to this large group of family.  Plants in this family grow as herbaceous shubs. 
Artermisia maciverae commonly grows in the wild in northern Nigeria. It is locally known 
as ‘tazargade’ and commonly used for various ailments. Locals believe it cures up to 99 
ailments. For this reason, this plant is found in various herbaceous mixtures and is the master 
ingredient in the concoction of several herbalist.  
3.3.2 Bridelia ferruginea: 
It is a shub belonging to the family Euphorbiaceae. Sometimes it reaches the size of a tree 
under suitable conditions. It is the most common savannah Bridelia. The tree is 6-15 m high; 
the bark is grey and often scaly. Geographically, it spreads though West Africa all the way 
to Zaire and Angola. It has various local names in different languages, kizni (Hausa), 
iralodan (Yoroba), mareni (Fulani) and ola (Igbo). The leaves, bark and fruits are used for 
the treatments of various diseases (Dalziel et al., 1937). It is commonly used for various 
ailments including as a purgative and vermifuge (Imanga et al., 1999). The bark is used for 
the coagulation of milk and as a traditional mouth gargle (Orafidiya et al., 1990). It is 
commonly used as a chewing stick and the bark has also been reported to have molluscidal 
activity (Iwu, 1984). The root and bark are also used for intestinal disorders and certain skin 
conditions (De-Bruyne et al., 1997). It has also been reported to have anti-inflammatory, 
antipyretic and analgesic properties (Olajide et al 2000). It is used in various paediatric 
preparations the most common called ‘agbo’ by the Yoroba people of Nigeria. It is also 
commonly used for the treatment of malaria infections in both children and adults (Iwu, 
1993). The plant has several other uses as well as having trypanocidal activity. Studies by 
Atawodi et al., 2005 and Ekanem, 2008 compared different solvent extracts of the plant 
against Trypanosoma species and found the methanolic extract to be the most active. 
Pasternek et al., 1979 have also shown the plant to increase platelet counts in rats. The bark 
is also used in rural communities for waste water treatment.  Studies by Kolawole and co-
workers showed that the extract caused a significant clarification and sedimentation of total 
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suspended solids in a comparative manner to alum and ferric chloride.  Interestingly, another 
study by Owoseni et al 2010 and Tall et al., 2002 have shown the plant to possess 
antimicrobial activity against different microbes. This is an added advantage in its use for 
waste water treatment since studies by James (2000) have shown presence of human excreta 
in domestic waste water as major public health concern. 
 
 
 
Fig 3.1: Bridelia ferruginea  
3.3.3 Byrsocarpus coccineus:  
Byrsocarpus coccineus (B. coccineus) is a scrambling shub or small tree with leaves folding 
downward. It belongs to the family Connaraceae which grows in various parts of West 
Africa including Nigeria, Ghana and Burkina Faso. It has different local names in different 
communities for example  ‘kimbar maharba, halillua or tsamiyar kurmi’ in Hausa; ‘oke 
abolo’ in Igbo and ‘awuje wewe’ in Yoruba. It is used as a traditional medicine in various 
concoctions. Different parts of the plant are used for different ailments. The plant is most 
commonly used for the treatment of haemorrhoids (northern Nigeria and Ghana), venereal 
diseases and dysentery (southern Nigeria), swellings, tumours and malaria (northern 
Nigeria). Several studies have evaluated the ethnopharmacological properties of this plant. 
Studies by Akindele et al., 2010 investigated the hepatoprotective properties of the plant 
against carbon-tetra chloride induced liver damage in rats. The study further evaluated the 
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antioxidant properties of the plant, with the outcome suggestion that the plant has significant 
hepatoprotective properties. In the same study, the acute toxicity of the plant was expressed 
by the median lethal dose value (LD50). The extract was found to be safe up to a high dose 
of 158.4 mg/kg in the acute toxicity tests. Subchonic tests  in rodents revealed that the plant 
causes no significant changes in both biochemical and haematological parameters at that 
dose. Chonic tests however showed that the extract significantly increased white blood cell 
count, reduced liver enzymes, total cholesterol, triglycerides and total protein. The weight 
of certain organs including the heart and lungs was found to increase after prolonged 
exposure. This implies that the plant might be safe to take for short term use but some 
adverse effects could occur in long term use ( Akindele et al.,  2010). Other pharmacological 
properties reported include pain relief and diarrhoea (Akindele et al., 2006) and pyrexia 
(Akindele et al., 2007). 
 
Fig 3.2: Brysocarpus coccineus  
3.3.4 Bombax buonepozense: 
Bombax buonopozense is commonly known as the ‘gold coast bombax’ or red-flowered silk 
cotton tree. It belongs to the family Malvaceae formerly Bombacacea. It has a good 
geographical distribution across West Africa where it is primarily native, spreading right 
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from Sierra Leone to Uganda, Nigeria, Ghana and Gabon. It grows  typically at elevations 
of 900 to 1200 metres and can grow up to 40 metres (130 feet) height with buttress roots up 
to 6 metres (20 feet) in diameter. The tree is leafless and its bark is often covered in spines 
with  deep pink-to-red flowers emerging from it. It is called ‘bagaruwa’ amongst the hausa 
people. The plant material has several uses. It’s cotton like seeds are used as a source of 
clothing and pillow fibre. Different parts of the plant are used as part of herbal preparations 
by herbalist, expecially the bark. The bark is burnt to produce a smoke that is believed to 
drive away evil spirits called in certain cultures, it is used in treating wounds and swellings 
and also the gum is used as an incense preparation called’ turaren wuta’ which is a very 
common tradition within the hausa and kanuri ethnic groups. The wood is also commonly 
used in building canoes due to its light nature. The bark is rich in tannins making it find 
applications in the traditional tanning industry. 
 
Fig 3.3 Bombax buonopozense: Showing a Bombax buonopozense stem bark, its 
geographical distribustion and its flower. 
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3.3.5 Boswellia dalziellii: 
Boswellia dalzielii belongs to the plant genus Boswellia found in Africa. Boswellia dalzielii  
belongs to the family, Burseraceae. It is a tree of the Savanna forest recognizable by its 
papery bark peeling off in a ragged manner. The bark yields a whitish gum resin, which 
dries readily and is friable. The bark of the tree is popular among the locals in north-western 
Nigeria as a potent source of ethnomedicine. The Hausa speaking people refer to it as 
hannu, harrabi or ararrabi. The leaf extract is used for the treatment of diarrhoea in 
poultry. The root decoction of the plant is used for wound healing (Etuk et al., 2006). The 
fresh bark is eaten to induce vomiting and relieve symptoms of giddiness and palpitations. 
The root decoction of the plant boiled along with Hibiscus sabdariffa is used for the 
treatment of syphilis. The fragrant gum resin from the plant is used locally for fumigation 
of houses and as a deodorant (Etuk et al., 2006). Oil from the leaves of B. dalzielii was 
found to exhibit significant activity against Staphhylococcus aureus, Bacillus subtilis and 
Candida albicans (Nwinyi et al., 2004). The aqueous stem bark extract of the plant was 
reported to show anti-ulcer activity and reduced gastrointestinal motility (Nwinyi et al., 
2004) and to possess anti-diarrhoeal effects, which may be related to anticholinergic 
mechanisms (Etuk et al., 2006). Crude extracts of the stem bark of this plant have been 
found to show antibacterial activity against both gram-positive and gram-negative bacteria 
(Olukemi et al., 2005). Despite the widespread uses of this plant in treating a plethora of 
human and animal diseases in this environment, little work has been done on its 
phytochemistry and its effects on some major organs in the body. The plant products (such 
as the gum resin) and different parts of the plant are widely employed in traditional 
medicine. The gum resin is used along with other medicines as gastrointestinal ailments and  
for  the  treatment  of   veneral   diseases. 
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Fig 3.4: Boswellia dalzielli: Showing stem bark of Boswellia dalziellii and the whole tree 
in a typical sahara in North Western Nigeria. 
3.3.6 SNO5 extract:  
Preliminary in vitro work was done our laboratory and the plant is taken forward for in vivo 
studies by collegues at the NIPRD, Abuja, Nigeria.  
3.4 Phase I screening for initial phenotypic antimalarial activity determination 
3.4.1  Plant collection and extract preparation 
Bombax buonepozense,  Bridelia ferruginea, Brysocarpus coccineus, Artemisia maciverae, 
Boswellia dalzellii and the NIPRD coded extract, were all collected from Nigeria and water 
extraction was performed in NIPRD. The plant materials were shade dried, grinded and and 
soaked in water for 24 h on a shaker. The plant material was filtered using a Whatmann 
paper and the filtrate was evaporated o dryness in a water bath. The dried extracts were 
stored in dried bottles and sent to the University of Salford for use in our laboratory. 
3.4.2  Antiplasmodial screening of extracts 
Plants were screened for antimalarial activity using the three optimised assays decribed in 
chapter 2, namely the SG-Microplate assay, SG-FCM and Giemsa light microscopy. The 
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extracts were screened by initially challenging K1 P. falciparum  parasites with three 
randomly  selected doses (20, 40 and 80 µg/ml) of the extracts. The parasite culture was  
incubated for 72 h under standard culture conditions described in section 2.1.5.  At the end 
of 72 h, thin blood smears were prepared for each sample for analysis by Giemsa microscopy 
as well as following the respective protocols for the SG-Microplate assay and SG-FCM.  
3.4.2.1 SG-Microplate screen of plant extracts: 
Following the SYBR green assay, the results were collated and dose-response plots were 
obtained by normalising the percentage parasitaemia values for each group. Experiments 
were represented as mean value of triplicate data from three independen experiments,  on 
Graphpad Prism. Fig 3.5 below shows the dose-response analysis 
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Fig 3.5 Preliminary phase I screen using SG-Microplate assay: Showing the preliminary 
phase I screen of various extracts against K1 cultures using the SG-Microplate. Control and 
extract- challenged extracts at ring stage for 72 h.  Each curve represents independent 
experiment. Experiments were performed in triplicate and IC50 values were generated using 
graphpad prism   for SN05, B. buonopozense,  B. coccineus, B. ferruginea, A. maciverae 
and B. dalzielli were 21.63, 31.28, 29.23, 15.33, 27.50 and 33.48µg/ml respectively.     
Statistical analysis of the preliminary data represented in fig 3.5 using a one- way ANOVA 
analysis on Graphpad prism showed a significant difference between control and extract-
treated cultures with a P < 0.0001 in all six extracts. A Bonferri post test analysis was 
performed and there was no difference between extracts P > 0.05 in all six extracts. 
The results of the preliminary screen for the six extracts using SG-Microplate assay shows 
that all the extracts exert antimalarial activity on cultures in a dose-dependent manner.  
3.4.2.2 Giemsa light microscopy screen for plant extracts. 
Slides prepared for Giemsa light microscopy were visualised under light microscopy and 
parasitaemia counted using oil immersion at X 100. The results were plotted using grouped 
data analysis on Graphpad Prism.  
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Fig 3.6 Preliminary phase I screen using Giemsa light microscopy: Showing the 
preliminary phase I screen of various extracts against K1 cultures using the Giemsa light 
microscopy. Control and extract- challenged extracts at ring stage for 72 h.  Each curve 
represents independent experiment of triplicate data.  IC50 values generated using graphpad 
prism   for SN05, B. buonopozense,  B. coccineus, B. ferruginea, A. maciverae and B. 
dalzielli were 21.70, 14.64,, 20.95, 15.29, 27.38 and 33.48µg/ml respectively.     
Statistical analysis of the preliminary data represented in fig 3.6 above using a one- way 
ANOVA analysis on Graphpad prism showed a significant difference between control and 
extract-treated cultures with a P < 0.0001 in all six extracts. A Bonferri post test analysis 
was performed and there was no difference between extracts P > 0.05 in all six extracts. 
The results of this assay compares with that of the SG-Microplate test. There was a 
significant difference observed between control and all extract-treated groups at all dose 
levels. 
3.4.2.3 SG-FCM Screen for plant extracts 
Results for control and extract treated cultures that were analysed using the SG-FCM 
analysis as described in chapter two were analysed using Graphpad Prism 6. Grouped data 
method analysis was used. The graphical and statistical results are presented below: 
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Fig 3.7 Preliminary phase I screen using SG-FCM assay: Showing the preliminary phase 
I screen of various extracts against K1 cultures using the SG-FCM. Control and extract- 
challenged extracts at ring stage for 72 h.  Each curve represents independent experiment 
of triplicate data.  IC50 values generated using graphpad prism   for SN05, B. buonopozense,  
B. coccineus, B. ferruginea, A. maciverae and B. dalzielli were 30.42, 31.87, 29.27, 13.26, 
28.44 and 30.47µg/ml respectively. 
Statistical analysis if the data for the SG-FCM analysis using one-way ANOVA revealed a 
significant difference between control and all six extract treated cultures with P values < 
0.001. A bonferri post test was used to investigate differences between the various extracts 
and there was no difference with each showing a P value > 0.05.  
Hence preliminary tests have revealed that the extracts show strong antimalarial activity in 
all the three assays used with a high level of significance and low IC50 values < 50µg/ml in 
all six extracts. 
3.4.2.5 SG-FCM, SG-Microplate and Giemsa assay of chloroquine and dihydroartemisinin 
(DHA) as positive controls 
Chloroquine was used as a positive control in order to validate the assays and compare the 
IC50 with reference values. 
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Fig 3.8 IC50 determination for chloroquine (CQ) and DHA using SG-Microplate, SG-
FCM and Giemsa light microscopy: Fig 3.8A  IC50 values of 130.4, 145.2, 171.2nM were 
obtained for Giemsa, SG-Microplate and SG-FCM respectively for CQ using normalised 
plots with Graphpad prism software. IC50 values of 2.27, 2.21 and 2.58 nM were determined 
for DHA from the Giemsa light microscopy, SG-FCM and SG-Microplate assay 
respectively. 
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3.5 Phase II Screen of plant extracts 
Preliminary Phase I screens showed  significant an promising antimalarial activity on the 
multi-drug resistant K1 P. falciparum strain of the parasite. The collaborative nature of the 
project with NIPRD meant that phase II screening responsibilities were shared between the 
two institutions. Bryoscarpus coccineus and Bridelia ferruginea were sleceted to be taken 
further for second phase screening at the University of Salford due to their effectivity and 
wide biodiversity, hence availability, in West Africa. Furthermore, B. ferruginea has already 
been developed as a phytopharmaceutical drug for the treatment of diabetes mellitus, hence 
will have a defined toxicity profile data which could be accessed in order to go into clinical 
trials for malaria at the NIPRD clinical trial unit. 
3.5.1 Bridellia ferruginea collection 
The stem bark of B. ferruginea was collected from Odenigbo Nkalagu Obukpa district in 
Nsukka, Enugu State, Nigeria. The plant was identified by its leaves in the department of 
medicinal plant research at the National Institute for Pharmaceutical Research and 
Development (NIPRD), Nigeria. Specimen was deposited at the institute’s herbarium with 
the voucher number (NIPRD/H/6414). The international index label is Euphorbiaceae 
Bridelia ferruginea Niger FL. [W.J.Hooker].5111.1849[NOV-DEC 1849](IK). The plant 
bark was cleaned and cut into pieces and air dried at room temperature for a week . The bark 
was grounded to a powder form from which aqueous and methanolic extracts were prepared. 
The grounded plant material was soaked in water and 70% methanol respectively and left 
on a shaker for 24 h. The dissolved extracts were filtered the next day and the filtrate was 
evaporated to dryness in a water bath equipment. 
3.5.2 Dose response analysis for Brysocarpus coccineus using different assays 
The three assays (SG-Microplate, SG-FCM, Giemsa light microscopy) were used to obtain 
a dose-response analysis of B. coccineus in order to estimate the median inhibitory 
concentration (IC50). This is the dose required to kill 50% of the parasites. In order to 
calculate the percentage parasite growth inhibition for each dose level, the following 
formula was used: 
Percentage parasitaemia = (Control-Treated/Control) *100. 
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The values were plotted on a graph Prism software and the three assays were compared.  
All three assays were comparable and the IC50 value was in the region of 72 µg/l. 
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Fig 3.9 Antiplasmodial activity of B. coccineus using different assays: Showing the 
antiplasmodial activity of B. coccineus against K1 cultures using three different assays (SG-
Microplate, Giemsa light microscopy and SG-FCM). The IC50 value was in the region of 
72.83, 78.98 and 81.37µg/ml for SG-Microplate assay, Giemsa light microscopy and SG-
FCM. This was obtained through dose-response simulation using Graphpad prism software. 
One-way ANOVA analysis was also performed on the data represented in Fig 3.9 aove to 
determine if there was any significant difference between the three methods of analysis. The 
results showed that in all three assays, there was a significant difference between control 
values and treated values with a P value < 0.01 in all treatment groups across all the assays. 
Further analysis also revealed that there was no significant difference between the SG-
Microplate assay Vs Giemsa light microscopy with a P value of 0.0823; SG-Microplate 
assay Vs SG-FCM with P < 0.05; SG-FCM Vs Giemsa light microscopy with P < 0.05. 
The results of this study shows a dose dependent parasite growth inhibition of the extract. 
The IC50 value in all three assays was in the region of 72 µg/ml and analysis by Graphpad 
Prism (see table 3.5 above) show that these findings are significant. The treated culture is 
significantly different to control cultures at all the dose levels tested.  
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3.5.3 Dose response analysis for aqueous B. ferruginea using different assays 
The dose-response activity of aqueous B. ferruginea was evaluated by incubating ring stage 
parasites for 72h. On the final day of incubation, the challenged parasites were prepared for 
SG-microplate assay, Giemsa microscopy and SG-FCM using methods previously 
described. The results of these assays are presented in the graph in fig 3.9 
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Fig 3.10 Antiplasmodial activity of aqueous B. ferruginea against K1 P. falciparum 
cultures using different assays: Showing the assay results are the same for the three assays 
with a comparable  IC50 value in the region of 50 µg/ml for all the three assays as indicated 
in the graph.  
The IC50 values determined using the Graphpad prism software for the data represented in 
Fig 3.10 above were 48.25, 55.95 and 54.32 µg/ml for SG-Microplate, Giemsa microscopy 
and SG-FCM respectively. There was no significant difference between the three assays 
with P >  0.05 in all cases. 
3.6 Comparing aqueous and methanolic B. ferruginea 
For the scope of this study, B. ferruginea was chosen as the candidate to proceed with. The 
main reason for this decision is, it already exist as a phytopharmaceutical drugs for diabetes 
hence commencing clinical trials for malaria will be likely. The extract has also shown an 
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IC50 dose range within an acceptable value for plant extracts (up to 100 µg/ml) and also 
lower than that of B.coccineus. Furthermore, the plant has a proven track record of extensive 
use within various communities and it grows abundantly in the wild. In view of these factors 
the methaonolic extract was explored to see if it is more potent due to the fact that 
methanolic extracts tend to be rich in flavonoids and terpenoids which have been previously 
implicated in malaria (Ntie-Kang et al., 2014). 
3.6.1 Comparing the aqueous and methanolic extract of B. ferruginea using the SG-
Microplate assay 
Both the aqueous and methanolic extract of B. ferruginea were incubated in trophozoite 
stage cultures for 48 h and subsequently analysed using SG-Microplate assay. The results 
are represented in fig 3.10 below: 
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Fig 3.10 Comparing the activity of aqueous and methanolic B.ferruginea against K1 
cultures using SG-Microplate assay: The results show that the methanolic extract of B. 
feeruginea showed a higher inhibition of parasitaemia at all dose levels compared with the 
aqueous extract. The IC50 for the aqueous extract was 22.52 whilst that for the methanolic 
extract was 14.75 µg/ml. was generated using the average of three independent experiments 
on graph pad prism.There is a left-ward shift in the dose-inhibition curve. 
The results were further analysed using one-way ANOVA in Graphpad Prism . The 
statistical analysis showed that the aqueous and methanolic B. ferruginea was significantly 
different with P value of  0.013.  
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3.6.2 Comparing the aqueous and methanolic extract of B. ferruginea using Giemsa light 
microscopy 
Aqueous and methanolic extracts of B. ferruginea were incubated in K1 cultures at 
trophozoite stage for 48 h and the cultures were analysed using the Giemsa light microscopy 
described in section 2.1.4. The data was analysed using Graphpad Prism and presented in 
fig 3.11 below. 
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Fig 3.11 Comparing the activity of the aqueous and methanolic extracts of B. ferruginea 
against K1 cultures using Giemsa light microscopy analysis: The results showed that the 
methanolic extract exerted a higher parasite killing compared with the aqueous extract. The 
average IC50  for the aqueous extracts was 24.05 whilst that for the methanolic extract was 
15.31 as generated using graphpad prism. 
Results analysed using one-way ANOVA in Graphpad prism showed that the methanolic B. 
ferruginea was significantly more potent than the aqueous extract with a P value of  0.002. 
 
3.6.3  Comparing the aqueous and methanolic extracts of B. ferruginea using SG-FCM 
assay 
K1 P. falciparum cultures at trophozoite stage were challenged and incubated for 48 h. After 
the incubation period, the cultures were prepared for SG-FCM analysis as previously 
described in chapter 2. 
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Fig 3.12 Comparing antiplasmodial activity of aqueous and methonolic B. ferruginea  on 
K1 P. falciparum cultures using SG-FCM analysis: The results show that the methanolic 
extract is more efficacious with a lower IC50 value of 16.14 whilst the aqueous extract had 
an IC50 value of 25.69. 
Column Statistical analysis of the data represented in Fig 3.12 above using One-way 
ANOVA showed that the difference observed between doses are significantly different P 
<0.001 whereas there is no significant difference between the three assays P > 0.01 
3.7 Time point assay for methanolic B. ferruginea 
As the methanolic extract seemed more potent, with an IC50 near 15 µg/ml, a time point 
assay investigation was performed using SG-FCM assay, as it is the most specific and 
accurate amongst the three assays. Cultures were split into 5 ml culture volumes in 25 cm3 
flasks for each timepoint. Moreover, each timepoint had  a control and treated flask with the 
control being the unchallenged culture whilst the treated culture was challenged with 20 
µg/ml of the methanolic extract. The experiment was initiated at ring stage. The 
parasitaemia of the culture was checked at the commencement of the experiment and at 
various intervals i.e 0 h, 2 h, 4 h, 6 h, 24 h, 48 h and 72 h.  The experiment was repeated 
three times for statistical analysis. The data was analysed using Graphpad Prism and the 
graphical results are represented in fig 3.13. The experimental data was represented after 
calculating the percentage inhibition of the challenged extracts relative to control cultures.  
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Fig 3.13 Timepoint assay for methanolic B. ferruginea: Graph representing the 
percentage inhibition of parasite growth during the time point assay after challenging 
cultures with 20 µg/ml methanolic B. ferruginea at ring stage.. The extract showed an early 
onset of action as early as 2 h post challenge. 
The results of this experiment showed a time dependent parasite killing. At 2 h, 4 h and 6 h, 
percentage parasite inhibition gradually increased to about 20% and about 58% inhibition 
was observed at 48 h and 72 h. One-way ANOVA shows that at 2 h, 4 h and 6 h, although 
a difference was observed, the results were not statistically significant with a P value of 
0.18, 0.15 and 0.12 respectively. At 24 h, 48 h and 72 h, the statistical analysis shows that 
there is a significant difference with control with a P value < 0.005. 
3.8 Effect of B. ferruginea on erythocytic stages 
Different drugs act on different stages of the malaria parasite via different mechanisms. The 
main aim of this experiment was to investigate the effect of the extract incubated at different 
erythocytic stages of the parasite life cycle. Synchonised cultures at either ring or 
trophozoite stages were challenged with 20 µg/ml of the extract and harvested at 24 h, 48 h 
and 72 h. Different flasks were set up for different timepoints and each timepoint had its 
control flask in parallel with the treated culture. The results of this assay are  graphically 
represented below. 
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3.8.1 Effect of B. ferruginea extract on ring stage cultures 
Cultures were synchonised using method previously described in section 2.1.6. Briefly,the 
synchonised cultures were challenged at ring stage with 20 µg/ml. The effect of the extract 
was evaluated at four time points (0 h, 24 h, 48 h and 72 h). Each timepoint was set up with 
three 12.5 cm3 flasks (5 ml culture volume), challenged with 20 µg/ml B. ferruginea, a 
positive control flask challenged with 5 nM DHA and a negative control unchallenged flask. 
Hence a total of 12 flask per experiment. The experiment was repeated with the same 
conditions in triplicate. The results are graphically presented in fig 3.14 below: 
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Fig 3.14 Effect of B. ferruginea sand DHA on Plasmodium ring stages: Shows that the 
extract is effective on ring stage parasite stages with the highest activity observed at 48 h 
and 72 h for both B. ferruginea and DHA. DHA was used as a positive control as it is known 
to act on all parasite stages. One-way ANOVA analysis of the data using Graphpad Prism 
6 also showed that there was a significant difference between control and treated samples 
at 48 h and 72 h.  p < 0.001. 
3.8.2 Effect of B. ferruginea extract on trophozoite stage cultures 
Synchonised cultures at trophozoite stage were challenged with 20 µg/ml of methanolic B. 
ferruginea and also 5 nM DHA as described in section 3.7.1. At 0 h, 24 h, 48 h and 72 h, 
the cultures were harvested for SG-FCM analysis and the results are graphically represented 
below. 
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Fig 3.15 Effect of methanolic B. ferruginea and DHA on Plasmodium trophozoite stages: 
Showing the effect of methanolic B. ferruginea and DHA  on the trophozoite stage parasites 
with a higher inhibition compared to the ring stage experiment. One-way ANOVA analysis 
using Graphpad Prism showed the difference between control and its parallel treated 
culture was significant, P < 0.001. 
3.8.3 Comparing ring and trophozoite stage challenged cultures 
The graph below shows a comparison of cultures challenged at ring and trophozoite stage 
with B. ferruginea methanolic extract 
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Fig 3.16 Comparison of the effect of B. ferruginea on ring and trophozoite stages:  
Showing the the percentage inhibition of parasitaemia by methanolic B. ferruginea on 
parasite erythocytic stages. 
One-way ANOVA analysis using Graphpad Prism 6 showed there was a significant 
difference between inhibition in ring and trophozoite stage cultures at 24 h for  B. ferruginea 
treated cultures, P < 0.01 and at 48 h P < 0.05. The difference between the two stages was 
not significant at 72 h  (P > 0.05). The inhibition was noted to be less at 72 h at both parasite 
stages possibly because the parasites have gone into the next cycle. 
3.9 Phytochemical screening of B. ferruginea 
Qualitative phytochemical analysis were performed for alkaloids, saponins, flavonoids, 
terpenes, tannins, sterols, glycosides and phenols using standard procedures. The results 
could be used to establish the possible active secondary metabolites in both the aqueous and 
methanolic extract of B. ferruginea. Aqueous extraction methods are known to extract 
anthocyanins, starch, tannins, saponins, terpenoids, polypeptides and lectins. Methanolic 
extraction method on the other hand is known to extract anthocyanins, terpenoids, saponins, 
tannins, flavones, phenols, polyphenols and lactones (Tiwari et al., 2011). 
 Phytochemical test results 
  Test    Aqueous                     Methanolic 
                                                    B. ferruginea Bark        B. ferruginea Bark 
Alkaloids Present Present 
Flavanoids Present Present 
Tannins  Present Present 
Terpenes Present Present 
Cardiac Glycosides Present Present 
Saponins Present Present 
Phlobatannins Present Present 
Anthaquinone Absent Present 
Sterols  Present  Present 
Cyanogenic glycosides Absent Absent 
Resins Present Present  
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Table 3.2 Phytochemicals in aqueous and methanolic B. ferruginea stem bark: Showing 
the presence of different phytochemicals in B. ferruginea stem bark. Anthaquinone was 
found to be absent in the aqueous bark extract but present in the methanolic extract. 
The results of the phytochemical test have confirmed the presence of various bioactive 
compounds including alkaloids, saponins, tannins, flavanoids and terpenes amongst other 
constituents. 
3.10 Conclusion 
The five plants screened in this study have several ethnopharmacological usage, including: 
tumour management, malaria, fever, diarrhoea amongst other disorders. The bio-evaluation 
of the pharmacological actions of the plant extracts in the current chapter shows that they 
have a strong antimalarial activity. Based on the results, B. ferruginea was chosen as a 
candidate fo this study due to its wide biodiversity and also the fact that it is already used as 
a phytopharmaceutical drugs for diabetes in Ghana. The extract showed a dose-dependent 
inhibition of K1 P. falciparum malaria culture, supporting the ethnopharmacological claim 
of its activity against malaria. A very interesting finding is the fact that the extract showed 
an early onset of action as early as 2 h, 4 h and 6 h  post incubation. The results were however 
statistically different to control, with a P value > 0.05, but they were consistent in all 
triplicate experiments. There was a statistical difference between the control group and 
treated groups at 24 h, 48 h and 72 h post challenge with a P value < 0.005. The results in 
this chapter have shown that the methanolic B. ferruginea extract has anti-malarial activity 
and is active against all both the ring and trophozoite stage of the erythocytic parasite cycle. 
The results also show that the extract has an early onset of action, hence will be potentially 
relevant  in the clinical application for malaria. 
The results of the phytochemical analysis in this chapter revealed the presence of several 
secondary metabolic compounds (phytochemicals). Phytochemicals have shown to be a 
useful source of human medicine (John et al., 2013). The results of this study can be used 
in crude plant quality control and elucidation of the therapeutic mechanism of action of the 
plant extract. 
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CHAPTER 4  
 
Investigating the mechanism of action of methanolic Bridelia ferruginea  
4.1 Introduction 
Over the years, several antimalarial targets have been discovered some of which have 
already been discussed in Chapter 1. Quinine, for example, has been implicated in targeting 
the haem detoxification pathway whilst other drugs like atovaquone have been shown to 
target the mitochondria. 
The malaria parasite consumes host cellular resources to grow and multiply as explained in 
the parasite life cycle (the erythocytic stage). During this multiplication stage within the 
host red blood cell, the parasite consumes up to 80% of its host cell haemoglobin. This 
digested haemoglobin is used by the Plasmodium as a source of amino acid as well as for 
maintaining osmotic balance. The entire process occurs in the parasite food vacuole which 
is acidic in nature. Once this digestion occurs, haem is released ( a porphyrin) as a by-
product. Haem is potentially toxic to cells as it catalyses the products of certain reactive 
oxygen species (ROS). Haem degradation is very critical to the Plasmodium as 
concentrations as low as 20 µM have been shown to lyse the parasite within a span of 10 
minutes. The Plasmodium has a mechanism of detoxifying this toxic product to a safe 
insoluble crystalline product called haemozoin. Haem has been shown to disrupt cell 
membranes, damage cell structures and cause cell lysis (Fitch et al., 1983). The haem 
detoxification pathway hence is an attractive target for antimalarial drug candidate. For the 
scope of this study, the haem detoxification pathway was explored to determine if B. 
ferruginea acts though this pathway. 
4.2 Haem detoxification 
The mechanism of haem detoxification is highly efficient. The malaria parasite consumes 
and digests about 70% of the host haemoglobin releasing free amino acids. About 16% of 
these amino acids are used for protein biosynthesis. As a small amount of the released amino 
acids are used up, the excess are discharged out of the infected erythocytes to the 
surrounding plasma (Rudzinska et al., 1965; Krughak et al., 1986; Zarchin et al., 1968; 
Kutner et al., 1985; Trager, 1994). The exact reason why parasites expend so much energy 
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in ingesting and digesting excess haemoglobin is yet to be understood.  The mechanisms of 
the haem detoxification pathway is also not fully understood, although several controversial 
pathways have been suggested. One pathway that is believed to be the most important and 
predominant is sequestration of haem into haemozoin, also known as malaria pigment. 
The process is a biocrystallization pathway converting the haem from a soluble monomeric 
form to an insoluble dimeric form, haemozoin (Hempelmmann et al., 2007). Each hemozoin 
crystal consist of 80, 000 haem molecules. Haemozoin accumulates in the parasite food 
vacuole which is acidic in pH. Several proteases including cysteine, aspartic and 
metalloproteases have been characterized from the food vacuole of P. falciparum. 
(Rosenthal, 2000). A multi- step mechanism has been proposed, suggesting more than one 
protease is involved in the degradation process, with the proteases cleaving the protein 
molecule at different sites (Sijwaoli and Rosenthal 2004) . These proteases digest the 
haemoglobin into small peptides and subsequently amino acids in a multi-step process 
involving cleavage of different proteases. Once the amino acids are released, a free ferrous 
protoporphyrin IX (Fe (II) PPIX) is released and rapidly converted to Fe (III) PPIX (haem) 
by oxidation.  When this multiple degradation process successfully releases haem, the free 
haem becomes a toxic by-product as mentioned earlier. This non-sequestered haem once 
accumulated, could lead to red cell lysis amongst other biochemical consequences. 
Other pathways that have been suggested for haem degradation include the involvement of 
enzymes. In mammals, haem oxygenase breaks down excess haem into three components 
(biliverdin, carbon monoxide and iron). Kituchi et al., 2005 have however shown that the 
Plasmodium lacks this enzyme hence it is a pathway unique to mammals. This difference is 
clearly exploitable for antimalarial drug design 
More recently, Huy et al., 2013 have proposed a phospholipid membrane-mediated pathway 
for haemozoin formation. Other groups have previously reported the involvement of 
histidine rich proteins (Sullivan et al., 1996). It is likely that a combination of these 
mechanism occur as different pathways have been speculated. In support of this,  Pandey et 
al., 2003 showed the involvement of both lipids and histidine rich proteins in haemozoin 
formation although another pathway  has been proposed outside of the parasite food vacuole. 
This is the glutathione-mediated and enzymatic degradation pathway. There is however no 
evidence of how the haem molecule translocates into the food vacuole (Egan et al., 2002). 
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4.3 Structure of haemozoin 
Haemozoin was initially thought to be identical to haematin but this has been proved 
otherwise due to their differential solubility characteristics in weak bases such as 
bicarbonate buffer and  DMSO (Slater et al., 1991). Haematin solubilises in both solvents 
whilst haemozoin doesn’t. 
Haemozoin  extracted from parasite lysate that accumulated in the liver and spleen have 
shown similar spectroscopic characteristics and solubility. Infrared (IR) data of haemozoin 
shows some peaks which are characteristics of the Fe-carboxylate bond at 1664 and 1210cm-
1 . Haem is a porphyrin molecule found in haemoglobin which has an extensive aromatic 
structure with a rich phytochemistry consisting of several π-π transitions appearing in the 
visible part of the electromagnetic spectrum. The UV absorbtion spectra of haem consists 
of an intense soret band around the region of λ=400 nm and also medium bands appearing 
at λ= 450-700 nm. The figure below shows a descriptive spectra of haem. 
 
 
Fig 4.1 UV spectra of haem and haemin: Showing the Ultraviolet (UV) spectra  of haem 
and haemin at 405 nm. 
(Source: http://pubs.rsc.org/en/content/articlelanding/2013/an/c3an00310h#!divAbstract). 
The infared spectrum of haemozoin shows that it is significantly different from haematin or 
haem but very similar to β-haematin. β-haematin exist in a dimeric form consisting of two 
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haematin molecules that are joined by H-bonding, just like the haemozoin molecule. Each 
haematin molecule consist of a central iron molecule which forms an iron-oxygen 
coordinate bond, linking the central iron of one molecule to the carboxylate side chain of 
the next haematin molecule, forming a dimer. These corresponding iron-oxygen bonds are 
unique to β-haematin and have not been observed in any other porphyrin structure. The 
molecule can exists in both linear and cyclic forms but never in a polymeric form 
(Hempelmann et al., 1994). 
4.4 Haem aggregation 
Haem aggregates as a result of mutual attractions between several haem molecules that are 
held by hydrogen bonding. These aggregates that form may vary slightly, but all have a 
similar absorbtion spectra ranging from 395 nm to 450 nm. This is why during in vitro 
studies for haemozoin assay, non uniform aggregates form, leading to excitation at different 
wavelenth within the stated range. The formation of side products can be minimised by 
several measures including using haemin rather than haematin as a starting material in the 
assay. 
4.5 Role of haemozoin in malaria pathogenesis 
Free haemozoin is released into circulation during the re-infection stage (i.e once the 
shizonts rupture). The haemozoin is phagocytosed into host cells leading to several 
biochemical changes including inhibition of erythopoiesis and red cell lysis. This is the main 
reason for anaemia in malaria patients (Skorokhod et al., 2010). Livers and spleens of 
patients with malaria appear dark and black upon necropsy after death, hence it is not known 
where and for how long haemozoin is deposited in the body (Hanschield & Egan 2007). 
4.6 Haemozoin as a target for antimalarials 
Haemozoin seems a very interesting target for antimalarials due to several reasons. 
Haemozoin formation is critical to parasite survival as the build up of haem is toxic to the 
parasite. Hence blocking the pathway will lead to the accumulation of haem in the parasite 
food vacuole causing parasite death. Another crucial factor that supports targeting 
haemozoin as a drug pathway is the mechanism of haemozoin formation. Biocrystallisation 
seems a unique pathway to parasites. As mentioned earlier, mammalian cells rely on an 
enzymatic pathway for haem formation, this enzyme is absent in the parasite. Hence by 
targeting the biocrystallisation pathway, the drug will be selective for the parasite and safe 
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to the host cell. Several blood schizonticidal antimalarials including quinolone drugs such 
as chloroquine and mefloquine act via the haem biocrystallisation pathway by inducing 
disruption of haem  (Tripathi et al., 2001). Some 8-aminoquinolones have also been shown 
to inhibit this process (Vennerstrom et al., 1996). The drugs bind to both haem and 
haemozoin crystals, forming a non-covalent complex with haem, hence preventing the 
addition of new haem units to the crystals (Sullivan et al., 1996).  
Haemozoin formation inhibition has been demonstrated in several in vivo and in vitro 
experiments. In vitro, the quinolones block the polymerisation of micromolar haem into 
haemozoin which is mediated by crude trophozoite lysates. Quinolones generally act by 
incorporating a drug-haem complex into the growing polymer of haemozoin. Polymer 
elongation seems important for significant drug-haem interaction. Without polymer 
elongation, the interaction with haemozoin is weak. This mechanism of haem-quinolone 
complex incorporation into the growing polymer might be a possible explanation to the 
dramatic accumulation of drug in the parasite food vacuole. Chloroquine for example, has 
been shown to hyperconcentrate to near millimolar concentration in the acidic parasite food 
vacuole of P. falciparum from the nanomolar concentration in the plasma. The rate at which 
this drug accumulation occurs in the food vacuole could lead to a 1 mM concentration 
(Sullivan et al., 1996). Once the drug accumulates, it disrupts haem biocrystallisation either 
from drug-haem interaction with sequestration of the monomeric substrate or by direct 
interaction of chloroquine with a protein that is involved in haem aggregation (Yayon et al., 
1985). 
Studies of the chemical reaction of haemoglobin with artemisinin have shown that the 
protein bound haem in haemoglobin reacts with artemisinin much faster than free haem 
does. It seems that the uptake of haemoglobin and the accumulation of artemisinin into the 
parasite food vacuole together with the preferential reactivity of artemisinin with haem in 
haemoglobin, may make the haemoglobin the primary target of artemisinins as 
antimalarials. Two haem artemisinin derivatives have been isolated, which include the 
monoalkylated and the dialkylated haem derivatives. These have been shown to inhibit 
haemozoin formation by binding to PfHP II, ultimately killing the Plasmodium (Kannan et 
al., 2005). 
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4.7 In vitro methods used for haemozoin detection and inhibition 
Studies using X-ray crystallography, nuclear magnetic resonance technology (NMR) and 
spectroscopic techniques have shown haemozoin and β-haematin to be identical in structure 
and solubility profile (Slater et al., 1991). Hence β-haematin formation has been extensively 
studied in vitro to aid in the understanding of haemozoin formation and aggregation. 
Monomeric haem aggregates in acidic conditions, pH  < 4.5. These aggregates are soluble 
in sodium bicarbonate buffers and DMSO. Interestingly, β-haematin is a higly insoluble 
substance and can only be dissolved in sodium hydroxide solution. This differential 
solubility has been invaluable for the separation of formed β-haematin in a reaction from 
unreacted haem aggregates. Haem can be converted to β-haematin, although certain 
conditions have to be met for this chemical synthesis to occur.  Simply incubating haematin 
in glacial acetic acid at high temperatures of 70-80°C for 18 h leads to β-haematin formation, 
with a reaction yield of about 40-50% (Bohle et al., 1993). Several different reactions have 
been used by different teams for chemical synthesis of β-haematin. Egan et al., 1994 
proposed that the reaction is spontaneous in the malaria parasite. He suggested that for  the 
reaction to be spontaneous, there are certain pre-requisites namely pH (acidic), temperature 
(60-65°C) and certain buffer conditions, in most cases, acetate buffers ranging from 0.1- 4.5 
M. These conditions are certainly not physiological. Although β-haematin is identical to 
haemozoin, its formation cannot be achieved under the same physiological conditions as 
with haemozoin. This has led much research in the field. Further work has shown that β-
haematin formation in vitro can be achieved in aqueous acidic conditions under 
physiological temperature only in the presence of certain biological factors. These factors 
include the parasite lysate, histidine rich proteins, preformed haemozoin or β-haematin and 
certain unsaturated lipids (Fitch, 2004; Tripathi & Tekwani,1999; Dorn et al., 1998; Fitch 
et al., 1999). 
4.8 Method optimisation for the inhibition of β-haematin formation for extract 
screening 
Several methods were explored to achieve the optimised protocol used for this study. The 
three methods that were used are described in this section. 
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4.8.1 Protocol 1  
This method was designed based on the method previously described by Egan et al., 2001. 
4.8.1.1 Materials: 
Haemin-Cl (Sigma, UK) freshly made in DMSO (Sigma Aldrich); O.5 M acetate buffer 
made with acetic acid (Fisher scientific) pH 4.8, 100 mM Tris HCl buffer (Fischer scientific) 
made in 5% SDS (Sigma, UK) pH adjusted to 7.4 with HCl (Sigma, UK); Sodium 
bicarbonate (Fisher scientific) buffer adjusted to pH 8.8 with NaOH (Fisher scientific); 2N 
NaOH; Drugs included chloroquine (Sigma, UK) and  B. ferruginea (Nigeria). 
4.8.1.2 Method:  
Assay mixture: Haemin-Cl was prepared at 5 mg/ml in DMSO. 0.5 M acetate buffer was 
made with acetic acid to achieve a final pH of 4.8, Tris HCl buffer was made to 0.1 M in 
5% SDS and pH was adjusted to 7.4 with HCl. 0.1 M Sodium bicarbonate buffer was made 
to pH 8.8 by adjusting with NaOH. Chloroquine and B. ferruginea stocks were prepared 
such that 1000 µl was added in reaction mixture to achieve 300 nM and 30 µg/ml 
respectively. Eppendorf tubes were labelled as: control, chloroquine and B. ferruginea. The 
reaction mixture was prepared in each eppendorf by adding 1000 µl of the 5mg/ml haemin-
Cl, 2000 µl of sodium acetate buffer and 1000 µl of test compound (sterile water for control 
tube). The reagents were added in the order mentioned and the reaction mixture was mixed 
gently and an average  pH of 4.9 was recorded. The reaction mixture was incubated at 37°C 
for 24 h. 
Washing step: After 24 h incubation, the eppendorfs were removed from the incubator. The 
mixture was centrifuged at 13000 g for 5 mins. The absorbance of the mixture was taken at 
two different wavelength (405 nm and 750 nm) using  a UV/Vis spectrophotometer. 
4.8.1.3 Result: 
There was no separation in the reaction mixture after 24 h incubation. A pellet was not 
formed when the mixture was centrifuged in both treated and control mixtures hence 
haematin did not form under these conditions. 
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Treatment Abs @ 405nm Abs @750nm 
Control 0.018 0.002 
300 nM Chloroquine 0.017 0.008 
30 µg/ml B. ferruginea 0.018 0.009 
 
Table 4.1 Absorbance values for β-haematin formation inhibition: Showing the average 
triplicate data for the experiments. There is no difference between control and treated and 
the absorbance readings are negligible, hence no haematin formation. 
The results of this assay were not as expected. After 24 h incubation, there was no separation 
of the reaction mixture into two phases indicating that β-haematin did not form. The washing 
step should have produced a pellet (haematin) which could have been washed with the Tris 
buffer for 5 mins twice. A final wash in sodium bicarbonate buffer would have been carried 
out. The expected β-haematin pellet could have been dissolved in NaOH. NaOH breaks 
down the hydrogen bonds and converts the formed dimeric haematin aggregate  back to the 
monomeric form allowing for high absorbance reading at 405 nM. In this reaction, the two 
last steps could not be performed as there was no pellet. The reaction did not form β-
haematin as expected. 
4.8.2 Protocol 2: Optimisation assay of β-haematin formation 
The method used in section 4.8.1 was repeated with minor modfications. 
4.8.2.1 Materials: 
 Sodium acetate, NaOH, haemin-Cl, Chloroquine, B. ferruginea, DMSO, double distilled 
water. 
4.8.2.2 Method: 3 M sodium acetate was prepared (modification: not the buffer in this 
case), 0.1 M NaOH, 6.5 mM Haemin-Cl in 40% DMSO, 5 mM chloroquine working stock 
solution, 40 mg/ml working stock for B. Ferruginea and finally, glacial acetic acid which is 
17.4 M. 
The reaction mixture consisted of the mixture  below in the same order mentioned: 
 100 µl of the haemin-Cl 
 50 µl of either drug or water in the case of control 
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 200 µl of 3 M sodium acetate 
 50 µl of 17.4 M acetic acid (glacial) 
The reaction mixture was mixed gently for 5 mins and the pH reading taken. 
The mixture was incubated at 37°C for 24 h after which the eppendorfs were removed from 
the incubator. The eppendorfs were centrifuged at 13000 g for 15 min. The supernatant was 
collected in another eppendorf and labelled fraction I. The pellet left was washed in DMSO 
for 15 min @ 13000 g and supernatant labelled Fraction II. The pellet was re-suspended in 
DMSO amd washed for the third time to obtain fraction III. The final pellet obtained which 
should be the formed β-haematin was re-suspended in 600 µl of 0.1 M NaOH and this was 
labelled fraction IV. An aliquot (100 µl) of fraction IV was further diluted into 3 mls of 0.1 
M NaOH. Absorbance was read at 405 nm. 
4.8.2.3 Results: The average pH for the reaction mixture was 4.92 (triplicate data). The table 
below shows the absorbance recorded at 405nm which represents monomeric haemin. The 
pellet formed in this assay is the dimeric form, β-haematin. But β-haematin is only soluble 
in NaOH. In order to read the absorbance to obtain a semi quantitative value, the β-haematin 
was dissolved in NaOH which converted it back to the monomeric form, allowing for 
readings to be taken at 405 nm. Fractions I, II and III represent the unreacted monomeric 
haemin whilst fraction IV represents the dimeric haemin that was converted back to the 
monomeric form. The results are represented in the table below: 
 
Fraction I Fraction II Fraction III Fraction IV 
    
1.872 1.376 0.323 1.967 
1.733 1.238 0.285 1.899 
1.897  1.031 0.216 1.888 
 
    
Table 4.2 Absorbance of supernatant fractions: showing  average triplicate data set for 
the supernatant fractions I-III (unreacted haemin-Cl and the dissolved pellet fraction IV 
(formed β-haematin). 
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Table 4.2 above shows monomeric haemin readings at 405 nm of the different fractions 
obtained from the reaction with fraction I, II and II. Fractions I and II show high readings 
which represents the unreacted haemin that solubilised in the DMSO. Fraction III has a 
much lower absorbance because much of the unreacted haemin had been removed after three 
washes. The β-haematin pellet left was insoluble in DMSO. In order to obtain the 
absorbance value of the β-haematin, it was dissolved in NaOH. The absorbance was 
recorded as fraction IV which gave a high reading indicating a high β-haematin formation 
in the reaction. The results of this protocol has demonstrated that a good  optimisation was 
achieved. The incubation time for the reaction was 24 h hence, protocol 3 was designed to 
see if the reaction rate could be increased.  
4.8.3 Protocol 3 The effect of varying temperature on β-haematin formation. 
The reaction was performed under different temperature conditions to investigate its effect 
on reaction rate. 
4.8.3.1 Method:  
The reaction was carried as previously described in section 4.8.2 with slight modifications. 
In this case, the reaction was performed in three parallel sets. The experiments were set up 
on the same day,using the same stock solutions and conditions except for the temperature 
variations applied. The reaction was carried out by adding the reagents to form the reaction 
mixture just as described previously. 
The reaction mixture was mixed gently for 5 mins and the pH was checked. The eppendorf 
tubes were split into three sets with each set consisting of control (water) and treated 
samples. The sets were incubated as follows: 
Set 1: Incubated at 37°C for 24 h 
Set 2: Incubated at 60°C for 1 h 
Set 3: Incubated at 70°C for 1 h. 
After each  incubation period, the eppendorfs were washed 4 times in DMSO, removing the 
supernatant with each wash, until all the unreacted haemin was removed as indicated by a 
clear supernatant.The final pellet was solubilized in 0.1 M NaOH solution and the converted 
β-haematin was read at 405 nm. 
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4.8.3.2 Results: 
 The average pH reading for the tripilicate experiments was 4.88. The results obtained from 
the absorbance reading at 405m in all triplicate experiments was plotted in a graph using 
Graphpad Prism 6. 
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Fig 4.2: The effect of temperature on β-haematin conversion: The highest conversion  
occurred with a 24 h incubation, although a reasonable conversion was obtained with a 1 
h incubation period at 60°C and 70°C. One-way ANOVA test on Graphpad Prism showed 
that the means between the three groups were significantly different with a value of  P < 
0.05, when compared to the 37°C in 24 h incubation period. Bonferri post test was 
performed to investigate  if there was any significant difference between the two groups 
incubated for 1 h (60 and 70°C). The results of this tests shows that there is no significant 
difference between these two groups P > 0.05. 
 The data in this experiment shows that the incubation time for β-haematin conversion can 
be decreased with increasing temperature. High absorbance readings were obtained at 60°C 
and 70°C. Increasing the temperature from 60°C to 70°C increased the absorbance reading 
hence more β-haematin had been converted. There was no conversion at 37°C within 1 h 
incubation.  
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4.9 Preliminary investigation of the effect of  B. ferruginea and chloroquine on β-
haematin formation. 
In this experiment, the effect of the methanolic B. ferruginea  extract on β-haematin  
conversion was investigated using protocol 3. 
4.9.1 The effect of chloroquine and B. ferruginea on β-haematin formation 
Several studies have shown that quinoline compounds are classified as inhibitors of haem 
detoxification (Egan et al., 2000; Egan & Ncokazi, 2005; Sandlin et al., 2014). Furthermore, 
structure activity  studies of 4-aminoquinoline antimalarials have shown that the 4-
aminoquinolone nucleus is implicated in haem binding and the chloroquine atom at position 
7 of the quinolone ring is vital for optimal inhibition of haemozoin formation (Kaschula & 
Egan, 2002). The effect of chloroquine on β-haematin formation is well documented and 
several studies have shown that chloroquine inhibits β haematin formation. This was the 
basis of its choice as a positive control in this study. 
4.9.1.1 Method: Preliminary experiments were performed using protocol 3, to investigate 
the effect of β-haematin formation on 300 nM chloroquine (the IC50 in literature) and 20 
µg/ml B. ferruginea (IC50 value) was used.  
4.9.1.2 Results: Absorbance readings were recorded from the experiment after incubating 
with chloroquine and water (control). The data collected were plotted in a graph using 
Graphpad Prism as shown in fig 4.3. 
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Fig 4.3 Preliminary investigation of the effect of chloroquine and B. ferruiginea on β-haematin 
formation: β-haematin formation was not inhibited using the IC50 values of methanolic Bridelia and 
CQ. There was no inhibition of β-haematin formation at these dose levels.  
4.9.2 Dose-response inhibition of chloroquine on β-haematin formation  
A series of experiments were performed to obtain the working doses for the experiment. 
The initial experiments used IC50 values of chloroquine (300nM). As β-hematin formation 
was not inhibited by this dose, a 10-fold dose escalation was performed until inhibition was 
achieved. As no β-haematin formation occurred, the dose was increased to millimolar 
concentrations. The results are graphically presented in fig 4.4 below. 
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Fig 4.4: Effect of temperature on β-haematin  formation inhibition by chloroquine: A 
dose-response inhibition of β-haematin formation was achieved with CQ, with a 100% 
inhibition achieved at a dose of 8 mM. Statistical analysis using Two Way ANOVA in 
Graphpad Prism 6 shows that there is no difference between control and 300 nM treated 
group; there is a significant difference between control and samples treated with 2 mM, 4 
mM and 8 mM samples with P < 0.001 and P < 0.0001 respectively for last two doses. The 
calculated IC50 using Graphpad prism for the beta haematin inhibition was 2.55, 2.245 and 
2.49 at 37, 60 and 70°C respectively. 
The results show that chloroquine inhibits β-haematin  formation at very high doses. Near 
100% inhibition was achieved at doses higher than 4 mM. The data for the 10 fold-escalation 
is not shown as there was no inhibition.  Hence though these experiments, it is evident that 
chloroquine inhibits β-haematin  formation. As previously suggested in other studies ( Egan 
et al., 2000; Egan & Ncokazi, 2005; Sandlin et al., 2014). 
4.9.3 Dose-response inhibition of B. ferruginea on β-haematin formation 
In an attempt to investigate the possible mechanism of action of B. ferruginea, which has 
shown strong anti-malarial activity in vitro, inhibition of β-haematin formation was 
explored.  
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4.9.3.1 Methods: 
 Methods used are as stated in section 4.8.3 (Protocol 3). The IC50 of B. ferruginea is 20 
µg/ml as determined by the fluorescence-based methods and Giemsa light microscopy 
described in Chapter 2. This dose was not chosen for the experiment based on the fact that 
with chloroquine, near IC50 values did not inhibit β-haematin formation. Dose ranges from 
200 µg/ml were tested until inhibition was noted at high dose levels, in milligrams/millilitre. 
Based on the series of preliminary experiments performed (data not shown), a starting dose 
of 1mg/ml was selected for the experiments.  
4.9.3.2 Results:  
After the incubation period described previously in protocol 3, the absorbance reading 
obtained were were recorded for each experimental set and the results were plotted in a 
graph using Graphpad Prism as represented in fig 4.4 below: 
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Fig 4.5: Effect of temperature on β-haematin  formation inhibition by methanolic B. 
ferruginea. The result of this experiment shows that methanolic B. ferruginea inhibits β-
haematin formation in a dose-dependent manner. At high doses of 32 mg/ml and over, near 
100% inhibition was achieved. Lower doses ranging from 20 µg/ml were tested prior to the 
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high doses seen in this graph and there was no difference compared to control (data not 
shown). The results of this experiment showed a lower IC50 with increasing reaction 
mixture. The IC50 calculated using Graphpad prism were 8.73, 3.73 and 3.95 mg/ml at 37, 
60 and 70°C respectively. 
4.9.4 Pyrimethamine and sulfadoxine controls for the β-haematin formation assay 
Pyrimethamine and sulfadoxine are drugs that are known not to work on the hemozin 
pathway. Their primary mode of action is by inhibiting the folate pathway enzymes, 
dihydrofolate reductase and dihydropteroate synthase. Hence in this study, they were used 
to further confirm that the inhibition of β-haematin formation was not due to any artefacts. 
Both drugs were used to investigate β-haematin formation inhibition using three doses (2 
mM, 4 mM and 6 mM). For all doses tested, no inhibition was noted. Control and treated 
values remained the same as represented in fig 4.5. 
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Fig 4.6: Effect of temperature on β-haematin  formation inhibition by pyrimethamine and 
sulfadoxine: Pyrimethamine and Sulfadoxine were used as further controls for the β-
haematin assay. The two drugs did not inhibit β-haematin formation. Control and treated 
values were the same.  
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4.10 Chapter conclusion 
The objective of this chapter was to investigate the effect of B. ferruginea on the haemozoin 
pathway, in order to gain some insight into its possible mechanism of action. The haemozoin 
biocrytallization pathway is an attractive target for many efficacious antimalarials due to its 
specificity to the Plasmodium. Drugs that have been shown to act though this pathway 
include quinine, chloroquine, mefloquine, lumefantrine, piperaquine and halofantrine 
(Hempelmann, 2007 and Kumar et al., 2007). Pyrimethane and sulfadoxine do not target 
this pathway hence were used as positive controls in this chapter. The haemozoin pathway 
appears a stable target for antimalarials and resistance has only been shown to occur due to 
removal of the antimalarial compound from the site of action, the parasite food vacuole, 
hence reducing drug accumulation (drug resistance). The inhibition of haemozoin 
conversion seems to only occur at very high drug concentrations, beyond physiological 
doses. In this study, it was demonstrated that for chloroquine, inhibition was only achieved 
at doses above 1 mM whilst for B. ferruginea at doses from 2 mg/ml. These doses are no 
doubt lethal to the human body. The only explanation to these dose levels is that 
physiologically, the drugs enter the parasite food vacuole and accumulate to a high dose. 
Hence in vitro, the assay could only be achieved with very high doses. Chloroquine has been 
demonstrated in several studies to enter the parasite food vacuole though simple diffusion. 
Once it enters, the drug is protonated due to the acidic pH (4.7) and this prevents it from 
diffusing out. It may be recalled that in this study, the experiment only worked at pH ranging 
from 4.6-4.9 which models what happens physiologically. This build up of chloroquine in 
the food vacuole relative to the rest of the parasite prevents further biocrystallisation of haem 
leading to a haem build up which is toxic to the parasite. Chloroquine resistance has been 
demonstrated to be due to less accumulation of the drug in the parasite vacuole  due to a 
mutation in the chloroquine resistant transporter (PfCRT), hence reducing its concentration 
to non lethal levels in the food vacuole (Ehlgen et al., 2012). Hence the results of this study 
has shown that B. ferruginea inhibits β-haematin formation and up to 97% inhibition was 
achieved at high doses which is probably what may be happening physiologically as is the 
case with chloroquine. It may therefore be right to suggest that the extract possibly mediates 
its effect by accumulating in the parasite food vacuole and possibly binding to haem, hence 
preventing the biocrystallisation process, just as it has been demonstrated with chloroquine 
in previous studies. 
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CHAPTER 5  
 
 In vivo animal studies in collaboration with National Institute for pharmaceutical 
research and development (NIPRD), Nigeria. 
All animal studies done in this study were performed at the National Institute for 
Pharmaceutical Research and Development following the ethical guidelines and SOPs of 
the deparment of pharmacology approved by Professor Uche Osunkwo. The extracts used 
identified at the NIPRD herbarium by Dr Jemilat Ibrahim and samples deposited at the 
herbarium. 
5.1 Introduction 
Animal studies are very useful as they limit the use of human volunteers,  addressing some 
ethical concerns. The use of animal models is also more financially viabile and practical 
than humans, where applicable. Although humans and animals may look different, at a 
physiological and anatomical level they are extraordinarily similar. Organs  and organ 
systems of animals, from mice to monkeys, function in almost the same way. Nearly 90% 
of veterinary medicines are the same or very similar to medicines used in human patients. 
Humans share 99% of their DNA with mice hence the similarities far outweigh the minor 
differences that exists. These similarities have meant that over the years, animal disease 
models have remained a critical tool in in vivo testing in pre-clinical drug screening. Testing 
usually considers different factors including animal species, age, route of drug delivery, 
treatment regimen amongst other factors. Another very interesting way animals models have 
been used in research is ‘knockout mice’. These mice are genetically modified by  
inactivating, or "knocking out", an existing gene by replacing it with an artificial piece of 
DNA. These  animal models play an important role in studying genes, which have been 
sequenced but whose functions have not been determined. By ‘switching off’ a specific gene 
in the mouse, differences between normal mice and the knockout mice can be observed. The 
result can be used to design better treatments for diseases. 
In malaria research specifically, animal models have proved very useful over the years due 
to the limitations on the nature of the interpretations of in vitro studies, particularly with 
regards to host immune cells (Michelle et al., 2009). Several animal models exist for malaria 
including the avian, simian and morine models. For the scope of this study, the main focus 
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will be on the mouse model. There are four different species that exist for the mouse model 
which include P. berhei, P. vinkei, P. chabaudi and P. yoelli. Each species has different 
strains which have proved useful in different areas of malaria research for example, P. 
berghei infects mature erythocytes and reticulocytes hence used in C57BL/6 and CBA/T6 
mice to investigate pathogenesis of malaria and immune mechanisms of protection (Shofield 
et al., 2005). Certain strains of P. Yoelli are lethal to mice, hence have been successfully 
used in vaccine research whilst P. chabaudi has commonly been used in the study of 
immune mechanisms as it only infects mature erythocytes. Due to the several advantages 
offered by animal models, including; the ease for investigating disease progress, practicality 
of using organs for research and finally the ease with which behavioural changes can be 
observed, in vivo activity of B. ferruginea is explored. The study objectives of this chapter 
are to investigate toxicity as well as antimalarial, analgesic and antipyretic activity of the B. 
ferruginea. 
5.1.1 Animal models used and ethical consideration 
Plasmodium Berghei infected mice were used as an animal model in this study. Other animal 
models used were the acetic acid induced writhing model and the tail flick model for 
analgesia; and the yeast induced pyrexia model as well. The welfare of the animals used 
were considered carefully and international guidelines were adhered to in accordance with 
NIH guide for care and use of laboratory animals was strictly adhered to (NIH publication 
23-83) revised (NIH 1985). The three Rs were also considered to ensure humane use of 
animals in the study which are namely replacement (in which case in vitro studies was 
considered and performed for preliminary data), replacement (in vitro models were replaced 
for the mechanistic studies) and refinement (only 5 animals were used per group, just enough 
to statistically validate the studies). 
5.2 Acute Toxicity: 
The acute toxicity of methanolic B. ferruginea was investigated using the Locke Method, 
1983 with slight modifications. This method has been shown to be very effective in rapid 
assessment of chemical/extract toxicity. It uses only 5 rats for each dose level. In this study, 
three dose levels were investigated hence the extract was assessed for toxicity using 20 rats. 
Acute toxicity in this method is represented as the geometrical mean of the dose that resulted 
in 100 percent lethality and that which caused no lethality at all.  
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5.2.1 Housing and diet 
Animals were housed in metal cages using saw dust as bedding. Standard laboratory food 
pellets were given ad libitum with free access to water from water bottles. NIPRD standard 
operating procedures (SOPs)  and ethical guidelines were followed. The experimental 
design was approved by the NIPRD ethical committee in accordance to Nigerian guidelines 
prior to commencement of experiments. NIH guide for care and use of laboratory animals 
was strictly adhered to (NIH publication 23-83) revised (NIH 1985).  Normal 12 h day and 
12 h dark light pattern was followed.  
5.2.2 Experimental animals 
Wistar rats of average weight between 250-300 g of both male and female sexes were used. 
Animals were randomly grouped into 4 groups of 5 animals each. Animals were marked 
with a yellow marker on their fur for identification and observation purpose only. Different 
parts of the body were marked differently for each animal including the head, leg, back and 
arms.  Below is a table with the weight and ID of each animal in the groups 
Control I (saline) Grp II 
(1250mg/kg) 
Grp III 
(2500mg/kg) 
Grp IV 
(5000mg/kg) 
    
Label         Weight Label   Weight Label    Weight Label    Weight 
LSRS          255 HD        280 LA          261 HDRL    292 
LARA         276 TL          254 LS           264 BK         300 
LLHD         281                            LL 293 RS          275 HDBK    255 
TLLS          261 RL          271 HDTL     284 RLLL      251 
TLBK        298 RA         256 HDRA    259 TLLL      259 
 
Table 5.1 Random allocation of experimental animals: Showing the random allocation of 
animals into groups, their weight and the labelling system used to identify each animal. (HD 
Head; TL tail; LL left leg; RL right leg; RA right arm; LA left arm; RS right side; LS left 
side; BK back, HDRA head right arm; HDTL head tail; RLLL right leg left leg; TLLL tail 
left leg). 
5.2.3 Extract preparation 
B. ferruginea bark was obtained and shade dried. The dried bark was grounded and soaked 
in 70% methanol for 24 h on a shaker. The extract was filtered and the filtrate was 
125 
 
evaporated to dryness in a water bath. The dried aqueous extract was obtained and stored in 
an airtight bottle until use. 
5.2.4 Mode of Administration 
Animals were fasted 6 h prior to dose administration with free access to water. Animals 
were dosed with a single oral dose using a rat oral cannula. Rats in Groups I, II, III and IV 
received saline, 1250 mg/kg, 2500 mg/kg and 5000 mg/kg of the extract respectively. Food 
was given 2 h post drug administration. 
5.2.5 Observation Period 
Animals were critically observed for behavioural changes periodically every 30 mins for the 
first 6 h and three times daily post 24 h for 14 days. Several parameters were looked out for, 
including hyperactivity, excessive sleep/coma, changes in grooming behaviour, loss of 
apetite, tremors and death. 
5.2.6 Results 
Following observation of the animals for a two week period, the following observations in 
table 5.2 were made. 
Dose            Observations 
1250mg/kg No different observations compared with control group, no death 
2500mg/kg No different observations compared with control group, no death 
5000mg/kg Abdominal writhing and signs of distress including weakness and 
reduced activity were observed from 72 h but no death recorded 
thoughout the observation period.          
 
Table 5.2 Acute toxicity in rats: Showing observations of the acute toxicity tests using Locke 
method. There was no difference between control and treated groups up to a dose of 2500 
mg/ml. At  a very high dose of 5000 mg/ml, there was signs of distress but no death was 
recorded. 
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5.3 Antimalarial activity of methanolic B. ferruginea 
5.3.1 Innocula 
Plasmodium berghei  parasitized erythocytes was obtained from a donor mouse from the 
NIPRD animal house. Tail blood of the donor mouse was smeared on a slide and normal 
Giemsa staining was performed for microscopic analysis to establish parasitaemia. Some 
blood was collected. Depending on the level of parasitaemia observed, the blood was diluted 
in normal saline prior to inoculating the new mice for the present study, The mice were 
intra-peritoneally inoculated with 0.2 ml of infected blood containing 107 parasitized 
erythocytes.  
5.3.2 4-Day Peter’s suppressive tests 
25 swiss albino mice of weight ranging from 23-30 g were divided into 5 groups of 5 mice 
each. They were labelled as below: 
Animal grouping and labelling table 
Grp I 
(saline) 
Grp II 
(60mg/kg) 
Grp III 
(120mg/kg) 
Grp IV 
(240mg/kg) 
Grp V  
CQ(10mg/kg) 
HD RA TLHD BKLL HDRL 
TL LA TLLL BKRL HDLL 
LL RALA TLRL RABK HDLA 
RL LLRL BKHD RLBK TLRS 
BK BKTL BKLA HDRA TLLS 
 
Table 5.3 Random allocation of mice: Showing the random allocation of animals into 
groups, their weight and the labelling system used to identify each animal. (HD Head; TL 
tail; LL left leg; RL right leg; RA right arm; LA left arm; RS right side; LS left side; BK 
back, HDRA head right arm; HDTL head tail; RLLL right leg left leg; TLLL tail left leg; 
BDY body). 
5.3.2.1 Experimental method 
All animals in the above groups were inoculated as previously described in section 5.3.1 on 
day 0 (D0). Treatment was administered orally 3 h post infection. Grp 1 received saline 
solution whilst group II, III, IV  received 40, 80 and 160 mg/kg aqueous B. ferruginea 
respectively and group V received chloroquine (CQ) 10 mg/kg to serve as positive control. 
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Mice in group I, II, III, IV and V were orally administered again with saline, 60 mg/kg, 120 
mg/kg, 240 mg/kg and 10 mg/kg CQ respectively on days 1, 2 , 3 and 4 post infection. On 
day 5, tail blood of the mice was collected and smeared on slides. The slides were prepared 
for Giemsa staining and microscopic analysis was performed using oil immersion light 
microscopy. Percentage parasitaemia suppression was calculated by comparing 
parasitaemia of infected control (Grp I) and mice from the different treatment groups 
Percentage suppression = 100 – (mean parasitaemia treated/mean parasiatemia control) * 
100. 
5.3.2.2 Results 
The parasitaemia of each mouse was estimated using standard Giemsa staining and light 
microscopy. The raw data collected is represented in the table 5.4 below. The percentage 
suppression was calculated relative to the mean value obtained in the control group. 
Group Percentage 
Parasitaemia 
Mean 
parasitaemia 
% 
Suprresion 
Grp I 
 Saline 
4,3.5,5.0,5.0,4.3 4.3 - 
Grp II 
 40 mg/kg 
2.0,2.5,2.0,1.33,1.28 2.0 53.35 
Grp III 
 80 mg/kg 
1.5,1.0,1.7,0.9,1.3 1.28 70 
Grp IV  
160 mg/kg 
0.5,0.7,0.6,1.1,0.6 0.7 83.72 
V  
CQ 10mg/kg 
0,0,0,0,0 0 100 
 
Table 5.4 Antimalarial 4-day Peters’ suppressive test: Showing the effect of methanolic B. 
ferruginea on malaria suppressive cell. The data was obtained on day 5 of the experiment. 
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Fig 5.1 Percentage inhibition of P. berghei in the 4-day suppressive test: The figure  shows 
the percentage suppression of P. Berghei growth in the suppressive tests where the extract 
was given on the same day as inoculation and daily dose of the extract 4 days post infection. 
Tail blood was taken on day 5. The IC50 value generated using Graphpad prism revealed a 
dose of 26.14 mg/kg. 
The results of the suppressive tests shows that the methanolic B. ferruginea posseses good 
antimalarial properties. This was demonstrated by the chemosuppression of P.berghei 
infection in a dose dependent manner during the 4-day suppressive tests. The 4-day 
suppressive tests have been as previously described by Knight and Peters 1980. In this study, 
parasite growth was suppressed all dose levels used, with the highest suppression of 84% 
noted at 160 mg/kg dose. Chloroquine suppressive tests at 10 mg/kg was used as a positive 
control and there was 100 percent suppression in the test. These results show that the extract 
might be very useful in ethnopharmacological usage for a suspected malaria contact or as a 
prophylactic. The results could be used towards the validation of its usage in 
ethnopharmacological medicine for malaria. 
5.3.3 Curative tests (Rane test) 
The curative test otherwise known as the rane test is a test that is performed on mice during 
an established malaria infection. This tests was previously described by Rhley and Peters. 
1970.  
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5.3.3.1 Method:  
Briefly, 25 mice of average weight 22-30 g were used. The animals were grouped into 5 
groups as in the suppressive tests with the same labelling codes and patterns. Mice were 
grouped 5 per cage and labelled grp 1 (control), Grp II (60 mg/kg), Grp III (120 mg/kg), 
GpIV (240 mg/kg) and finally grp V 10 mg/kg CQ. Infected erythocytes from a donor mouse 
was taken on Day 0. All mice were inoculated  i.p with 107 P. berghei.  Prior to innocultion, 
tail blood was obtained from the donor mouse and  slide count was roughly 5 * 107 , which 
was diluted to 0.1 * 107 with saline solution. 0.2 ml of the diluted infected blood was used 
to inoculate the uninfected mice in all groups on Day 0. 72 hours later i.e Day 3 animals in 
groups I, II, III, IV and V were treated orally with saline, 60 mg/kg  extract, 120 mg/kg and 
240 mg/kg extract respectively. Group V received CQ 10 mg/kg. Treatment was continued 
daily on days 4, 5 , and 6. On day 7, tail blood was collected from all animals and smeared 
on a microscopic slide for  Giemsa staining and subsequent light microscopy. Mice were 
returned back to their respective cages and fed ad libitum with free access to water. The 
animals were observed for 30 days and the  mean survival noted. 
5.3.3.2 Results 
The raw data obtained from the study are represented in table 5.5 below. 
Treatment Grp Pre treatment Day 3 Post treatment Day 7 
Grp I Saline 22, 29, 26, 25, 28 35, 29, 36, 31, 29. 
Grp II 60 mg/kg 29, 26, 20, 21, 26 13, 11, 12, 10, 12 
Grp II 120 mg/kg 26, 24, 24, 18, 29 10, 9, 11, 8, 11 
Grp III 240 mg/kg 24, 23, 29, 25, 22 8, 7,6, 7,16 
Grp IV 10 mg/kg CQ 23, 28, 25,23, 22. 2, 7, 5, 2, 3 
  
Table 5.5 Rane test results: Showing the raw data obtained from the rane tests for the 
percentage parasitaemia for the mice both on day 3 (pre-treated) and day 7 (post-treated). 
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Fig 5.2 The effect of B. ferruginea on the rane test. The results have shown antimalarial 
activity on established plasmodial infections. Repeated measures ANOVA test on Graph 
Pad prism showed that there was a dose-dependent parasite killing on day 7 post treatment 
compared to day 3 pre-treatement (P < 0.01). Upon comparing the parasitaemia between 
control, saline treated group and the treated groups at all dose levels (Day 7 data), there 
was a significant difference P < 0.001. The IC50 determined using Graphpad prism was 
74.91mg/kg. 
This study  results demonstrates the curative properties of B. ferruginea with an IC50 of 
74.91 mg/kg. The animals were inoculated and left untreated for 72 h allowing the parasite 
to go though a complete cycle. The results on Day 3, pretreatment show the parasitaemia of 
the animals before treatment commenced. After the commencement of treatment which was 
daily oral dose for 4 days, i.e on Day 7 of the experiment, the parasitaemia of animals in 
each treatment group are represented in the graph. It can be clearly noted that the extract 
produced a dose dependent inhibition of parasitaemia as compared with the untreated group 
(saline). Animals in group IV showed the highest inhibition with the extract treated groups 
and there was about 78% inhibition. Animals in group V were treated with CQ as positive 
control and a 90% inhibition was obtained with this dose. Survival of the animals was also 
monitored up to 30 days post treatment. Two animals in the saline treated control group died 
on day 4 and by day 10, all were dead. There was 2 death recorded in the 60 mg/kg treated 
group and no death in the other extract treated groups. There was no death in the CQ treated 
group.  
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The results of the in vivo antimalarial activity of methanolic B. ferruginea extract shows that 
the extract is effective both in suppressive and curative chemotherapy of malaria with IC50 
doses. This validates the ethnopharmacological usage of the plant for malaria treatment by 
the locals. Furthermore, the extract has potentials of being used in malaria prophylaxis due 
to the activity shown in the suppressive tests. It can also be used to treat established cases 
of malaria infection as demonstrated in the curative tests. 
5.4 Analgesic study 
Fever control is a common measure used in malaria infection. Although the use of 
antipyretics in malaria treatment control is highly controversial, the practice is very common 
(Brandts et al., 1997). In this study, in vivo analgesic properties of the extract was 
investigated as pain is known to be one of the critical symptoms of malaria. An extract with 
both antiplasmodial and analgesic properties will be highly beneficial in terms of treatment 
and will eliminate the need to use an analgesic, which is controversial. Two animal pain 
models were used to investigate the analgesic effect of the methanolic B. ferruginea extract. 
These include the acetic acid induced writhing method and the tail immersion test, both in 
mice. Each pain model reveals a different information about the mechanism of pain which 
will be discussed later.   
5.4.1 Effect of B. ferruginea on acetic acid induced writhing method 
5.4.1.1 Method:  
Method has previously been described by Koster et al., 1959.  Briefly, 25 swiss albino mice 
were randomized into 5 groups of 5 mice each. Three dose levels were investigated. The 
weight range of the animals were 23-28 g both male and female.   As the dose was i.p, lower 
doses were explored as compared to the antimalarial study which was an oral dose. In this 
study, animals in grp I received saline, grp II received 15 mg/kg extract, grp III and IV 
received 30 and 60 mg/kg extract respectively whilst animals in grp V received 150 mg/kg 
acetyl salicylic acid, aspirin (ASA). This was the positive control group. Animals were 
pretreated with the extract i.p 1 h prior to giving 10 ml/kg of a 0.7% acetic acid solution, 
which was given i.p. The animals were observed and number of writhmic abdominal 
contrictions were observed and noted for 10mins. Treatment groups were compared to 
control group and percentage inhibition was calculated based on the formula below: 
Percentage inhibition = (control mean-test mean) / control mean * 100 
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5.4.1.2 Results 
The results obtained from the acetic acid induced writhes investigation are presented in the 
table below. 
 No of writhes    
Mean 
Percentage 
inhibition 
Control (saline) 13,14,16,18,12 14.6 - 
15mg/kg extract 10,11,11,12,13 11.4 20.28 
30mg/kg extract 6,7,8,7,9 7.4 49.3 
60mg/kg extract 2,3,5,4,3 3.4 76.22 
ASA 150mg/kg 2,1,1,2,0 1.2 91.78 
 
Table 5.6 Effect of methanolic B. ferruginea on acetic acid induced writhe: Showing a 
good dose dependent inhibition of acetic acid induced writhe produced by mice after being 
administered with B. ferruginea. 
 
Fig 5.3 Effect of B. ferruginea on acetic acid induced writhe: Showing a dose dependent 
analgesic property of B. ferruginea. An IC50 dose of 22.49 mg/kg was calculated from the 
normalised data in Graphpad prism. 
Statistical analysis a One way ANOVA tests showed that there was a significant difference 
between control and extract treated mice at all dose levels (P > 0.001). There was also a 
significant difference between aspirin (ASA) treated mice and control. 
The results of this study shows a dose dependent inhibition of acetic acid induced writhes 
by the extract. Mice that were pre-treated with the extract showed pain inhibition at all dose 
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levels. The injection of acetic acid irritates the peritoneal cavity of mice causing a classical 
writhmic contractions due to pain. The positive control group was given ASA and almost 
92% inhibition of pain was observed. These results demostrate that the extract in addition 
to antimalarial properties possesses analgesic properties. This makes it a very good 
candidate for malaria therapy development as fever is one of the symptoms of malaria 
disease. The IC50 dose for analgesia is well below that obtained for curative and suppressive 
tests which is advantageous. Hence the dose for treating malaria would treat the malaria 
associated symptom of fever. 
5.4.2 Tail immersion tests 
As pain has different mechanisms, the tail immersion test was used to investigate the central 
analgesic  of the methanolic B. ferruginea extract. The test measures the complex response 
to non inflammatory acute nociceptor input. Opiod analgesics exert central analgesic 
properties via different spinal receptors (Nemirovsky et al., 2001), hence block pain 
sensation in this animal model. Any extract/drug that blocks pain in this model is assumend 
to have central analgesic properties. 
5.4.2.1 Experimental method 
This method has been previously described by Jansen and Jagenov, 1959. Minor 
modifications were applied in this study. Briefly, 25 mice were randomized into 5 groups 
of 5 mice each and labelled as in table 5.3. Animals in group I were treated with saline, 
groups II, III, IV and IV received 15, 30 and 60 mg/kg extract while animals in group V 
received 10 mg/kg morphine. All treatments were given i.p. Mice were restrained in  
horizontal cylinders (purposely designed for the study) leaving the tail hanging outside 
freely 30 mins post drug administration. The  hanging tail was immersed into a water bath 
maintained at 50°C ± 2. The time taken for the mouse to flick its tail out of the water was 
recorded using a timer. The latency was evaluated at 0 min, 30 min,  60 min and 90 min. 0 
min was the initial reading prior to drug administration. 
5.4.2.2  Results 
The raw data obtained from the tail immersion pain study are presented in table 5.7  
below: 
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Treatment 0 min 30 min 60 min 90 min 
Control 10,11,11,10,9 10,10,11,12,9 10,11,10,9,8 9,11,12,13,12 
15 mg/kg 10,11,9,12,10 10,12,11,12,10 12,11,13,12,11 13,12,12,13,11 
30 mg/kg 9,9,11,11,12 14,15,10,13,14 13,12,13,15,12 14,13,15,13,14 
60 mg/kg 10,10,10,11,13 11,12,11,13,11 13,14,13,15,12 14,16,15,13,16 
Morphine 11,10,10,8,11 14,12,11,14,13 16,16,15,14,17 19,18,19,21,22 
 
Table 5.7 Tail immersion test data: Showing the latency period at different dose levels over 
a period of 90 mins. 0 min is at the start of the experiment prior to drug administration.  
 
The results of the data from table 5.7 are represented graphically in figure 5.4 below. 
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Fig 5.4 Effect of methanolic B. ferruginea on tail immersion test: Showing a dose 
dependent increase in latency period for a mouse to flick its tail out of the warm water. The 
methanolic B. ferruginea extract has demonstrated a dose-dependent analgesic activity as 
seen with morphine. Statistical analysis using repeated measures Anova in Graphpad Prism 
6 showed that there was a significant difference between control and treated mice at all 
three dose levels. There was also a significant difference between control and morphine 
treated mice (P < 0.01). The data at 90 min was normalised to obtain an EC50 value which 
was 23.76 mg/kg. 
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The results of this study shows antinociceptive activity of the methanolic B. ferruginea 
extract in both the acetic acid writhe induced method, which mediates peripheral pain, and 
the tail flick test, which is selective for centrally acting drugs. A dose dependent inhibition 
of nociception was revealed in both tests. The EC50 value, which is the concentration of the 
extract that produces half maximal response was determined for the tail immersion tests as 
against IC50 value as with the other test. This is because the response in this case is not 
determined as an inhibition. 
 
5.5 Antipyretic study 
The aim of this study was to investigate the antipyretic activity of the methanolic B. 
ferruginea extract.  
5.5.1 Yeast induced pyrexia 
The brewers yeast method previously described by Loux et al., 1972 was used to induce 
pyrexia in wistar rats of either sex. 
5.5.1.1 Method: 25 rats weighing 200-250 g were randomized into 5 groups of 5 rats each 
and marked just as in the previous studies for identification. The body temperature of each 
rats was taken by inserting a rectal thermometer deep into the rectum. The normal body 
temperature averaged about 36.5°C for all animals. Pyrexia was induced using the Loux et 
al., 1972 method. Briefly, a subcutaneous injection of 20 ml/kg a yeast suspension in methyl 
cellulose was performed on each rat. The animals were returned to their cages and allowed 
access to food and water. Rectal temperatures were taken 24 h post induction. Extracts/drug 
were administered at different doses to the animals according to grouping. Animals in group 
I received saline while those in groups II, III and IV received extract at 15, 30 and 60 mg/kg 
respectively whilst animals in group V received drugamol , the positive control, at 20 mg/kg. 
 
5.5.1.2 Results 
Raw data for the antipyretic study are presented in the table 5.9 below 
 
Treatment O h 
Preinductio
n 
24 h post 
induction 
1 h 2 h 3 h 4 h 
Control 36.1,36.8,36
.5 
 
35.8,35.4 
37.9,37.6,37.1 
 
37.5,37.4 
37.1,38.2,37.4 
 
37.9,37.7 
37.5,38.3,37.4 
37.6,37.9 
37.6,37.4,3
8.2, 
 
37.9,37.8 
37.1,37.7,3
8.8 
 
38.4,37.6,3
7.5 
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15mg/kg 36.4,35.6,35
.9 
 
36.7,36.8 
37.1,37.9,36.9 
 
37.4,37.3 
37.1,37.4,37.5, 
37.2,37.1 
37.2,37.1,37.3 
 
37.1,36.8 
 
37.1,36.8, 
 
36.7,37.4,3
7.2 
37.1,36.9, 
37.2, 
37.2 ,   37.1 
30mg/kg 36.8,36.1,36
.7 
35.4,35.9 
37.4,38.1,36.9 
37.7,37.4 
36.9,36.8,37.1 
36.6,36.7 
36.4,36.6,36.8 
36.3,36.5 
36.3,36.5, 
36.1, 
36.2, 36.0       
34.8,36.2 
36.5,35.9 
,36.1 
60mg/kg 35.3,34.8,36
.1 
34.3,36.1 
37.8,36.9,37.5 
37.8,37.6 
36.7,36.6,36.3 
36.4,36.2 
36.5,36.3,36.5 
36.4,36.3 
36.1,36.3 
,34.8, 
36.2,36.5 
 
34.2,36.1      
 
34.5,35.8,3
6.7 
Drugamol 
20mg/kg 
35.8,36.8,35
.6 
 
35.1,36.4 
37.7,37.4,37.9 
37.6,36.9 
36.4,36.3,36.7 
36.1,36.3 
36.2,36.5,36.1 
36.3,36.6 
36.2,36.6 
,34.4, 
36.5,36.1 
 
35.3,34.7      
 
34.1,35.4,3
4.7 
 
 
Table 5.8 Effect of  B. ferruginea on yeast induced pyrexia: Showing the rectal 
temperatures recorded at 0 min (pre-induction) and 24 h h post induction of pyrexia. 
Temperature was recorded at 60 min intervals there after. Statistical analysis using 
repeated measures ANOVA showed that there was no significant difference between 15 
mg/kg extract treated rats and control P < 0.05; there was a significant difference between 
control rats and extract treated rats at 30 mg/kg and 60 mg/kg P < 0.05; there is a 
significant difference between control and drugamol treated rats P < 0.05. 
 
The results of the antipyretic study shows a dose dependent inhibition of pyrexia at dose 
levels of 30 and 60 mg/kg. There was no difference between rats treated with 15 mg/kg 
extract and control (saline treated) rats.  
 
5.6 Chapter conclusion 
The in vivo evaluation of the pharmacological properties of the methanolic B. ferruginea 
extract has revealed that the extract has several activities. The results of the antiplasmodial 
study showed that the extract is active against the P. berghei rodent model of malaria, 
demonstrating a dose dependent inhibition of parasitaemia. Both the suppressive and 
curative models for malaria were used in this study and antiplasmodial activity was 
demonstrated in the two models. This validates the traditional usage of the plant as an 
antimalarial herb by herbalistThe results of this study further supports, and is in line with 
the results obtained during the in vitro analysis of the extract. Moreover, the results also 
shows that the extract has a potential of being used as a phytopharmaceutical drugs both for 
prevention and treatment of malaria. 
B. ferruginea is often used as part of a concoction of herbs for the treatment of other 
diseases, according to information obtained by herbalist in Nigeria. For this reason, other 
137 
 
pharmacological properties were explored. Investigation into the antinociceptive activity of 
the extract revealed that the extract has antinociceptive activity. Two different nociceptive 
models were used in this study, including the acetic acid induce writhing method and the 
tail flick test. Extracts that show activity against the acetic acid induced writhing method 
demonstrate peripheral mechanism of nociception while extracts that show activity against 
the tail flick tests demonstrate a central mechanism of pain inhibition. In this study, B. 
ferruginea demonstrated antinoceptive activity in both pain models. Hence, this shows that 
the extract mediates its activity though both the peripheral and the central mechanism. There 
was a higher inhibition noted in the acetic acid induced writhing method. This means that 
the extract mediates its antinoceptive activity more though the peripheral mechanism which 
is discussed in Chapter 7. Interestingly, the extract exerted its effect at IC50 doses below 100 
mg/kg in all the in vivo studies. Hence the extract could be used to treat malaria and its 
associated symptoms of pain and fever. 
The results of work from this study can be used to develop a B. ferruginea phytodrug  for 
malaria in Nigeria, the use of which can spread across West Africa, just like the example of 
B. ferruginea currently used in Ghana for the management of diabetis mellitus in a 
standardised capsule form. 
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CHAPTER 6  
 
 HPLC optimisation for fractionation of Bridelia ferruginea crude extract 
6.1 Introduction 
Natural products are usually found as a complex mixture of compounds, often acting in 
synergy to produce a certain effect within a biological system. Natural product compounds 
exist in different forms and hence have different structures and stability. Isolation of a 
compound from a crude extract can be complicated. Sometimes compouds isolated do not 
exert the same response as the crude extract. The crude extract may exert a higher efficacy 
due to the possible presence of other compounds within the mixture, which might have 
additive, synergistic or  antagonistic interactions (Junio et al., 2011). 
Over the decades, several techniques have evolved for the separation and isolation of natural 
product compounds. Modern techniques like NMR have been invaluable in the area of 
chemical structure elucidation amongst other techniques. Several research laboratories 
explore small molecule research and discovery of new chemical entities from natural 
product scaffolds. Active natural product skeletons have been modified to develop natural 
product analogue libraries that have been used for the screening of several diseases by 
different research groups.  
Typically, separation/isolation of a compound(s) from a natural product extract requires 
multiple steps. Some compounds may be easy to separate and isolate while others prove 
very complex. Sometimes compounds may exist in very small quantities within a mixture 
requiring specialist techniques to isolate and enrich them. Compounds may also be 
chomophores or non chomophores. Non chomophoric compounds are very challenging to 
separate using conventional methods. 
A wide range of techniques are used for purification and isolation of compounds from 
natural products. In most cases of isolation of a compound, there is no prior knowledge of 
what is to be isolated, making the process a form of a ‘hit and miss’ situation. Furthermore, 
the choice of the technique requires some pre-requisite research and information about the 
possible nature of the compound that may be present. The stability of the compounds present 
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and their nature also play an important role in deciding the choice or sometimes combination 
of techniques to use. 
A very good example of the importance of how certain factors affect isolation was 
demonstrated in the isolation of penicillin. After the discovery of penicillin as a useful 
antibiotic, Alexander Flemming could not isolate it. For this reason, it was not regarded as 
clinically useful. Fleming was able to successfully isolate the compound in aqueous solution 
but the compound was unstable once water was removed. This is a clear demonstration of 
the impact of compound stability on isolation. It was not until the advent of new techniques 
like freeze drying and chromatography that penicillin was successfully isolated (Clayton et 
al., 1944). 
The mainstay method used for the separation of compounds is chromatography. 
6.2 Chromatography 
6.2.1 Chromatography 
Chromatography is a technique that separates compounds by distributing them between two 
phases, namely the mobile phase and the stationary phase. The separation occurs due to the 
differential affinity of the compounds to the two phases, leading to a difference in the 
distribution constants between the two phases. There are several types of chromatography 
techniques, the detailed discussion of which is beyond the scope of this project.  
6.2.2 Types of chromatography: There are three main categories of chromatography. These 
include gas chromatography, thin layer chromatography and column chromatography. Each 
type has different sub-types depending on the nature of stationary and mobile phases used. 
6.2.2.1 Thin layer chromatography (TLC): The stationary phase is a thin layer as the name 
suggests, spread over a glass or plastic sheet. The mobile phase is a liquid (solvent) drawn 
up plate by capillary action. Different factors will affect solvent choice for example 
hydrophobicity/hydrophillicity. 
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Fig 6.1 Illustration of TLC: system showing the tank with the solvent; the plate and 
sample spot. (Source from www.chemguide.co.uk) 
6.2.2.2 Column chromatography: The stationary phase is contained in a column whilst the 
mobile phase liquid (solvent) passes though a column. The sample is injected though an 
injection port and passes though the column. The separated compound, called the eluant, 
elutes from the column. The speed with which a compound elutes depends on its relative 
affinity to the stationary and mobile phase. Compounds with a high affinity for the mobile 
phase will elute first whilst those with a higher affinity for the stationary phase will elute 
last. The mobile phase is moved down the column by either gravity or pressure. There are 
different types of column chromatography. High pressure liquid chromatography (HPLC) 
is one of the most commonly used types of column chromatography techniques. 
 6.2.2.3 Gas chromatography (GC) 
In this case, the stationary phase is contained in a column while the  mobile phase is a  gas 
that passes though column (pressure). 
 
Fig 6.2 Illustration of a GC system: Showing the various components including the 
detector and recording system. (Source: from www.teachingshu.ac.uk). 
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6.3 HPLC and natural product separation/isolation 
 HPLC is one of the main techniques used for the separation of natural products mixtures. 
This method is highly improved over the traditional column chromatography technique 
where a liquid is allowed to elute though gravity. In the case of HPLC, the liquid is forced 
by a very high pressure. This allows for packing of small molecules in the stationary phase 
which in turn increases the surface area, allowing for more interactions between the 
stationary phase and the compounds passing though it. HPLC is a highly automated 
technique. There are several types of HPLC which include normal phase, reversed phase, 
size exclusion and ion exchange. 
6.4 Separation of  methanolic B. ferruginea using HPLC 
6.4.1 Choice of technique 
The choice of which technique to use can often be difficult especially if the compound to be 
isolated is unknown. Certain factors may however give clues as to what technique to choose. 
In recent times, HPLC has been the mainstay for natural product isolation. There are 
different types of HPLC techniques and  the nature of the compound to be isolated 
determines which technique to use. In this study, the extracts that were bioassayed were 
methanolic and aqueous extracts. Both had antimalarial activity with the methanolic one 
being more potent. The fact that these extracts were extracted with polar solvents is an 
indication that the nature of the compounds responsible for the activity is polar. This is a 
valuable tool in the choice of solvents for isolation. The extract was also evaporated to 
dryness in a water bath which means it is stable to heat. Phytochemical analysis in this study 
has shown B. ferruginea to contain tannins, terpenes, flavanoids and glycosides. Literature 
suggests that flavanoids play a role in antimalarial activity (Lehane et al., 2008) hence, the 
main compounds we suspect to be implicated in malaria in this plant extract are the 
flavanoids. Flavanoids have previously been isolated using reverse-phase chromatography 
and it is usually the choice for most organic compounds. In this study, we therefore choose 
reverse-phase chromatography as a separation technique for the crude extract. 
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6.4.2 Reverse-Phase Chromatography 
This refers to any chromatography technique that uses a hydrophobic stationary phase. In 
normal phase chromatography, the stationary phase is hydrophilic, for example silica or 
alumina resins. This makes the stationary phase have a strong affinity for hydrophobic 
compounds in the mobile phase. The hydrophillic compounds will hence elute first. In the 
case of reverse phase, the stationary phase is hydrophobic example alkyl chains (C18) and 
the mobile phase has a strong affinity for hydrophillic compounds. Hydrophobic compounds 
elute first. The polarity of the mobile phase can be decreased in order to reduce the 
hydrophobic interactions with the stationary phase hence allowing for hydrophobic 
compounds to elute. 
6.4.3 Solvent choice 
Choosing a solvent for separation can often be tedious due to the compounds being 
unknown. In this project, reversed phase chromatography was chosen, hence reversed phase 
TLC was performed to help choose the solvents to be used for the HPLC. Polarity of 
different solvents were considered as well as the solvent miscibility chart. This, together 
with information from literature  about solvents used in separation of organic compounds, 
were used as a guide in solvent choice. Table 6.1 below was used. 
Solvent Polarity Compound class 
Hexane 
Benzene 
Ether 
Chloroform 
Ethyl acetate 
Acetone 
Methanol 
Water 
Acidic water 
Lowest polarity 
 
 
Modest polarity 
 
 
 
Highest polarity 
Hydrocardon 
Aromatics 
 
Many classes 
 
 
 
Amino acids, carbohydrates 
Tannins, alkaloids 
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Table 6.1 Polarity of solvents: Showing the polarity of the compound depends on the ratio 
of the polar functional group (hydrophilic part) to the C-H moiety (hydrophobic) part of the 
molecule.  
6.5 Reversed-Phase TLC 
This was performed in order to determine the solvents to use for the reverse phase HPLC 
separation. 
6.5.1 Method development 
This was performed using a reversed phase glass plate precoated with silica gel. The 
methanolic extract of B. ferruginea was dissolved in water to make a 100 mg/ml stock 
solution. A 1 cm drop of sample was applied from the edge of the plate as illustrated in 
figure 6.1.  
Several plates were prepared and developed in different solvent systems and ratio 
combinations. The solvent systems used are described in the table below: 
 Solvents  used Ratios used 
Methanol: Water: acetonitrile in the ratio 70/20/10; 60/30/10; 50/50/0 
N butanol: water: acetic acid 70/20/10; 60/30/10; 50/50 
Ethylacetate:butanol:acetic acid:water      60/30/5/5 
Methanol;chloroform:petroluem ether      20/30/5/0 
Petroluem ether:ethylacetate      50/50 
Methanol/ethylacetate      50/50 
Methanol:ethylacetate:water  
       
    30/60/10 
 
Table 6.2 Solvent systems for the reversed TLC: Showing the solvent systems chosen for 
the TLC experimental run. More than one ratio combinations was applied with some solvent 
systems. 
6.5.2 Plate development 
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 The plate was developed by immediately drawing a line to mark the solvent front. Then 
visible spots were marked with a pencil. The plates that had spots that were not obvious 
were viewed using an ultraviolet (UV) lamp, allowing spots to be viewed and marked. 
 
6.5.3 Results:  
i) Methanol/water/acetonitrile system: This system gave a good separation and there was a 
spread across the entire plate, indicating the presence of several compounds, hence a 
complex mixture. The compounds however, travelled all the way to the solvent front with 
some of the ratio combinations used within this system. Methanol is a highly polar solvent 
with a polarity index of 4.1, hence a system with a lower polarity was investigated to  see if 
separation will improve. 
 
         70/20/10             60/30/10         50/50/0           
 
 Fig 6.3 Plate development for the methanol/water/acetonitrile solvent system: Showing a 
separation in some of the solvent ratio combinations. The first system was too polar. 
Too polar 
Smear indicating large 
number of compounds 
Solvent ratios 
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The results from this solvent system indicates that decreasing the polarity improves the 
separation. 
 
ii) N-butanol/water/acetic acid: This solvent system did not move the analyte from the 
sample spot, indicating that the polarity of the analyte is greater than that of the solvent. 
Butanol has a polarity index of 1 while acetic acid has a polarity index of 0 and water 7.2. 
It will be important to choose a different system with a higher polarity based on this result. 
Figure 6.5 below shows the image of the TLC plate. 
 
               70/20/10    60/30/10  50/50 
 
Fig 6.4   TLC plate of the solvent system, N-butanol/water/acetic acid:  There was no 
separation in this solvent system. 
This solvent system did not move the analytes to the solvent front hence, a better system 
will have to be explored. 
iii) Ethyl acetate/butanol/acetic acid/water. 
The polarity of the solvent system was increased by adding ethyl acetate which has a polarity 
index of 4.4. 
 
 
Mixture did not move 
from sample spot 
Solvent ratio combinations 
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               60/30/5/5 
 
Fig 6.5 TLC plate for the solvent system, ethyl acetate/butanol/acetic acid/water. 
 
A slightly improved chromatogram although the mixture has not separated sufficiently. This is 
indicated by the fact that the analyte has not travelled all the way to the solvent front. Ethyl 
acetate has a polarity index of 4.4.  
iv) Other solvent systems: In order to get a better separation on the TLC plates, more solvent 
systems were explored and the results of the plates are represented in Fig below 
          A             B                C                D 
      
Fig 6.6 TLC plate for other solvent systems: Solvent system  A was slightly effective whilst 
B was in effective. Systems C and D were effective and similar to the methanol/water 
systems. 
 
Key 
A  methanol(20)/Chloroform,(30)/petroleum 
ether (5) 
B  Petroluem ether(50)/ethylacetate (50) 
C  Methanol (50)/ethylacetate (50) 
D Methanol (30)/Ethylacetate (60) water (10 
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In view of the results, acetonitrile/water and methanol/water will be explored as solvent 
systems for the reversed-phase chromatography. 
6.6 Reversed-phase HPLC 
6.6.1 Method development analytical HPLC 
The HPLC analysis was carried out using a Gilson 307 HPLC pump with Varian Prostar 
320 UV detector.  The column was a reversed phase Luna ® on a C18 stationary phase with 
a 5 µm particle size and a 100 Å pore size. The column size was 30 mm length X 4.6mm 
diameter.  A Rheodyne 7725i injection valve was used for the sample injection. The mobile 
phase was chosen based on the results of the reverse phase TLC. An isocratic mode elution 
was used with 0.1% trifluoroacetic acid (TFA) and a methanol/water mobile phase. 
Different solvent ratios were used in the analytical method development this included 
methanol/water (20/80; 40/60; 60/80; 80/20) and acetonitrile/water solvent system. The 
separation was performed using an isocratic mode elution. A 50 µl sample was injected into 
a 50 µl injection loop and the  flow rate was set to 1 ml/min. Samples were run for 30 min 
to 1 h.  
 
6.6.2 Method development for preparative HPLC 
The preparative column was a reversed phase Kinetex ® on a C18 stationary phase with a 
5µm particle size and a 100 Å pore size. The column size was 50 mm length X 21.2 mm 
internal diameter. A guard column was used. The guard column was a SecurityGuard 
preparative mode on a C18 stationary phase with a 21.2 mm internal diameter. An isocratic 
mode elution was used with 0.1% trifluoroacetic acid (TFA) and a methanol/water mobile 
phase and an acetonitrile/water mobile phase. The sample was injected into a 500 ml sample 
injection loop. 
 
6.6.3 Protocol: The HPLC system is automated and uses a computer software system to 
operate. The pumps can be operated both manually or using buttons on the pump. Initial 
runs start with getting rid of the storage solvent and replacing it with the solvent system of 
choice for the run. This was performed by washing the HPLC lines with water and replacing 
with the mobile phase system.  Isocratic elution was used, hence a single pump was used. 
To wash the column, the purge valve was opened in an anticlockwise direction which 
transferred the liquid into the waste bottle (Closing the valve directs liquid to the column so 
this was only done during a sample run or column wash). Once the purge valve was opened, 
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the PRIME button located on pump A unit was pressed. The maximum flow rate on this unit 
is 25ml/min. For this study, a flow rate of 1 ml/minute was chosen for the analytical run and 
10 ml/min for the preparative run. The output signal was processed using a PicoLog data 
computer software (Pico technology Ltd, Cambridge, UK). All solvents were HPLC grade 
and the extract sample was filtered using a 0.45 µm filter (Millipore, Bedford, USA).  
6.6.4 Detection: UV absorbance was used for detection in this study. The detector was 
connected to the HPLC system. Different compounds absorb UV under different wavelength 
due their characteristic absorbtion coefficient. In most cases, short wavelength of 200 to 300 
nm are chosen when monitoring unknowns as most organic compounds fall within this 
range. Flavanoids absorb at 254 nm, hence this wavelength was chosen for the HPLC 
analysis due to their implication in malaria. At longer wavelength, compounds tend to be 
more specific.  Wavelength less than 200 cause interference with the mobile phase.  
 
 
Fig 6.7 A HPLC system: Showing a HPLC system used in our laboratory, indicating the mobile 
phase, pump, injection port, the column and other components.  
 
6.6.5 Column storage: The column was stored in 70% methanol after running five column 
volumes of solvent and kept until used. 
Detector 
Pump 
Mobile 
phase 
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6.6.6 Method optimisation: The robustness of the method was investigated by deliberate 
alterations in the method parameters. Different mobile phases were ran, sample 
concentrations was altered. The results of these validated the method. Samples that were 
ran under the same conditions produced the same chromatogram. Altering the test 
parameters altered the chromatogram. 
6.7 Results 
The results of the HPLC analysis was obtained from the software as chromatograms. 
6.7.1 Analytical HPLC results for methanolic Bridelia ferruginea  
i) Acetonitrile/ water as a mobile phase system for separation of B. ferruginea 
components. 
30/70 acetonitrile water 
 
Fig 6.8 A 30/70 acetonitrile/water chromatogram: Showing a chromatogram of the crude 
extract using 30/70 acetonitrile water solvent system in an analytical column. 
The solvent system used in Fig 6.8 above produced several peaks although the peak 
resolution was poor. Fraction collection will prove difficult due to analytes eluting too 
quickly. Hence increasing the polarity of the solvent might be useful. A more polar system 
was tested. 
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ii) 40/60 acetonitrile/water mobile system 
 
iii) Fig 6.9 40/60 acetonitrile/water chromatogram: Showing a chromatogram of the 
crude extract using 40/60 acetonitrile/water mobile system in an analytical column. 
The peaks were unresolved 
There was a poor peak resolution with this solvent system. Hence further improvements 
need to be made in order to increase resolution and reduce retention time. Hence 80/20 
acetonitrile/water was explored.  
 
iv) 80/20 acetonitrile/water solvent system 
 
Fig 6.10 80/20 acetonitrile/water system: Showing a chromatogram of the crude extract 
using 80/20 acetonitrile/water solvent system in an analytical column. 
This is solvent system has produced a poor peak resolution hence further mobile phase 
modifications need to be made. Due to this, a different solvent system was explored. 
2) Methanol/ water as a mobile phase system for separation of Bridelia ferruginea using 
HPLC 
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i) Methanol: Water 80/20 
 
Fig 6.11 80/20 methanol/water chromatogram: Showing a chromatogram of the crudee 
extract using 80/20 methanol/water solvent system in an analytical column. 
Several peaks were produced in this run as indicated by the chromatogram above. The 
analytes have however eluted within the first 5 mins of injecting the sample. There is a 
slightly better resolution in the first peak but the other peaks are unresolved. The solvent 
ratio is most likely too polar. Reducing the polarity might slow down the movement of the 
analytes though the mobile phase to give a better resolution and increase retention time. 
ii) Methanol:water 60/40 solvent system 
 
Fig 6.12 60/40 Methanol/water chromatogram: Showing a chromatogram of the whole 
extract using 60/40 methanol/water solvent system in an analytical column. 
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Reducing the polarity of the mobile phase system gave the chromatogram above, which 
improved the resolution. The retention time was increased.  
iii) Methanol:water 50/50 solvent system 
  
 
Fig 6.13 50/50 Methanol/water chromatogram: Showing a chromatogram of the crude 
extract using 50/50 methanol/water solvent system in an analytical column 
Changing the solvent system to 50/50 methanol:water has led to an improved resolution as 
can be seen in the chromatogram above. The peaks are more resolved  but the analytes 
have eluted within a 5minute time span. 
iv) Methanol:water 40/60 
 
Fig 6.14 40/60 Methano/water chromatogram: Showing a chromatogram of the crude 
extract using 40/60 methanol/water solvent system in an analytical column. 
This solvent system produced more analytes as indicated by more peaks although the 
resolution was poor with multiple analytes eluting at the same time.  
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Methanol:water 30/70 
 
Fig 6.15 30/70 Methanol/water chromatogram: Showing a chromatogram of the crude 
extract using 30/70 methanol/water solvent system in an analytical column 
Overall, methanol/water as a mobile phase seems to give a better separation compared to 
acetonitrile/ water in the analytical phase although the analytes eluted quicker most likely 
owing to the polarity of the mobile phase. Overall, increasing water polarity of the mobile 
phase improved resolution. One of the major disadvantages of the detection method used 
in this study is it is not quantitative, as with UV detectors. Although several small peaks 
appeared, they are not an indication of the sample amount, hence the small peaks could 
contain a reasonable amount of material rather than trace. Collecting fractions according to 
peak heights could mean reasonable analyte quantities could be lost.  Based on this, a 
timed fraction collection is planned for the preparative HPLC analysis. Based on the 
results obtained from the above analytical HPLC phase, the methods were scaled up using 
a preparative column. 
6.7.2 Comparative analysis of the aqueous and methanolic extract of Bridelia 
ferruginea  
The aqueous and methanolic extract were ran under same HPLC conditions in the 
analytical HPLC column. The Injection volume was 50 µl and the concentration was 20 
mg/ml stock. Mobile phase was 40/60 methanol water using an analytical column with UV 
detector set at 254 nm. The chromatogram below was obtained. 
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Fig 6.16: Comparing the aqueous and methanolic extract under the same conditions: 
Showing the two extracts under same conditions produced multiple peaks in the 
methanolic extract but just a single peak in the aqueous run. The run was performed for 
30 mins 
6.7.3 Preparative HPLC 
The preparative HPLC is a scale up from the analytical run using the preparative column. 
The columns have a high flow rate systems hence allowing for the collection of analytes 
unlike the analytical HPLC. Furthermore, the preparative HPLC can be used as a 
quantitative technique. Briefly, the method involved dissolving the extract in water and 
placing in a 37°C incubator for 1 h to enhance the dissolution. The first series of runs were 
performed using a 40/60 methanol/water solvent system with injection volume of 1 ml 
using a 1 ml sample loop at a flow rate of 10 ml/min with the detector set at a wavelength 
of 254 nm.  
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6.7.3.1 Methanol/ water system 
 Methanol/water system at the ratio 40/60. 
 
 
Fig 6.17 Comparing chromatograms between runs: Showing some peaks were lost between 
runs but most peaks were consistent. The lost peaks were identified based on peak shapes 
and retention times. Overall, the method was reproducible. 
The unstable peaks were identified in the chromatogram below. 
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Fig 6.18 Lost peaks in the chromatogram: Showing unstable peaks that were lost in some runs. 
This was used as a guide in determining what fractions to collect Based on these results, 
fraction collection was started and the fractions collected are labelled in the diagram 
below.  
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Fig 6.19 Fractions collected: The retention time of each fraction was noted and used as a guide during collection. Fractions that were lost in 
some runs example peak 2 were collected in runs that they appeared. A total of 12 runs were performed.
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6.7.3.2 Evaporation of samples to dryness 
The fractions obtained were dried in a rotary evaporator at 70°C under vacuum conditions.  
Fraction 1 was obtained in reasonable quantity (10 mg). The other fractions were however 
in negligible quanties hence collection was not possible. The process was performed by 
weighing a vacuum flask before putting the liquid sample. Once the fraction was dried, the 
bottle was re-weighed as detailed below. 
 
 
Fig 6.20 Determining fraction quantity: Fractions collected after several runs were 
weighed in the bottle as in the picture above.  It was decided to change the solvent system 
at this stage. 
 
6.7.3.3 Acetonitrile/ water system 
The acetonitrile/water system was explored in the preparative column. 
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6.7.3.3.1 Run 1 15/85 Acetonitrile/water (50 mg) 
20 mg of the extract was injected into the column and ran at a flow rate of 10 ml/min as in 
previous runs. This system gave a good separation and the time taken for all fractions to be 
eluted was an hour.  
The chromatogram is represented in fig 6.21 below.
 
Fig 6.21 15/85 acetonitrile/water preparative chromatogram: Showing a chromatogram 
obtained during a preparative chromatography run using a 15/85 acetonitrile/water solvent 
system with fractions eluting within an hour. 
 
6.7.3.3.2 Run 2  20/80 acetonitrile/water (50 mg) 
A 20/80 acetonitrile/water system was explored in the preparative HPLC with a 50 mg 
sample of the extract injected as a 1 ml volume in a 1 ml sample loop. The trace below was 
obtained and the fractions were collected in different tubes. 
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Fig 6.22 20/80 acetonitrile/water preparative chromatogram: Showing the chromatogram 
obtained for the 20/80 run and the fractions. 
 
 
6.7.3.3.3 Run 3  30/70 acetonitrile/water (50 mg sample) 
In order to speed up the runs, the amount of acetonitrile was slightly increased to 30/70 
acetonitrile/water and the amount of extract amount of 50 mg in 1 ml volume. 
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Fig 6.23 30/70 acetonitrile/water preparative chromatogram: Showing a chromatogram 
obtained from a preparative run with the fractions collected. 
Increasing the acetonitrile strength reduced the time taken for the run significantly. The run 
was shortened to 15 to 20 mins. The runs produced the chromatogram above but some and 
analytes eluted within 15-20 mins. Peak shapes were consistent in all runs allowing fractions 
collection. Below is a sample of a chromatogram that ran for over 15 minutes. 
Other runs with the same solvent system were consistent. 
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6.7.4 Troubleshooting for the preparative HPLC column 
Troubleshooting was required due to loss of some fractions after several runs. After about 
10 runs, fractions were lost. Various trouble shooting procedures were performed to 
restore fractions. A vigorous column restoration procedure had to be performed. The 
traces below were obtained. 
  
 
 
Fig 6.24 Trace for column restoration: Showing the first trace obtained after column 
restoration All efforts to restore peaks  after several washes with 40/60 acetonitrile/water 
did not restore peaks. Hence an intensive column regeneration procedure was necessitated 
after contact with column manufacturer. 
 
6.7.4.1 Column regeneration procedure 
Step 1 
The Column was flushed with pure 100% acetonitrile at a flow rate of 1 ml/min until 5 
column volumes were flushed though. The trace below was obtained during the cleaning 
procedure. 
 
 
Fig 6.25 Showing the chromatogram obtained during the wash. 
 
163 
 
In order to test the column. A sample with 50 mg extract was injected at a at flow rate of 
10 ml/minute in a 1 m sample loop. The trace in fig 6.27 below was obtained. 
 
 
 
Fig 6.26 30/70 acetonitrile water run after cleaning: Showing a 30/70 acetonitrile/water 
run after column cleaning. 
 
Based on the chromatogram in fig 6.27 above, it seems the 100% acetonitrile flush did not 
restore the trace to expectations. Hence, a column regeneration procedure was performed 
to regenerate the column. 
 
6.7.4.2 Regeneration procedure for reversed-phase columns 
The column was disconnected and reconnected to the the pump with the flow in the the 
reverse direction. The buffers were flushed out using  HPLC grade water. 25 mL of water 
was pumped though the column at 1 mL/min. The column was thereafter flushed with 25 
ml of isopropanol, 25 ml of methylene chloride, 25 ml of hexane, 25 ml of methylene 
chloride again and finally with 25 ml of isopropanol in the order mentioned. The column 
was reconnected back to the pump  in the proper direction. Then it was flushed with the 
mobile phase without the buffer, and finally the buffer was re-introduced. The column was 
equilibrated with 50 ml of mobile phase. A sample was injected to perform a normal run 
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and confirm if column was restored. The column was disconnected from the detector the 
restoration procedure to protect the detector from contaminants. 
The column was restored and collection continued. The trace below was obtained. 
 
Fig 6.27 Restored chromatogram: Showing chromatogram after column regeneration 
 
Runs were continued until enough was collected to dry in a rotary evaporator as described 
previously.The dried fractions were weighed and the weights  are labelled in the 
chromatogram below. 
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Fig 6.28 Fractions collected: Showing the fractions collected and total amount in milligrams after evaporating to dryness.
Prefraction1 
Amount negligible 
as this fraction did 
not appear in all 
runs 
F1 
25.6
mg 
 
F2  
73mg 
Not 
collected 
 
F3A 
55mg 
F3B 
7.5mg 
F4  
15mg 
F3C 
Not 
collected 
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6.8 Bioassay of collected fractions: 
The collected fractions were made into stock stock solutions of 5 mg/ml. The fractions were prepared for the SG-Microplate assay as previously 
described in section 2.2.5. Briefly, P. falciparum cultures were challenged with 20 µg/ml of each fraction. Control cultures with no drug was 
also prepared as well as a positive control group of cultures challenged with 20 µg/ml methanolic B. ferruginea. The results of this screening 
procedure are represented in fig 6.29. The results of this assays shows a near 50% inhibition by  methanolic B. ferruginea. This was performed to 
validate the assay as well as compare the crude  extracts with individual fractions. Based on these results, it can be seen that the antimalarial 
activity is distributed across all the fractions with the highest inhibition observed in fraction 1 and fraction 3B. Increasing the dose of the 
methanolic B. ferruginea and all the other fractions gave an  even higher inhibition as can be seen in fig 6.30 This shows that the fractions  exert 
their antimalarial activity in a dose-dependent manner.  The highest inhibition was  observed with fractions F1 and 3B in the higher dose levels.  
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Fig 6.29 Bioassay of fractions 20µg/ml: SG-Microplate assay 
showing the effect of 20µg/ml fractions or B. ferruginea on P. 
falciparum culture. 
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Fig 6.30 Bioassay of fractions 40µg/ml: SG-Microplate assay showing 
the effect of 40µg/ml fractions or B. ferruginea on P. falciparum culture.
168 
 
 
Tukey's Multiple 
Comparison Test 
Mean 
Diff. 
Significant? 
P < 0.05? 
Summary 
Control vs Bridelia ferruginea 11418 Yes *** 
Control vs F1 12524 Yes *** 
Control vs F2 6976 Yes *** 
Control vs F3A 7759 Yes *** 
Control vs F3B 9387 Yes *** 
Control vs F4 12493 Yes *** 
Control vs BLOOD 13342 Yes *** 
Bridelia ferruginea vs F1 1106 No ns 
Bridelia ferruginea vs F2 -4442 Yes *** 
Bridelia ferruginea vs F3A -3659 Yes *** 
Bridelia ferruginea vs F3B -2031 Yes * 
Bridelia ferruginea vs F4 1075 No ns 
Bridelia ferruginea vs BLOOD 1924 No ns 
F1 vs F2 -5548 Yes *** 
F1 vs F3A -4765 Yes *** 
F1 vs F3B -3137 Yes ** 
F1 vs F4 -30.67 No ns 
F1 vs BLOOD 817.7 No ns 
F2 vs F3A 783 No ns 
F2 vs F3B 2411 Yes * 
F2 vs F4 5517 Yes *** 
F2 vs BLOOD 6365 Yes *** 
F3A vs F3B 1628 No ns 
F3A vs F4 4734 Yes *** 
F3A vs BLOOD 5582 Yes *** 
F3B vs F4 3106 Yes ** 
F3B vs BLOOD 3955 Yes *** 
F4 vs BLOOD 848.3 No ns 
 
Table 6.3 Statistical analysis for fractions data:  Showing statistical analysis of the data 
represented in Fig 6.30. The results were analysed using One-way analysis of variance 
and and a tukey post test. The results showed that there is a significant difference between 
control and all B. ferruginea fractions. There was however no significant difference 
between B. ferruginea and F1 and F4 with P > 0.05. There was a signififant difference 
between B. ferruginea and F2, F3A, F3B with P < 0.05. There was a significant difference 
169 
 
between fractions for example F1 Vs F2; F1 Vs F3A and F3B. There was no significant 
difference between some fractions however for example F1 vs F4, F2 Vs F4, F3A vs F3B. 
 
6.9 Chapter conclusion 
HPLC separation conditions were optimized in order to achieve separation using different 
solvent systems. The solvent systems were chosen based on the results of the reverse phase 
TLC. The methanol/water and acetonitrile water gave the best separation in the TLC plates. 
These solvent systems were hence chosen to optimize the HPLC separation of the extract 
using an analytical column. The results obtained from the analycal HPLC were used to scale 
up the technique using a larger preparative column. After several runs of methanolic/water 
solvent system fractionation, good resolved peaks were obtained as seen in this chapter. 
Evaporating the fractions to dryness however produced a negligible amount of fractions 
except for fraction 1. About 10 mg was obtained from fraction 1 but the other fractions could 
not be collected. Based on this, acetonitrile/water solvent system was used as an alternative. 
The results were a very good separation with reasonable quantity of all fractions collected, 
with up to 73 mg collected in some fractions as can bee seen in Fig 6.28. Bioassay of the 
fractions has produced a good dose-dependent antimalarial activity in P. falciparum K1 
cultures using the SG-Microplate assay. The antimalarial activity was spread across all 
fractions, hence isolating a single active compound would have been both tedious and most 
likely not offered an advantage.  The results of this chapter hence make a very good  case 
for B. ferruginea to be put forward for further optimization into a phytopharmaceutical drugs 
for malaria.
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CHAPTER 7  
 
 7.1 General discussion 
As with most developing countries, plant-derived natural products constitute a significant 
source of medicine for the majority of the population in Nigeria. In this study, we evaluated 
the in vitro and in vivo antiplasmodial activity of some commonly used plant extracts for 
malaria. Different assays were optimised for use in the antiplasmodial screen. Fluorescent-
based assays including SG-Microplate and SG-FCM assay were validated against the gold 
standard Giemsa light microscopy. Based on the results obtained from this study, all the 
extracts showed activity against the K1 (multidrug-resistant) P. falciparum strain. 
Recent evidence  has shown that malarial parasite viability can be detected using DNA stains 
like SYBR green I (Karl et al., 2009; Johnson et al., 2007 and Rason et al., 2008). The SG-
FCM methodology had the additional advantage of being able to differentiate between the 
uni and multinucleated stages of the erythocytic phases of the parasite. The SG-Microplate 
assay could not detect individual parasitic stages. Another major limitation of the SG-
Microplate assay is that the actual parasitaemia of the culture could not be established. The 
activity of the extract/ drug could only be detected by calculating the percentage inhibition 
relative to control (untreated) cultures. The optimisation assay further established other 
issues with regards to the SG-Microplate assay based on background fluorescence. It was 
discovered that blood and complete media increased background fluorescence hence 
interfering with the reading. A high background fluorescence meant that drug inhibitions at 
certain low doses could be masked. Upon comparing complete media with wash media, it 
was established that high fluorescent background was indeed due to added albumin in the 
complete media. This was a novel, previously unreported finding (Rason et al., 2008). 
Moreover, the SG-Microplate assay performed in this study omitted the erythocyte lysis step 
previously reported in other studies. It was found that the assay could still be performed 
without this step hence, simplifying the procedure. 
Previous studies have used a 72 h treatment cycle owing to the fact that the parasite life 
cycle is 72h, spanning from ring, to trophozoite and finally schizont stages. Previous studies 
by Wein et al., 2010 have demonstrated a 72 h treatment period in order to obtain reliable 
results with SG assays.   In this study, treatment was established using a 48h cycle starting 
at trophozoite stage. The extract showed activity when treatment was initiated both at ring 
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stage and at trophozoite stage. It may however still be more preferable to treat for 72 h for 
drugs with unknown action, starting with the ring stage and analysing at the trophozoite 
stage. This also covers for drugs that act selectively on specific stages of the erythocytic 
cycle as well as slow acting drugs. 
7.2 Validation of the ethnopharmacological properties of selected plants in Nigeria. 
Five plants namely, Artemisia  maciverae, Bridelia ferruginea, Bryoscarpa coccineus, 
Bombax buonopozense, Bosewellia dalzellii and a NIPRD coded extract were evaluated for 
their antimalarial claims. The results obtained in this study supports the traditional usage of 
these plants for malaria hence validating their ethnopharmacological usage for malaria. B. 
ferruginea and B. coccineus were chosen  as candidates to take forward for the scope of this 
study for reasons previously discussed.  One of the main concerns associated with the use 
of unregulated herbal/traditional medicines is the issue of  appropriate dose and drug-
induced toxicity. A dose response analysis of both extracts  gave IC50 values of 15 µg/ml 
and 72 µg/ml for B. ferruginea and B. coccineus respectively. Rasoanaivo et al., 2004, 
suggested that extracts with IC50 greater than 50 µg/ml should be considered inactive, hence 
B. coccineus was excluded from the study after its IC50 had been established.  
Phytochemical analysis of the aqueous crude extract of B. ferruginea extract revealed the 
presence of tannins, terpenes, flavonoids, phenols, cardiac glycosides and sterols. 
Flavanoids have been previously implicated in malaria. Studies by Lehane et al., 2008 
revealed 11 dietary flavonoids to be active against certain P. falciparum malaria strains 
including the CQ-sensitive (3D7). Flavonoids are a common constituent in several 
medicinal plants but their exact molecular mechanism of action have not yet been 
elucidated. It is believed that inhibition of fatty acid biosynthesis in the parasite is one of 
the possible mechanism (Freundlich et al., 2005, Elford, 1986). Others groups have shown 
flavanoids to inhibit the influx of L-glutamine and myoinosotol into infected erythocytes 
(Yenesew et al., 2003). Flavanoids come in different forms including chalcones, isoflavones 
and retinoids. These have been previously implicated in malaria (Yeneswe et al.,2003; 
Midiwo et al., 2007; Yeneswe et al., 2004). Phenolics, which were also present have shown 
activity against malaria parasites in various in vitro studies and been used in combination 
with other antimalarial compounds including artemether to demonstrate synergy (Pimenta 
et al., 2014). As methanolic plant extracts tend to be rich in flavonoids, phytochemical 
analysis of the methanolic extract was performed. Interestingly, the results revealed the 
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presence of the same compounds including anthaquinones which were absent in the aqueous 
extract. Anthaquinones extracted from the bark of some medicinal plants have been shown 
to possess moderate antiplasmodial activity against certain P. falciparum strains (Hou et al., 
2003).  Based on this information, the methanolic bark extract of B. ferruginea was 
investigated for its antiplasmodial activity using the fluorescent-based assays and Giemsa 
light microscopy. This allowed for the comparative analysis of the aqueous and methanolic 
extract. The methanolic extract was more efficacious than the aqueous extract with an IC50 
value of 20 µg/ml. The higher antiplasmodial activity seen in the methanolic extract could 
be owing to the presence of anthaquinones, which were absent in the aqueous extract. The 
methanolic extract was hence used in all further experiments. Moreover, the phytochemical 
tests can be used as markers for quality control and standardization when a 
phytopharmaceutical drugs is developed and also for argonomic selection of the best plants. 
(Patel et al., 2012, Pandey and Tripathi, 2014; Lapornik et al., 2005) 
One major drawback  associated with using natural products as a source of medicine is the 
seasonal variability that may occur with phytochemical constituents within the plant. In this 
study, the plant was collected from two regions in Nigeria. Seasonal variations have been 
demonstrated in phytochemical properties of certain bulbous plants in South Africa (Ncube 
et al., 2011). Certain phytochemicals, including phenols were shown to be higher in spring 
compared to the other seasons. The B. ferruginea plant in this study was collected in June 
and November. There was no variation observed in the IC50 values obtained in the extracts 
collected between the two seasons. The phytochemical analysis performed in this study 
supports this finding. The phytochemical analysis in this study was qualitative rather than 
quantitative. The comparative analysis antiplasmodial study between the aqueous and the 
methanolic B. ferruginea was used to bridge this gap. 
7.3 Investigating the mechanism of action of methanolic B. ferruginea extract 
The malaria haemozoin pathway plays an important role as an antimalarial target. Malaria 
parasites produces large quantities of  inert haemozoin though a highly efficient mechanism 
the detoxifies lethal haemoglobin degradation products (Roth et al., 1986). Several 
pathways have been described for the degradation of haem (Tekwani et al., 2005). The most 
critical pathway and predominant mechanism is the sequesteration of haem into haemozoin. 
This is also called the biocrystallisation pathway in which, haem is incorporated into a 
crystalline black pigment, accumulated within the parasite food vacuole (Saliba et al., 1986). 
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The biocrystallisation pathway is unique to the Plasmodium. This selectivity makes it an 
important antimalarial target. Several studies have been performed to gain further insights 
into the actions of antimalarials on this pathway. Studies on this pathway have shown 
haemozoin synthesis to be inhibited by chloroquine in both P. falciparum and P. berghei 
species of the parasite (Chou et al., 1993; Chou et al., 1992; Orjih and Fitch, 1993). The 
haemozoin molecule has been studied by several groups over the years. One major finding 
that has aided the study of this molecule and the mechanisms involved in pigment formation 
is the similarity between the haemozoin and β-haematin molecules revealed by X-ray 
crystallography studies (Slater et al., 1991; Pagola et al., 2001). Investigators have 
previously taken advantage of this similarity between the two molecules to study the effect 
of extracts/drugs on β-haematin formation. Screening of 178 plants extracts from the 
pharmacopeia of Bolivia ethnia Tacana using the β-haematin formation assay revealed 
promising in vitro antimalarial activity of several extracts (Baemans et a., 2000). In this 
current study, we take the advantage of this similarity to investigate the effect of methanolic 
B. ferruginea extract on β-haematin formation. The inhibition of the β-haematin formation 
assay takes advantage of the differential solubility between haem and β-haematin in NaOH. 
Different assays were used to optimise β-haematin formation as described in Chapter 4. The 
results demonstrated that for chloroquine, inhibition was only achieved at doses above 1 
mM whilst for B. ferruginea, at doses from 2 mg/ml. These doses are no doubt lethal to the 
human body as explained previously in Chapter 4. Physiologically, the drugs enter the 
parasite food vacuole and accumulates to a high dose, this has been demonstrated by CQ. 
CQ enters the parasite food vacuole though simple diffusion. Once it enters, the drug is 
protonated due to the acidic pH (4.7), which prevents it from diffusing out. It may be recalled 
that in this study, the experiment only worked at pH ranging from 4.6-4.9, in line with the 
physiological pH of the food vacuole.  This build up of chloroquine in the food vacuole 
relative to the rest of the parasite prevents further biocrystallisation of haem leading to a 
haem build up which is toxic to the parasite (Ehlgen et al., 2012). Unfortunately, the assays 
currently available cannot model the concentration effect in the food vacuole and hence 
require higher than physiological doses of the drug. They are however, useful surrogates to 
investigate the parasite haemozoin pathway. 
7.4 HPLC analysis of methanolic B. ferruginea. 
Chomatographic analysis of the extract in this study demonstrated the presence of several 
compounds as revealed by the presence of multiple, well resolved peaks. This study 
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optimized HPLC conditions for the extract using a suitable detection technique, the UV 
detection method. The main objective of the HPLC was to contribute towards 
standardization procedures in the development of the phytopharmaceutical drugs. The 
collected fractions were tested and all fractions demonstrated antimalarial activity, albeit 
some higher than others. Isolating an active compound was not pursued for two reasons; 
firstly, the antimalarial activity appeared in many fractions with evidence to suggest that a 
collective advantageous, synergistic trait contributed to the overall effectivity of the whole 
extracts and secondly the main aim of this study was to  work towards developing a 
wholesome phytopharmaceutical drugs for malaria. For a drug to be classed as a 
phytomedicine, it must contain purely natural products. Additionally, the work supports the 
argument that phytomedicines as crude compounds might offer a better alternative for the 
treatment of malaria due to previous history of resistance that has developed with known 
antimalarials when they were dispensed as  purified active ingredients. In addition to 
impeding the development of drug resistnance, maintaining the extract in its crude form 
might offer additive and synergistic benefits that might be lost when a single active 
compound is isolated (Wilcox et al., 2011). Based on the results obtained in this study, it 
could be argued that this is the case with B. ferruginea as antiplasmodial activity was 
demonstrated in different broad fraction collections obtained from the HPLC analysis. The 
HPLC could prove invaluable in standardization procedure of the extract for 
commercialisation.  
7.5 In vivo activity of methanolic B. ferruginea 
In vivo antimalarial activity of B. ferruginea confirmed a number of its pharmacological 
properties in mice. The extract showed significant antimalarial, analgesic and antipyretic 
activity. Compounds sometimes show activity in vitro but loose activity when tested in vivo, 
due to factors like lack of absorption and other pharmacokinetic related issues. The fact that 
this extract demonstrated good antimalarial activity both in vivo and in vitro makes a very 
good antimalarial candidate as it is unlikely that pharmacokinetic issues will be encountered 
in clinical trials. 
Hence the results of this studies have successfully demonstrated that B. ferruginea as a very 
good candidate to put forward for clinical trials and it is likely a good phytopharmaceutical 
drugs can be produced in the near future for malaria from it. Its usage as an antimalarial 
traditional medicine is hence validated. 
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7.6 Future directions 
The results of this study revealed a strong antimalarial activity of  six different extracts that 
are used for malaria treatment in West Africa. Various in vitro and in vivo techniques were 
used to ascertain the antimalarial claim. The in vitro work focused on the K1 resistant P. 
falciparum strain. Future studies could investigate the activity of the extract on other malaria 
strains. The phytochemical studies in this study was qualitative. The results revealed the 
presence of various phytochemicals in both the aqueous and methanolic extracts of Bridelia 
ferruginea. Future work could further investigate the quantitative phytochemical presence 
of the various compounds found. This is likely to give a better insight into why the 
methanolic extract of B. ferruginea was significantly more efficacious than the aqueous 
extract in both in vitro and in vivo assesments. As stated earlier, flavones and terpenes have 
been implicated in malaria. These compounds were revealed in both the aqueous and 
methanolic extract. It has however been shown that methanolic extraction technique tends 
to extract  more flavonoids and terpenoids than aqueous extraction methods (Ncube et al., 
2008) Hence it is very likely that the amount of these two compounds are higher in the 
methanolic extract than the aqueous extract, hence the higher antimalarial activity observed. 
B. ferruginea has long term use within communities for various purposes, hence it’s safety 
is established to a certain extent. Moreover, this study evaluated the in vivo acute toxicity 
profile of the methanolic B. ferruginea extract and found it safe to use up to a dose of 5000 
mg/kg. In vivo sub-chronic and chonic toxicity studies were however beyond the scope of 
this study. Pursuing these investigations will prove invaluable in establishing and 
documenting an improved toxicity profile for the extracts. Once this is established, clinical 
trials could commence towards the development of a phytopharmaceutical drugs. 
In addition ome of the fractions showed strong antimalarial properties. These could be taken 
further in order to isolate the active compound which could be a new lead for antimalarial 
drug development.  
Finally, the HPLC could be use to determine fingerprints for the extract as a quality control 
tool in further development of the extract as a phytothraupeutic drug. 
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